var title_f12_35_12848="Flank pain child PI";
var content_f12_35_12848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Location of pain in pyelonephritis (kidney infection)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the area of the back and sides, called the flank, that can become painful in children with a kidney infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12848=[""].join("\n");
var outline_f12_35_12848=null;
var title_f12_35_12849="Multiple exostoses";
var content_f12_35_12849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple small osteochondromas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 445px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG9ATIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5wU4IIyCOQRxTHAOD3709CAucHpihcnjgjHWgCMYPAA/Cl2HnHUDOMUqjgjPzGgjjNADSO2PrSnGFBxj6dKcvJ+bsKZgkkH8OKAGAY7CjGck4pxH5D2poJ29BgUAXNIwLrPfFdppixvKIyVUkgZPT8q43RwftLYBx7V1dnnjaMnjgdc0AdlLZ28aIqxIRjIZhUBsYZsjyVyfQnFa9hbG4s45GyRtyc0+GzYq7IPl6j2oA4bVbcW07xLtKjGPyriNYIN2QMdPSu88RFvtrZ4fAyD1rg9YGLw54yO9AFIgY6YP0pTwvQEg00E4wcEUpx07elACDlRkAZqzp0PnXYwvC8nNVjyDgfhWzoEAZTI+Rz8tAHQWCjaAemfTrXolrCfskSquFAz0riLCIM6AAnJAr1a2sMWMTHBAjAAoAwPs5MzYyGC5wvTrWF4mh8m4UFCPkxnsa71dPUKHCE4ABx3rhvGE+67eGMjbGTuwepoA8718ndGgwM8kVlABSQACM56dau6rJvvGAzgcdaqLtOd3Q+tADG2jPyrT4wOFCjOe3em+nOABxV7SbcSXG48jHBxQBoWNsI4wdnzE8/wCFbVvB5qZRO/PFQRLtCr056V0EFqvlrvGAOi9zQBkT2o2kOu09M9qw9Ss/LzJGowOuO/vXb30CiE5UKCucVzV79whcAnjFAHPoE+YkBQO/rUjFMj5ccfnUO4rJ8wLDpz3qfIBxnaG7dxQA7oC2AB0xxU0D4BAA5qvIGGAWxk1ISQc5/KgCeWbJGMHAyTVcSKTkBQc80mfQHjvTTyWPDL7UASswyCOvfir+m43Z+9nvWWTgYPIHXHatbTxwMDn60Aau76fpRTPNf2ooA8+ByOc05ME/OAAOBz+VRk5BJPXHTilGDIVBAFACbcHBxnNLldp45PXmhiODkbvpxSdO/wClADiSQckZppb6HI60zBxnqfc0qY9OM0ALLkN3xTeMj+dBJGc9MdKbuA/+uaANTQeZW3E9a6m2DhgyHDD5gRXO+HY9yuR1zXYafbtNPHGoXdIQoNAHf+HWY6NEXydy9T1J9atrJEGWJgNjg549aqRN5SRxRH93Em0Z71GXLTNhh90ge1AHH+LovL1WZWJJwOa861xCbwY6kdq9a8ZW/nst0q7iuFfjqD0NeY+JYSkkTDOSSKAMM4AHXPf0H0puRnPWlPpikOdxz+VACk4THHPaur0KApaoCoz1rlbeIyXEaD+Ij613+nwEqq4OfpQB0Hhix+06jEAP3afMa9PQK0agDCqMVzPh6wNjYpGP9dJ8zkdfpW+JVynIyO3pQBLPcCHTZnGMg56dsV5Dq0hIlkbPILE16f4mby9CkwcE4/8A115H4hk22k244JGAc96AOMY72eUt95ifWmjpkcdsY60gJxj0Ppg0EDGBgnrQADkcf5NdRo9r5dug28kZziuetYvMvIo+CDya7uxtgUXBxxk5oAn06w8+UDGIwcs1dA9sSnyLhV4A9ql0aCLkEkDsOP5VtXdnHFDI6nzAq9R2z7UAcVrruWMKr8iADOeTXO3AKKWYAj1FdFqQ3SyMvAJ71zOruYoWC8E8ZFAGC2SxIPU5xmnjGTnGevIohAdiNyjPJJOKbnBIIOD+lAEhIJBJHHODxmkkIJz/AA59KaWyCByo46YoCsG+YlTj+IUASO+RkEbh+QpgcBhwQe/tUROCcDgHjjFKO+TgmgB4lAJCrgn0rX09yMHG3j86xQPnGM49a1rBDtIA6UAaJbnqaKTy37MPyooA4ONvkXnmhfv84GeppkZO3A+7x260u7PUDj3oAVhuAI9PWgHAY9+3eo/cZB78UvAXI9aAHqw/j3YPoO9Jzhcd+/rQD0HGOuDSqByQefSgBjHjgfpSNjBzz9KeVJwoA57k4pki9VJzt9DnNAHT+GIw1qp4HJ/nXoHhuE7TIiZcAqMDOPwrg/DOFtYwMHH+NdppTIkgMu8Ke68fnQB1cMUnkHakgbHX/wCtS/ZpVRS67D/Cz/LkVNp93YrFj7RgqBgEMefzqO91W1i3YbzpMdxtA/rQBYl0qIWE032iKWIxkbY+cH3rx7xbCsdrIpwXibjg8V2t1fXJ3mKRoh02pwK4LxdOfLZXOWZgPfFAHKMS2SAAOuAMCmnHGacvzN3+tIVZ8hBnAJOPQd6ANPw3B5l55rDIHyj616b4et83CzScKnTI4Lelcd4NsyI4pmHzbt+CODXpuhW+8FlkX5yWZSucEnsKANKKQHB5BB5JNWImJlUDke59qtiyAQcRu2PdT/hUckKwNvk8yNT3YZX8xQBQ8TXDvYyxuRuCr09u1eS+KpQLcKpyWbnAr1PV57Zopne6jbCFdg557V5F4qlLzIM89aAMHbknggfzpwwHwcfyzSKQoGDz0pygM2ABknHSgDT0GFpblpmyccA9a9D0WIXE3IJVFyeM1ymjWwhhUMBjufSvRvCenbrQSsPvsQvOKALlikSsFkHGcZ7VLqkkVvbgxsT2wOlWWtsyuu7CKMY9TWRrhWCFY0wecnmgDm9TlDksAAuc8VxOrzb7gKpG1fQ10mvXaxQOxJ/Pqa49iHOSDk8k+9AAjEN978aTP3jgEZ6g8ULgoeSSTzx0FIm4qy5HSgCVWIGAMDPNI/zP0J49eaRSCwyB/SlkAYFmPIIwPWgBAx+7nd/SmgYyBj1oUZkCrlsHjjpQInViJAQM9MUACA7iOgPtWvpzYPy9uB7VkhgWAB+p9K0bR9oCkEA+/egDXE2ABz+VFVi2STxRQBwrBdqkZGRzTByMkZB61M/zKvPT8KiOd3NACMxJ5J+tKB3xzQQRgr8x+lLj5cn19KAGkginZ460i8r0HHNGOcH9KAFOD69KQ5CdRj2ox8o4JFDc8jpQB1Xhlh9njycYPT8a7PTY/NmTn5WPIA7VxXhhSbSPHPJH613nh7AvFV9xwO3NAHQLZRqg3QJ6DjrSwxKWUKqqOOAB+tabAMpyOOOvbiizhUuNikN15PagDnPE0H2d48AbiMnA215b4yk3SoB93ccce1eyeNwEsYi4Ckt8vfjFeN+Ll3eSRgHcRyeKAOcRgOgyfepLW2N3cxwqcbjg57ComGP/ANdbvhSHfM7HHHFAHeaHYPsSKBTkDGAK76w0VrWOOSR2VnHIC8Af41S8HW8SWolIDTOcDPQAV17r9sUBjiTlcH+L/wCvQBnN9qsmAQxyx/wkgHFbfgiCfXfE1rBNFAtlag3FwF2gyAfdXHfJxn2zWVsKSmIYA5+hGKfbzTaURqNjKEubcF4yeR9CO4NAGZ8ctETQ/EoubaALp+poZVAACpKOJFGPqG/4Ea+e9Wm8y+lYYYAAdOlfYviqOH4p/Cy5k0UBdRg/fxxNwY7lBloz7MpIB9xXyA+k3z+GT4jeAx6ZLeCyilfjzZSrOwX2ULyfU49aAMzoOTWhotqbi4V2GEXpnuaq2sLXEvlgcnr7V2ei6c3yRQJuY8Y9KANDSrQz3CxRoCxGOBXpmnIltbJDEBlV/I1gaNaxWUTiMHzf4m/oK24G2ngFlUc5FAF/aFtjI3GCa8+1W7M93KScDPAJzxXa6vcH+yJ8AE4PevOrxgqyFxjjIoA5LxDctLeFB8yjnGcDNZkYO4HA55PepZ5GknaQ92POM8U2MBvlJ7UAMDKWOCeuOKkUfNu4B7D1pCu75g20Hgg0mB/Dz2FAC4DNgAg5qe2gN3IFUkRjqaijjMsgVT83oa6aztxFCE2gYoAggskiwdq4PHT9amlt0ZSFX8fU1fhgDyRooz61qeWSjqwUJg5GPu0AcDf23luNuMHkDFJbRktwGz3rR1VQE4OTn16U/T8LjKjvQA3ypP7rfnRWqJEAA8oUUAecTRFYweOetQEc9aulVWLoQDwM1WXAYAggGgBoBCjBwegx3pvJwN3I9ae45GMHJ4GabjGQQc0AJjGefelQL0Pr1pQuDtJ59PSgZySOe4oAAvIBYKCOrVH/AE9qkP5H3pr9OeKAOq8LkCyQ4Hft15rs9Bk8vUIGJwQwGR6GuN8MAG1QPxye2e9dXa5FxHgknIOemKAPThAFMbD7vOR2p2mwbrvIGTzgdKntubRB36ZqW0zBcq+MgHHFAHIfEskTwRADaiE7c15B4rx9nt+M/Oep9q9e+I4/4mCc9FxXkni8E2cZO0gP6e1AHKnkn0rp/B6jy2buWPOa5g56Cun8KcQLx1Y4NAHtHgyWGeyMbuVngO7AH3kP/wBeulhlPmCQZBOV47muC8Dy7NWQAkeYjLx07V6N5GzdLwcFjn3xQBXQhrvLA5dv0qvq6w29vI85mWBSQ/lYLY6cA8E1NbKxlTbjg+tUPiBMIbNIgMNK2fwoA7T4M6XodvdXeo6D4jvLyeeIRzadMiRNGVIIZk5JIzwwOOTya5n9quxhs/hlocOn20dva2+sIFihQIq7o5ScAepJP1NeJa/fT6f5N7YXE1tqEEoaGeF9rxkHqCK1/EnxV1Dxr8Pf+Eb8TW/2jU4bmK5g1KHCiUqcESoMAHazfMOvHHegDkfDdmWVCAQ0h7npXqWkaR5dkTDGrPxuYt8xHtXE6NAQi7VwBzwOldhp15NGwE4MkQx0GCtAGvAjQDc6kH/dNW1kAHBOMY/CpoJt6DyT5qEcBXwR9QatIA8EjSWrDnqQOPyoAyNQHmadclcgbMADHbmvOddcR2coDEHHNei6vLbpp0jQlkYKVwx6k15X4onXbHED97rn0oA54EBiG5IOB70v8I4OBxTCpKkZBHUHNOTnHOO5waAFAw4IJPueaGIJJ2nB9DSZweuMnj3oCkvt4JPTrQBq6Lbl5DKR0OBxXSRJkjJzj09Ko6VbmGFFwVbAzW5a25kbCYyBnNAEthaFV86VSGI+RR1+tGof6Np5wCGmbv2ArWWF3UP9wDueQay9cKvHHFuyygk89M0AcPqj7pV29yQAaksnkBGScAce9RX5xc4J3DOKtwumwBVFAGiso2jK849KKUICAcjmigDgWA5XIGPyqvgnnA4q5Ip2gEAcdqhAIHy/rQBXboAFUHnnHWkKnAABzmpcccjjtSADP3uv6UARgYYnv6UvJGB+NOAOT3zweKO454oAaAQQAcDvUb9OSfbipX4HHPbNRuuF5H50AdR4XOLNM5HJ/nXU2xyytyTxn2rlPDAb7IueBuJBz15rrrTBKcjO4dKAPVbIgWMeMElVqwxXI4G7nOagB228Sk4woPFDTE4xyO5xQBzfxEQ4tJQBhhjP4V5N4oi36bKdvKtuzXr/AI7UT6JBMv8ABKAfpXmWqwiS2miP8akZoA86Lcdea6jwvn7GMA8H0rmbmNoGKupGD1rr/CkTGyjYYAIyPegDu/Ce5tVtA3Qt+NerjLQHKgfMcgcV5Z4MRjrtuCSMKWr0y4lAb5CB3IFAElrAhkAJGSc4rkfiO+L2Ec8KfwrrYZVaUscjIxXH/Etg9/bdcbCfrQB5L4wb9yvzcFx2rF0NA92N3O0dK1PFpYwoexfH0qj4bYGeQn2/CgD1vwpbotpEQihmAJwMk10tzHA0J2ogkXG7auCa57wgwms2UY3Rdf8AdPSugt1CoTIWA5wcUAZyWpaU+R5ic/wcA/WquoQTW3zmSUjOOc5zXTRW7LEueS3TBqj4qfzLaKRfljDY56k4oA4jVb0uT5kmdvOOeK8/1K5+0XhP8IO0V1XiScRWsjHq3yiuI7txlfUGgCYAnjI5460rRjd8p+q5qNPl2lsYHQZqRHAYuxyxOOOaAGyna2FHPerul25mlVzgIDxxxmqqr59wiRct3rqdMtfLhVRzj9aANGwh6bVLMTgY4rfjs/s6owJDY7DpTPDumPI3nMMqOBkd62Hh3Nx0T9aAM83aBXjcOjY5z0Nc/flFckEqvOK29a2RbY1+91PPSuQ127wgiBwSMfhQBiTuZJXZWOSx5pYpSrDr17CmEcN061Yt0EjqBj6igC0LmXAwTj6UVeGwADA4ooA5C6hkhA85So6YI5+tUiNy4JAAr0u5sV2N8g+ZSPwIwa4rWNGktwzwBmQdVznFAGMRnPI6+vFJgY5PJ4pWAC8dB14oUAAHK5J+9npQAgXIJxj6UqHDnIz6ijaSf4cHnFByuOCPfOaAI1I2neMr9elRyYK8D9akZhg4HIqFyAP14NAHWeFQBZJvHOTgZ967PR4BcalbIoOTKuQeuK5DwxzYRnPJ7fjXovhWICZ7l8AxjCgjuaAO0unDzMFxsX5Rj2qiJuvzDI7HkmlPzNy4YYycDOKhVC7Z+UjJ74oAdeCO4sLi2lbMUvTH8LcYNebajbGNnRlIZcqcjoa9EuirAIqlRtB5PGfUVzGvxo75dgMg9evtQB59cWCXE4VlDAnrXT2cGxY40QqFXAxxgVUEALjJ79K2tKs5bmeOCDcXc7eelAHR+B7TFxNcyL8oGxTjvXWyjJwmD6454qhaxQWNqLaEnCtkkj7x7moftMhkGG+ZjgAcAZoA043LRZznjI5/Sub+IShpbGQdCmMHFbNo2Ywj4zg8GqfjOAy6RDKq48tgDjtQB434yty1gHQMSj5P0rG8MqWnkK/dAGa7PV4d8bAgEE9KztKso7RGVEAZ2yTigDtvALD7VJGzEB4yP1rs7qIrCAuSH5Nch4EgaTUvcYPTjrXc6hsaTYg+UHr60AP0lmSEiT7mc81yni67YSJBkDaC5AA6npXYR7Y7PeOSp4GPxrzHxLc+bqE7M+eQOtAHF+LLgqIo8jlskGuaJY/dUjPYHrWl4km8682qcgdqySRnIwoBxQA8yurDy2VPXuakd8jgbs9ciovkKjOO1WtLtmup1wP3Snk+v1oA1/DtnhQ7g7j3Pau80nTA6iS4yI+oXPLVjaZaBVXH3uecV2dpCzQpkMrFRhgcg0AXrbCxqEXCYxjNSvMsFpJLIvyr68Z/CoVRkwMHj9KzvEd1tiWBGDbjubr296AOX1S7lLtKyKFPzMScbR2+tcbdTmeUuzZzwAB2ra8Q3RC+UD94/Xiudl2hwWUk5wCB0oAerKeCCQR1q9ayBHXGcnpxVBRg5BO30rV08RMqhscetAGhlTyY8n13f/XoqYJFgfIv5iigDpXhKjYwJI7Vm3dsJA2V6nvXX63YCLEi5Ck4JHYVgSxrkjhs9KAPONf0lonaaBMgHLJj9RWFt+Qkj9a9Tu7YOpU4JPYVwOu6ebK6LqMRP+QP0oAylxsC569hzQQFJXOPf0qRQCrAgZ9emKZgYJ6qKAK7AgHODio3HB45qaTaAB8ufaon5AP4fjQB2vhhCthCMEZHA9a9D0F4jbLE0qxEdcgnFcJoQEdvEoPRcdRiu40WNfLEuct06dKAO2s49Pktz80q4XglOG46+tU0s7UO6xXkJbuGUg/yqWxgneMSiQogA3OxCgVdF/ZW8eJLiadup2hQPzNAGZcWSKu9rmPgYywIH54rltdWNgiRyxuwJLMn3a6661TSpCx3XinrggMDXMay9tKw+zK+znJKgH8hQBzKrg7ieR3zXS+FE2SzTjOY4+OOcmsNk2k5GAOmO4rofCs0CvJBdTGKOVcCTbnaw6dKANGDLLl2xglj9KI1Y4ZlJUEYxW5DDo8EGya+Z5H/AIYl5P51JHptvL8i74znqwyCO1AGWi+Wg2yEN3xzVi9AvLOWBj8smFMmM8+tabaSPKXbNCZOmDkZ/Os7UbC5tYMSKEBP3wf5UAeb6jBtd0bBIJHpWfBENwBBwDjrwa3dZ2vdyFeecE+tZkSYX5R79aAOx8EReT9oudo2jCqfeuhLh2yfx9KzNGtvsui26NlZJTvP49KuD5CWPIHGPWgC3JKgsp1IwNu/p0xXkGq3G/cSBy2a9PvZGOmX7BgdsBAxXlt6jOCpIxx+FAHDanJvvZCMZzVXhsYxt9qsakDFfS7vvButVvvZA+9nj3oAkQGQiJMb2rs9GskggCBBnbk+5rH0OxKNvIXzD7V2ugWpmvYYwM5bkewoA2tI0otEJXjAQjAwcVqWsv2MBW+aHGDnnbWtHagK4IbykHbkg1UW33h2kwsYG4kmgCvqd5ELfMEwYegP9O1cjq10/mkupxgEFu/tVu8mA80x/dydv0rktfvjjykOGYZP0oAyL+Uz3BfA25wMdqrcr1IUEcmhTjI7UoYH3OODn+lADgSMlun86sQsQ6qAxJPYVWAODlRzQqs5+Vep6UAb4uwBgg8exoqiLAEAlv1ooA96jjWS38u4GYJBtJzyp9a5fUtOeymdGIaMjKOP4hXXz2/7yRVGFU8d81TvLUNZmKUjCndGc9PUYoA4maEMAeAelc94hsEubSRHBzjIye9djPb4LccE8Csy5h3KQOg5xQB5HKpiJXDKV4OfWoXIxnJGe/Sui8U2SxXIlx95sNj19aw2AYKSMGgCq44J3fSonCtyf1qzIoHXGc96ikUbxj6UAd3oqqyoACDwenFdhpkskDB4iyA8Z65H0rldAQtHGRg5HPFdnZxfu8cgZ70AX4o575/nd2wOWZuAPQCti30uI4LAucdzVrS7PyoASM5APpk1aQgY2/K1AGPqOjqqFolKHHrXNSRsNysMHpjPSu/UM7BXGeSPWuV1e28u6cenWgDmHgJMgB5zxuq3D8kYzzjqBzUrRfPnbQE7EEHsRQBv2tiUZHt4WkyMhwdwratQ8KDz7hV9g/P6Vx1sJAVETOpPXbxW9bQvt/eSl+nXGKAOllvUkC5ug4xjY3Q/pXKa3GZC8n71e4w2VxV94mIIRyuO/BrC1KScsUlkZlHGM4BFAHPzht3BAAzU2jWJubqJAPlJ3Pjso60+eMkjAHpk1u+Hrcpas6KN8mUHsBQBr+bmcfdCheMdsVRDiSdiduHJ/AfStCGxkdAu9A7DnLDFMbSrhQCq7iT96MggH35oApgtLHcwgjZJC64PtXnl2G8sAHOP0r0WaCSGbC7g4I5x0rhNWhUXUiKSME4zQByGsWiTNvYDI9qqWtoqycKo9sV0lzbFyc4Ppn+VFpahCOOfXFADbS3EaKAM556ciu/8F6fgtdOpDbSFzjpWHoekvf3A3HES8sxH6V3Xy28KxRjaoHQd6AHQwM7FuOtU9flFlp8mSPn+UDPNati3ynp8o3EY6AVwfiTUjfXjkOfKThFx196AMK/uRFG7nIRe1cRPL9onllPU9M9a1/EF2XcQqeOp71jDby3XPPSgB3PB4oyCQcKc+vpTAxzxgA84xTucEg546dcUAKNqjbg4Axj2qzayKDgZx6YqsobcGx1qSL5pNu2Qds44oA1ftC+v6UVGIkAxu/SigD6D02+t5YLYOv2i6lAUQL6irN9CqBo5QolxgjtH/ia5/wAI39vbhzNOIHYYD7Cxx3xjpWybywuXeG2aZ1xzIU6+9AHPanbqCCeSD1x1rEvEyAWw+OBn0rp9Tt1lICFx6A1z12rIzLt+ZeCD6UAcb4otTJaOMdsjPNeft3UhgRwc9q9Q1KPzAdx46YNefeILcQ3IdeFYnP1oAyWzjnHWopGGck8jpipHUtjP401cM6LvXGcckCgD0zwumYYyBkFcjmu40q3aRowq7mJ4UVxfh+eBYoVWVMngANyT6AV6V4dXa5aRMMG2OCMFfw9aAOzaxkWFt2z5FGR14xVb7AZlXaRGRkYHQVetLkwW5dt0iYxg85pJHaQGSVSFI+SFT19zQBRa2igTYZN7k8pHyxP16Cuc8RWaxRJcJGYzIxUqWz0FdLJcO6kRqqY4OwY/WsrxgnlafpcWPmk3ufftQBxSoe4O7060xEO4kDP9K0BFtJ6elIY9re/vQA/ToPlLdT0UVtRAAhcDOKXRbTdHGzKxbtgd6v8A9lusrNu3ADqvb6igCsA2CwGRjFYWsxgmJggBOc8V1UNk7KfNPfqcYrI1qD92W2qEU/L6mgDkmTD/AHc+ma0NKWaIBlDvGSRsU8H60x4v3mSppYElDnySw3f3Tj86AOmglUld1ukAwMjIOPekvxHGGl8yMITkkKRn8qy47VhGC8xJ/wB3p+NV7t7y2RmSUsgPIx0/CgBl9rH2dmSNHY44Z26e9cjc4aTnknr3rYvHeSXzGAXjoKzZY1Zwxz7DFAFOKDznSNVbcTjHSunstDtYWQTjzGI3EdPyrOtF8uVflBPTBrrrVReQbSdkyjCllxn2oAZAVWNEWNYkPG3pxS5Z5Gdfu9BSSBo1KyKQw4xjoabE3BI4PTFAC6veLZ6M+CN8zeX9R3rzjUpRGjnO0Dn2Ndf4on3W1qrEEKzE/WvOfEtztj8voHJHSgDAuZXnuGdsDJ4OaRs7ffFMjIBGTgAc5pRgc5/OgBVGTwevp2obJUkHOOnvTsk55B7cCgL04PsaAHbiFwOTjHXFS2soDLkVEMoe1PiyX4HHrQBfNzH6H8qKYIxgcfrRQB6fp0u7YgOCxA68DNd/Zww2lisUS43csxHJryTRNRBjicMNwr1Xw9J/aOmGVH8zA6Dk+4NABc26su6PJx1xXNa3FskUgcsMZz6V2dgoeNkbPBOecEYrO8T6U8mmSFNskkZD5AzxQB5ndoCGPU/WuW8QWgnifaDk9DXZTxEnIAGeeKTQvC9/4q1ZNP057aJ3B3SXEoRVHsv3mPsoNAHjU+1d3mNsUcHNfUP7POnT6vpc8+v/AA+0G3tAoFrqn9nxwyT4xkGMglvXeMD610XhP4TeEPAkLa7rrxXl9aKZJtQv8LBB7pGflHsTlsmvNfiD8YdR8V3Yh8NT3WmaJC6vvPyz3TI24MccqnAwvfv6UAe3+OtVs/Cfhhns7O0gurhjb2ixwqgVyMl+AMBRk/XFePaVefZZBuYsGOGJ5P196Z8RfEg8V+NbiWzkZ9Nsx9ntc4246u4/3m/QCobaJVjXOSR60Aei2sjXFoPJ+cKoKgcBx/jUc0rlX3qRhsFSayPC96VlFmWA3D90Txg9cV0V9GUGX+93oAos3mMFC7SRgHsfwp3j+3CxaSyrx5JXpTbZMyjPHPWtXxzCJNC02XA+Rypb6igDz0rzwTionQuMnAA4z3q4ynioJEDHkZNAHUaRHN9i3QAbk4JIyFHXNLJLGZ8u8jP6qcgU3QN01wkiKSroUbb6kd6hu4Gt5WjJBIOD60AaIuLZcDErnvuGBTbu4XyMskWGHTHQVXgtljsxPMCvPyLn17mkkBkQsctxj9aAOZ1WNVvMqANyA4A4qTS7cvucj5QCcnjpRdlZ71wvCA7Rj0rahVY4WigB4G1gwzmgDMUFwvTIODg1FLDuGw8gg5wD6VeeNo8Kylc8YI70qII2Lvg4Xgg98UAcfNEAoHfpk96qiIEEYrpLq0WWJnIG5ec+1ZaRgt90ccelAFSIGNgwPK4ODW7p00Mrqis0E/o/KN+PamLYIiBpowzMcgZpLiwjZB5SlJB+TUAbEdyoYpKibehEi5Kn1B9Kq3T2pBWJh5gzwRwPpWcL4vb+VcHDIMK3t6GsnULnzOhJQcc0AZ+vXSs7xhtyoOT2JrzjU5hPeMqnKDgYrtPEtrPY+F7XWpiqWl5NLBBn+LywNzZ9Mkj8DWn8J/hBqXjIw6rrZm03w9uBBK4nvB/0zB+6vT5z+GetAHlqxSeQ8wjlMCOI2l2koHIJClumSAePalA+X5SM9PrX0d+0ZY6J4e+GGj+HdHSzsvJ1KKVLKNh5pQRSgyMPvNzjLHqTXzf264NAEqAfe5oz8p+YE00EGQEAnA55xSuVA3kHjr8tADmJJJGeOoxUsE22QKhGSD259OTUB25G0/0pVyrADJx/nmgDSHmYFFVA74Hy/oaKANjRLgxzeUxGzGQO9epfDrW/7N1+GJmH2a4YRyA9M9j+teOWsvk3kbBsg8EV19jI4CsGwy8gg96APd9YtvsGqPgkQN8wA6YNQLdRxyEFfMhIwQf51Ld3P9peH9MvCQ8hhAc++BmsGRnXCMxGe47UAYPivRW0+bzoBuspOQyj7vtXI3cKtHuHJU5DDqp7EGvTpLh0iKS/PG3DIRuGPxrB1LT7eWN/IgVMgk7Rg/hQBwfifV9b1zT4dK1bVr68sI2DJbzSblyOhPdsdsk4rF0+yZJRGR8g/iA6+1dEti0s7lgBg4GetXI7OMDYOv8AWgB2nxrEoCKOOmTW/a8rtz3yRWdY2bAHzMNitiBNuO340ASRkxSB0wpQ5z716FbSR6nplvcKQX27WGO4615+B14/Oup8FXmJZbI4AI8xM9N3egCygMc25SOODmt7Xo/tfhKYKQTCwkHHas7UYSkmSCN3K8YzWvpf+mabeWrj78JAGetAHmjqCD15qB1IYDII9xVtlMeVYdCQeaikUevegCfRtRl0e/juYCCoYb17MO9eheI7ewaeO7gtkxcorhwOCMcGvNCvBHb0r0LSnN54Osy+WeEmM47DNAGBK0s0gjkO5A2fpVnWk/s/QmdSA8mFXmmKGEmQOAeuKs+PvlstPiHCsufxxQBw9oVE4yce5FdRZxAWsdxsyjZUkf3q5cDAwAa6bwReul7cWUjiW3nhYqj8gOOf5UAWJpoGiZdzREYyPvfzrLiCSzqySKY1IJLA/lWrfix3GRrUhjgbRIduaq6dAJ/tMj4itYvmIX7v/wBc0AYepykQOxUBpT8ox1Hc1S0q1+0XA3DCjnmi+uGvbsuxxGThR0AXsK19HtF2zDdt2ruGaAHywxGV87QOwxkVnTpsuoweY++O1aFwpL+Wy8nuP881UCKciTbj2oA5q6/1j5GVzwc+9RaNo114j1610mxBWSc5kfP+qiH33P0H6kVs6hFbtE/lxJEAOoJ6/jWRpfirU/DP2l9E+xQXE+Fe4ktxLJt/ugngL3xigD6B1Twn4fvNP0u2utIW7tNGbzrG16gOFwPlJAYn/a4ycmvnz4mfHDxXPqd1pGmWUvhVrdtkqygPeH05I2oMf3QevBrnvEPxg8eveNDH4iNvFtx+4s4U6987Sc/SuI8QeI9Z8QyRS69qtxqMkQwj3AUso9AwAOPbNAFO6nlurmW7uZpLi6mYvJPK5eRz6ljyabnKnOMetQhsjIwe3pTwc9fzNAEuN2CORjg0EkH5iMj9aYjc9TnoKdnBwT170AKxyQSevfrToW+cZ2/SomJ2naCMHFIGYFuaANkMuOQ9FZolfH+t/nRQBO2UdSDgqQRXYaS6yIpJ68dcCuOucqSR3Fb3hu4DRKpIBXg5HSgD2/SLxoLC2gVtgRMY/CpWzIWIBADZJNYGgHz44mDEDHIye1ei2VppkVgr304kYqcJGcsw7AAUAcnJucHgkHjHes7UEkigf5cufuqRk127R25INvb/AGdT0VgZJj+A4WsLVbTrjag6kOw3f40AcMkDhWaRSA7cnFOSP97yM8dK273ykg8lGDMTng5wKoJDyox+QoAlt1Pl+3arsag9+/XNMhHZhwB1IqdBheByOmaAEYcAcYqxp1x9jvYJ1xlWx+B4NQBVC9BkdKZgk8cY46UAenXaJLaxsG4OCD6UaKzRXKFTkN8p/OqvhyYXmiJv5dQQc9qltz5UgyM4zyRQByviS2Nrrd5GRgF9yjHY81lOBjrXWeOIN0tldgZ8xNjH3HSuVkQHGCDQBAVIPHc12/giQyaPdwnqrEj24ri9nI459K67wKcG7UEfMB270APGEuWYDBPODUPxGIebTgO0Z/pVy7ANyxC7W/u1V+IKZj06TGCUNAHEsAHzn61o+HH8nXbBueZNv58VnOWPXPPpV/RAf7VssDgSqf1oA6HV4/LmdFxgMSah1xks/DW0ZDTkA47iruu/PqEgbAUtxxWX40Yi2sIWGAE3YAoA5DI4J9cj1rufC8Ams7i4TayBCD7Vw205zuH0rsfhzKRealASxie0YkZ/iBoAxtRObklWC84BNRm4XYWcnzD6dD71JegiYhurDmq9paPLcqCcKeoAoApaqRFZCQ5BkG1FPf1JritSKFW6/ljFdX4juftN+QBiOEeWgArjNVc7WJyTjqaAOB1gh9QkZTkggdaoqcHDZGe4qW7YSXczMf4jgH0qEZxjNAEnAPHNGTgYBG6oA5yeMHpxUqu6xldxK5zt96AJI3+fI9+lSRtu6E9c46fnUAJ6ZBHpT0ZtihiNqdM/yoAlKkdCckZ6U0r8g6nOKaCQcrjHpmnIvzEEZ44OKAFxjjav50U4g56p+ZooAuXPJJB98E1LoV0ILspnAfpz3qGfIKjGR61TZikoYD5gwIKjH60Aev8Ah3V3tYyqcnOVPvXbeHbiOS3e6vLpAc4OSMgDsBXkui3HmRRc/eA5rs9JUzSoin7xGPpQB3P9vvKGg0izITGC7HGR7/8A66p3Nldzp+9uYgSeVVP61f0uBVTYiYQdAP51omASYQDaMHnGTQBx1zpjWq5VxL67eMVAkeTkD3NdnJYkMDLGwUrwxHGPeucvYDaz7TnY2SD+NAEKrnPApwBCkZxn3pVJBGBkU5cNk9SaAIm6dMe9NHuakK89OAe1Ifuk4I5oA6/wDKvl3ED9QdwH1rVkXY0gcZ549zXMeDpSur7edrL611l58krgk+vSgA1O3OoaBLEBukj+ZBjniuAY5HIxjrXf2Fz5M45yrHBrl/Elh9g1JgmTFMN6HHHPagDF25z069a6nwO7LNOvbArmJAc9ea6PwowRUPI8yQAH6UAat+n+lknsSMj1qv45iL6NaXHGEO0+340t1MWuGzgZPFWp4v7U8O3VqPmmA3ID3I5oA82bggDrjt3rS8OJv1m2IOQGzj6VmOu2QbgMg4IPat3wr8uptITgRxs3tmgDXumMt82c53Vl+OiRd20TH7sXIq6r7rncTnBznNUfGw36lGzc5hU5oA5ZFO7H8667wOvkxalcMMfIIl7da5cAv9PSut0qL7L4cRWAEkrl8E9qAMu9j8ybgEZ4yafIBaWE0hA34Kg0T5aUJk8cgdeaq6vIV050bOCQo/rQBx11/ExPJ5IIrldefbDIxHABIOeldTekqeefqK4vxPLttpNrADHSgDhC42nnlmznPambsZxQjOVOMenWmq5D5ywz39qAFABBxyacxHbOe4pivjPHB5pPvFt3HHXNAE5JOSvUGnqxz0WoA3QdsetSLzkcjuKAJyMNnj/Cmxsp4PHNO3ZVQDnHUE1Zto0JBIGM9CKAIvKP9wn8RRWtsi/uj8qKAILnB5X07VQlGcqvQdc1fum+UHk9utUZTyBjn1oA6LwrdZhCcEocY9a9E8PzrFOkkhbbn8uK8h0W4NteBWICuf1r0rQLtPtMLS4VfMB+lAHrumBSu5H3DGTkEEVdFzAkLsxfLj5SBgVh6bfyoVIkLI/IBOR+VawkBt8hgm7kHFAGnbL9rOEIAyMfN1rnPEtmYoRcANtR8cjpnqK0IJsEqgKyN6dMit22ji1uzltLxfmdMBvf/GgDzePIOBzUnAByeakvrKfTLuS0ugQ8Z69mHY1AhLZwRn60AOUjoev0oYL3NIvJLYJ9qHHPfpQBp+GsDV4WbgEEV1t05EAbcxHOa47RDt1GEZO3cTj14rpJJt6bMd+c0AOgzI5KHOOcVoXdoup6YYMgTIS0RP8AKseElSRk+vHWt2G9VQrKBwOSVzk0AcFNE0cjJICrjIKnsa39CQhowoUlAeM98VoeIrSK7iWdBhx0cdx71T0nylkeJuHZCVI7nGaAGyEE5HHfgVcgma2KneBjk1AF34MbqhPLDvj6VIwJt1cEgrz8w6/lQBkeKbBFl+1IqjzCDhen/wCuotCUpY3M3ALNsyfYVc1ZpLuKGJAGkUjpxgVbgto7XSI0beGZi5BI+lAGZbkq5OABgZqLxhnfYSgcNFtznPSrRRXV+oPXPoKi1ZTJZxxE7toGM+tAHPWNs13epCg+8cn6d66bVbld6rFjYoCLz6VS02za0geRgBcMM4z0HpVedyQD1wcnFADnbEzEgbwOtZ/iZjttlIwSu8gVcckyLknIGfzrM8SNm/wOdsYxz0oA5bUT8u49zgVwvis5t5Qc9K7bUnG1uDnHQetcD4tfFtJ6/dyKAONJJwc8HgUA84BP+FGV8tBghgclh0xSFhuGR+ZoAVmwwIIwRyacGyQD+QpjZycUZCnjOfegCTdnPGM+1TBhsGOWquhIPU46damHKgA9Oc0ATBhvHIq5ZfOQM5OaoDGMscZ557VatHxIMgZPegDT8r/aP5UUomXHQ/nRQBDONxwfSqcwwQRyPQCtG79QRnviqDj5cgYHUZFAFWThSwPOQOOv1rqfD2riWMRPtV14OT1965hxhjkH8DUayPDIskZxKp7enpQB7f4c1r7OyRXB3QdAe6e/0rvbeQNCEUb4iMhlOeD0IrwnQNUW6gB6MOCpPQ16H4W1z7K6QXEmbdsbWJ/1Z9vagDu0clSq5JAyDjBAq5bXrxkOrkHGcjuRVI+UdpLHDLkFTnP0NBfYe4U/dPrQB0t2LLxLaJBdkRXsYzHOO/sa4fUtKvtOmZZomMY6SoMo341o2lwYiR0KnP0PrWzbX7SIVlcBWHz85x7igDjIsleRhvQjFL1HseuO1dPc20M3mRyRqwY7g69R7isW9sHswGY7kb7px2oAXSTtvIjleuOfeumcrEoLAYbgHPSuUsCBcRFjxuFb8jsQyNwOoPvQBOoJbeSMDA96kjlw7hc7eo5yPyqlE7ZwXwAOVI7VciRujhsdueooAvwFZLNo2HXpg9KoWkDW90meRgquR1PpV+AY+Vh94etRXxEELOfmCsGXnvQBRbzEuG2kAA9xT2clAzsS2RjpxUgvYJgHMSrJ3Bc9fUVWmnDDahROe3NAFCWd4bss/LHAweOK0tUulaKNVDY2555rGu4Jnm37GIHc1Y85p4k6MBx16UAS24jVWZ8ZPB+lT21uruZCwEacc85NV1iGNxfCgZyeBWgs0aWSRxAO3LEn1NAFW5IePGFJHA461nSRYAAwce1XJuQdwJOeh5qKESTldqZ7nigDOkTdKJB0zWLruftZJJOUXk8ZrobmJxMBJuRV/vfyrC8RFTckocnGORjjtQBymoHAYAkAeledeL2U27YPVhXoGpE8hjjANeZ+LJixCf7WfwoA5wnrjIFLnP3s/nTeOMj1/CncH7vagADZGf0pSRzwSaaDjOeBTtxA4oAcOp7D1NTAAj7pA+vWoACQBTwzKRgnn9aAJ1+ZRlTj6VLDuAJ4GKhViAwx1PSrMHA7Z60AWxOuBlhmiq29f+eZ/OigDVuSd+CpXGMgis+ZeBg8EZA4q9chh97gmqDZDDG4+9AETEd+h746moSPl689gTUzgkZP3s/hUMh+ckfnQAWd09ndJLHnGcMPUV6Do2opLGrq3yNyK84kGD8x59qv6LfGyugrN+6Y4PPSgD3rwzrSKBZ3jE2zcpJnJjP+FdbPGUJG3krnjnmvHNIvVkCAkc9OleheGNXaQpbStuZeIi3celAGzGBuY5O3rxVq0k2lk3d8DjpmogEViy9T+ntip4R5gyvCoOcDkD39qANK2DsxUfeHXAo1H9zZuJVJU5IU8gH1q9YwCAJKwiCsAcsc0zUpFkC+cdy5yEHA9if8KAOOhXY25BjvW3DKZVJVRzwc9qfqFunlAlQGZgAehyanitynyLwq9aAIEuEUhY8ySjsOB+daEUs5TMcER9OGNO+yKI98QUzt1Y8Zqa2EuSJGYEdQDigCs91PCQ09vtT2NQSTSX3yBfLiXk9ya2JGLRSRvhownAbk5qhZwJCCCBycge1ADLaw+TcEyR3bmpHi8qM7mAPXAq4+SFyTtHTjgVFLvC5CBsdiMigDIlUk7kz0zx2qsUPmp5RKu/pWm6AREqMN2P8ASjSrZTdMzqG2AYB+mTQBnzQfwyNI/XPNOtwYhjlwex9PrWpJJtcsgVW69BUeVmkPmEBsemM0AVFRZVJt3+YdUfg/h61TlMkDjyWyONwNW5kaI7ojhwcg+lUdUumCgtGBIerZ4zQA3V7+MWuMq0obO0kkLXHX0jO7MzZZuSa0bo5Un5SM+vesa8c4IyvTvQBzetybUcD6V5j4im33ojyPkFeheIZ1O5i3yqCSa8puJTPcSStjLE0AMOc7gvHoacF47nnPFN5xgg8U4MNg459KAF6k465xincAc/iOuKanBzjB7U5cgZUsMccHBoAXuD1/rTlA3jI4HemqxzlsGnoe/HNAEgGSSCcDpzVqJyq84yfQ1UUgD5eD60oYKvOG+lAF7P8AndRVPzm9v++aKAN+5OWAwOO9UJQoHT8au3JHHqOtUpAuWOTgc49KAIXy2COOKhbgk5+bGB6VM+Q7kDGOeKru3zglcH3oAjPLYOT3qI4YHnJ71M4BXLHPYHFRkAfdGRigDovC+pHIgkJDjoemRXoVheZEbxnaVAPXvXjAdopBLEfmU8HpXd+H9VWaJZAQvABHoaAPabDUjd2iSj5nJ2yKRnB9a2bWeNJUDMSm3JVeNx9PWvMtG1J4JTJEzcjDAHtXTwaqPMUrIMt95scj8aAO2e5l4LDMjj04UdgKls4zNKuThDy5PRfWsizuS4BcMTtHFPu9QzG0EZ69ccEUATXN6L7UYlTIiQjaD1OO9bIGXYNnnvjpWDokQMzysPudPrW8r8HOBx270AXI4w0aEY4GORUjpkYyATxVSGfy+o3Z7dMU++v9lv8Au1IkPAJwaAHzERxN5rLHu/vHk/QVUgmVpF2H5QPpWVM5Zi7nczHqatW2VQMMYz0oA2FJZc8Fc9PWkuX2jBUbSeeSeKSzkGwlycd+KbeBgpwoKg8Z9KAI2fztyopAOMrnp703RMTtcycbVYnrj2FNd/Lic5wdjHjt2o0YJHpmW6yN1HXAoAbJATIcjv8Aw8j86RoWEoCfOx64HNWyV3BUHyZqLUNQjsYQluuZ36v6e1AFC8iaLcGZVIHILcfSuY1OcM21SHOc5WtO9hndS88jMT/CKx7u32Hcu4A+tAFCRx5WOPyrC1HGGAGT0+tbVww2EfxLyCOa57VZAo5x+dAHAeN7kQ2bIh+Zm2n8+1cF0bkGuj8byeZqMUSnIUEnA965wD0yR9KADJ5BPOO9Kp+U9DQcbmIwB6ZpB2GaAHqeD2pwP5VHzjHtQGwMLx+tAEwOV24AxznvQTkZzn1qPdgDj8qUHg80AS7mHAH0zTg4HfBzURPynPalzzkYAoAm8xvf86KhIbPG3FFAHT3HIG38qpTAKzd2ParNy2QT6iqMrbQCfpkd6AGy7gATgZ6DNQHG4hT706ZwGwDkDvmq75Eg4B+lACuQfvcseaZx0GOR6U0nrxjOec0xmOf/AK1AA2efSp7C9ewuA45Q8MP61WYnaMmmMOeSfrQB6VpGpq8akOSO3NdRZXRYLznIx1rxawvpbKQZ+aLOSP6iu50XWBLiSNyy/wAj70Aep2V3IEC+a23pgNir9vJ0JPTtXG6ZdqxRj0FdHazZHLZz0NAHV6TdiMOucBjnPvW0kkhYZB9sVxltKwxnI+prXgupBHtD7VoA6J5sDLHAXtTIIGvp8yfJFjA9TVbSLcXLNLMSUjIwD3NdApMZBABz0A5oApXVlFbwrhVOehPJ/WqlsvybR1BPTmtzUI2ktkKDcqjJIHArC0+Q5kTnj5sigDRiwFAI+U9/WpZgpToOv8XbtUKtlCegJ6mpHJ2sTyRxxQBm6ix+ySswHOEHHan2JP2OBVbgAn6ZNV9RJEG3vv6fhVS3vvJhKPu9iKANkzbMsGIAFZtipuruWaTlFGQTzz2qrPcm4+RDgHj61v2sCWlqsS43jDSH3oAzL4qqEDge4rEuctHIG3bcZ6c1v3ybfmB/AY5rE1BQkJPILnH0oA5q5AIYjOD1NcprgwcAYGfvV1t4RsfjBA4JFcfrRGCSDjHTPBoA8q8VSCTWWPOQuBgVjdjjrWn4hJbVXOQcis0jA4HHrQAYHTA/woI4I9DR/k0pJyD3FACH9O9Gee3NHf5qTqeOmKAFHHOaUnOM5zjvSHljzR3I6jt70AOBwfUU4MM46EGovpxTs4P+FAEn5UVAevX9aKAOkmcdTnHFUWb5SNucckE1akznhevb1qq4YRvt4HfIoAjPK4wASMj2qIHDYPJHelLNjIPI9ajGVJ4A45FACMecnPP86YzFRjt0pXA4GSOeh7mmuuDjrzQA3eeSKaDnBJ4pcc4zSMAeM/nQA0nb64+lOtLma0mMkDlT3HY01sbvlHBphHzGgD0fwxrS3UalmKsANwHY13unXnmIoDL0wM14VoVw9tqC4J2vwR616hod0xG0PyMY4xQB3cU5BGe/Ug1r21wvbmuVtJWdU/iz3rXtcYADc0Ad7otwhs02cHeSxPr2rXWbepDYx3zXB2FzLbtlTwcZUnrW4l2JH+R9wXqoOcf/AFqAO0gaO7tnhfHzDAOf1rjSZLW5ZHUq6HBB71q6XdEO3UEjt2qLxIUcxTg4d8qcd8d6AEivI9nJI9eM1Kl8pTbGrls9MYFYasRjd0z1Het3SUTzEP8ACOT6nigBr6fJcEGTLNjgDgCoptBkw2CqjqAWxW9K74KxLsHqOv51TnJO12bJ5HSgDmCJLO6HmKQyNuAIraaZZJPMDYWT5gcfpVbUIzPB82TIvKnv9Kyre8MMZUqGRuCp65oA2JXha4VnBEeOecnH4VR8S+SyK8TLgDAGeaz7m9UZMYbJ7MOgrJklPOWJ96AKV+w2uScKBXIaqQYDnnIwfWul1CUeW6sTzwMnqa5PVQPLcAZ9QB0/GgDy3XTnU5dvXjFZwBIOM1o67ldSkwuOODms9SMdcUAABJ6n86Xb8vI5p5I3gYxkfhSE4I6UANPfsP500r1qQDrjjJ546UgGRhc9fzoAjIK9ADQDj+I0/p1H1NIQD1oAaMdSDQAcf/XoK+lISemKAF3E9z+dFL8vqfyooA35iQnB4IzVV1KjHHzd8dqvT8Rnpx61nyNlsZAIHpQBBIw9jkYqHPOfWpnHJyR+NQkcgmgBrYJHXHWmn5gGBOaeQAxyTjsaZ1XANADP4iRjPXnihsHBJOPUUHg47YoHfnHHFADGX7x/rTCTjtTtxBOcnPamjofWgAjcxOjg4IbPWvS/D8pLowJ5XPPSvMG5PbjtXe+E5w0EDE/eGDntigD0ewJOMnnqa6LSoDMx3NtAPX39K5jTGzj1PrXZaYAlujkH52P50AakemeYiiKZN57Pxn8aml0rULNVm8hxGRgOh3D8xT7eQlflx0xzzW1p2oy27KqMGUjODyD7UAZFreTJHtMWTzyVxSXM8twwEhbAHCgHFdtHc2N4v7+3VTjJKqKc+l6a+GTIzQBwq8YBH51oaddmDhgHT0zgj6V1Mej6e7hQW3DjipX8LRsAYS3PPPFAGUNRtCozLjHHzcVDc3cJP+sjAJz96rl14SuAP3BUj3NcxqOm3FkoEyBccZHagC3c3cUYZw4d8dF71gSMfmxjOac4wMD1qFlOOP8A9dAEM7AljyTjmqckrLDIigbXAzmrU+FjznArNnOSQDwOhzQBlX4Yr8p4x68VzGqbjE33h69CK6TUPmUZA3Dg5rAvYuH38EDrigDzHxIm29BOQCvGfrWWCcYAH1rqvGFpmBbgDJXqfbNcsp5yQeRxQA7kEAkfzoXJHzDjtzScMynGMUHJPyjrQA5epx6+tOXnNMXGcEHJpy4DDOaAALhT3x0zSEcc4/xp4yQBk4604qDwOtAEB+vH06UHr0wfepWX6+vFMwcjj680ANwPb8qKkEYx0QUUAb111OAAT0HWqEw5JOcgVoSDBGRwOTkZqlJzjHyn1oApy89MBQOTUe044yVI9KnJO85B445qM/Nxnj1oAjOck4AIphBUYIPWlOCW25xmmAFmx3H60ANHHB/GjPIIHHoaDwTu+9nNAAA56+vagBhAwc0wjnpyO9SckjOTnrjvTXUZxg0AQkc4rq/B8uISvB2v3rmuAOR9a2/CDf6XKhBAIzQB61pZ4Unj1IrtNFxPG8PAYfOhP61xGjE7U5wCOa63TJvJuIpVz8pBoA6K0YoMYLE8E1sQfOw25wOR6+9Z9vDJOweJC8ZOdyjgZrobBUtmRgC0yjqR60AXNFszIx3Qvs55PHPpWuUtbcHz5DMR0VMAe31NQJDcXS+ZdyeVEOka8Zq5HLaQRAxQgt13Ec0AMjvLyRSbCwW3TGBJKefyqVBPJgS3BaTORzxQ11M6buNp/u1GGLMMKefT1oAsZlVyWbDHjIPBrF8T2095boIxgg8tjmtZFlbkEgDg5pZ9sVpJLL/CCQPWgDy+4geIskqkMvBBqs6YBGeR3rU1CZ7m7klfGXPAHaquzcxKgntwM0AZcygK2ASQc4zWXLGQzcfhW7cwsrEspUGs2WEux2jPNAGJdpvXggD3rCvI+TnOzFdnd6cfLYLIrMB93H6VgXluSMY6diO9AHF6nAJUKlcg9cjFedahaPaXLRkcdQcda9bvYtzMNnJHIWuR1/ShcxbkJEiA4549aAOMTPpSjk9Biggp8rgqQcEYo7nb3NACqcE5GPTNO3HpngnNR88kCnqPm5OB0zQA7oeKcMFgDknHFMD44xkVKmdwoAV1wc9vemlcn5u3tUjkAZwSQc01Gw2dvy8ZFADNh7Bv0oqbEnqB7ZooA27nKt0BxjnPas6YAvnHHtWjcsFz8uf896z2wckgjHAwcCgCsx2kE46VA3J4wBipnw5wcAe9MBABHce1AEDA4A7D0pgUDoMnuakwRu4yR+FKAecdMUAQFSQc4wO9NK4zz0qYjg4x7YpGHI6enSgCNjyCG9hTWVezZIzmnnJQ8Dg0hyeMDGM+9AERGRg5welaPh6YQaxAxJCtlT+NUWUlcgHjihWaJ1cZDqQaAPatDkHCjPArrdOG6RVXJJ/DmuC8O3a3Ecb5+8oI7cV2+k3Jhmjk4bHG096APSNB0iT7MoNy0atzx61vxx29kincrsOvfNZgcpbWckPzJKm5SemD605mydzE4GBwPagC/HdGZiSW68Z6D2q2srbFycj1rChmJfaSGXHToa14XRNqfMxyM0AXYC5PA6jj2qeMAEAt82cELzVUyF4m3ELGOgXqals3ymEXHrQBft1DMFRt2eTxUmpwrJYyLgAGixBILdB9KTVSVt8EgA9zQBwV7pwBLRscqeVPSmfZ/Li2rjJ6mt+aJTBJJlcDriqcUQlbLDr3oAwri3IcApyaoGPZuyozzgKK7WaxjGfn3cAisia1JlxwQwxxQByF2jH5sls9fY1k6hCSEcLy3UgfrXcS6XGAXadY++xgT/Ksw6aZJ9wkjcDhVGcCgDz2+tQRlT2zmuevrMqGBUhiK9V1jT45MiJArgAEqOGNcVqNoRlXTGPWgDyTxNp5icXCDkn58VhHgcjtXpmrWatGysPvDBrzq5hNrcyQnGVOBnuKAIowm/D7ivovWmjOcEd/WpDjdnoO1NUYbBzQA7A5z09acvBw2RzxQe5Axz2p3yjBGeKAFkYkkMCOOO1NBGMn0poIPy9zQTnIPA/OgB/mEcbVopNy+g/KigDbn5TIAIPAweaoycSc9qtzOwHfjn8KqPySR1J5FAFYkhSDnHvzimEDaAo564zUxzj046UxwMfKOg65oAiXK8nkHng0hILMMnGKcEIJGDn196a+dxBGB7HFADCfmIxTSoz0ye9PHXPYds00LhwCRjHWgB5BHYAdsUx1BVefofSpWOFI2/iKYx4JA5xQBVfjoDmkcevHrTx2559uaaRgc/yoA7nwNceZYbMnfGxUgHt1r0fSZflUE5zxXj3gq58rUZIQflkTIz6g16no04JBJbPTOOgoA9k8Nz/bvDhj3KXszxx/Cf8A69XYXzEFf0zjHHWuZ8BXKx6iLeRh5dyPLbn1/wDr4rpvL8md4WyGVivX0oAYrYYgA7M9Sc1fglwVwRuJx7kVSJDQq+wE9DUttIF6ffX+VAG1AMNgMrDqeau2+PM7HJ521m27hlx/dwcY61oRsOmc/T0oA27RBgjByDVTVMY7k1csOIznjmqt8u6Q9vSgDnrwhbWUNgKVxgdz2qO0by4kVsdB2p2sowtlBxw+4e9LZuGto+e2Dg0ATzKHjKxrhhyD6iqEuE+Zk/eZ469aurL5JKyLuXtnsDUSwm5uljxwec+goApx6e9ypb7uOpLcn86qzW8NjDKsAMkx5JIwAa6iZfkYR8xj15yKxdRtwU3mRcY4UDBH40ActLHvw4XB6Yz0NY2saZ59rIwQbk5VsfpXTW8cURbcWIY5w3Y1HeOPOICgxn170AeOalCGRsjp2xXmniy3EV5HKgwGyCa9p8TWP2e5lCACNiWU/wBK8u8aWwNqXwPkbPTmgDjSSCDnPFJ3BGSfegKcDjnPelHUcHgdKAHLjOOePUdKcM/NkZyaZ3z+lPByxxg8Y+lADWxk7sEUnAfp19aeRk4UfjimE/Mdx5oAcGTH+rb9aKjOcn7v/fNFAG7Op2EjPuKpy4BAHBzmtG4HHAHHpVB+hY9/boaAIDgtwOgwaZJncCRwalxzgDj1xTf4eR36CgCBecgcmmnuOODnHWpScDCgc47UwAjv+tAEbKQD2z7VGcEHnAJ9KsMCQD/F0z61G64J4ORQAmTjGe/I65qJuSe3rUjE7QM9femEs3ykscdBngUARjqAcY+lN75z+VSP9OKRQCTkDPXmgB9lOba7hmUkbWBP0r1zR5lbbtY9AevavHjzyR24r0Dwbfebp8e9iZIvkbnr6UAep6PdPDLDMj/OhBH4HivXr5UuDa6iigxXcSsQP72Of1rw3TLjpnPT9a9b8GXLX/hOW3JDS2kuYwf7pH+NAF1ACrJj0wOvNRKSh2uCGIwPYVLECxkCZ3KN2cdqa6LkbM7Tz070AaViSH8vPII9q0oFxwOCBWXb5LgsBuYenSta0w3b5qANnTjiEg4JHFV9XkFvE8rDgDrVnT1ATHvVLxWudKlPcEUAcbNqDX8sitKsjQMFdVIJQkAgEduCD+NWdMf940RJO7kelfMXjHxdqvg/4y+IL7Spd6tLFHPbSHMU6CJMA+hHYjkfmK9y8E+MtJ8XWDXWizMtzCFNxayDEkDHsf7w6jcOKAPQfsxYEF8cce1SW6x2wdt+SBy3oKImEsUbk4DKDmorhtkLKMFj1z3oAZ5wMjBPvHr2BrLu5Y2dk6Fzg5PensAdzoWI9c1XcmdmJxwOT0JHrQBmyZcPvIUg4+XpURUqj/IQSOhHT3q3dJ+78xAQSMHcf1qC1DPcRqzkvn+Lr9KAOP8AGPyXotSF/dqCxPJJIya8q8ZQj+zrjHQfrXrfjQH/AISDUPkGSwOMdsV5r4niEthc4UklD270AeUgDv09qAcdVBNA9QKdgnJUDP0oAdyCM4x6U4EZ6getMTDN0JC9qdwWDMSPagBh4696Q9cEjHpUsyZHQjA6+tIVHIJ7ZxmgCLJ9B+dFLn/ZooA6SdRzj0qnKvyMBWhcnJBAyccnFUn74yc/rQBTHqg6D5j61E+S28DGff0q2RhSvQDqMdfeoWTOOACOeaAKxOVBxjHSmsD5mR1x37VMyjDDsO5pn8O4bi/cigBpwc5HPrUYOc9MnrmpD6ge3NR5LOAVOPX1oAa6kL0zj06VCcox561YYYTbx1601lI3Ej8aAIO5JzgdCO1Jkc9/pTzkr16U0YD4P6UAIRjIA4rX8KXYt9RaMn5JRj8ay2HORnPekhJikR1yGBB45oA9k0eUeXg5JXHK/wCFeo/DS+MWsNA5xHcREHjuORXjGhXSyW8UihsOoPeu88L6ibbVbOcZARhk+x4NAHr0iSQTsEY7AxyPY05wG2sF4PpxU1980wkByjANlecetSKim3IDFsNkE9waAI7TaUAUnA/Ote0P7zdg57ms6Hh1HQE8/XtWlbgq2G69c4oA27PO7Hb0pmsQ+fYTpwcr3p1oOnFWLpN0bA9CCDQB8R+KPAmp61ZeMvGksqx24upp7OL+KeJZSrOc9AEHHrj0xnvvgta+Fdb8M6fqFpotta69pjCC4mhZkfzAOHyDyHXkg8ZyO1eo6pp8F/b3em3i/wCi3UbW8i5/gZSp/nXy98K9bm8CfESXTtTnWKzlmbTr4n7qsrFUk9sN39CaAPr+xl820XPVTtpJCSNrEkr05qPR1VVnVx8w4PPerjAq+0jIycEdh6UAZhA3OVyGHOKqx8ysvIcD17VelgKnd844qvFhpAcAZGOBjP1oAqeWXY4IIbjn0FRPHsUrnDKc5xyKuvb4fO4BQefoafexjblTxgA5Oce9AHC+NYi2oiVxjzYlJPuBivPtZgykgbklSCK9a8XWwl0yCbB3Rsytx2Neaakgzt259DQB4TcII7qWMnhGIOPY0wZ2kfjWr4ltjba5dqRwzbwMdjWXjjI9aAFABYYPXjntTwdrleQOnrUYGTgAGpIx1BUZHcGgBRyPun8uKXAY8AHHpSjAOCcE/rQRxnOc/mKAF3LRQA+OAcfT/wCvRQB0lwoAOwjHUgd6oSdMEsMVozBV6kkYxVF1I/kPegCqcbSeCT1zUTgADvtHRT1qeZOCQwXHJyRURAyD1GPTFAEZAdQCBkEtu7n2qIqR97I9walYYGcZ4zimFcMM4G71FAEXVmxkgdSRSMuUBOCePpTiSNx9ODmmFskggA0AN2DA+X8etMcDnkGpsqBx/wDrqJiMqR+VAERU446UmMsPl9s1I6sQcjgDPA6VGfvDb9RQAFcEc80hJPQAHOc0/wCb04pGGOmfpQB0nhK8fYYmzlDxz2r0XTpydrA9uleSaHcG31BP7rfLgn9a9I0ucCNeuevFAH0VZ3Rm0+ynUBg0a7lz7dq1LaNmgc4yE4Bz27VyXhWcS+HrLn7vbPPFdRAFkjZAeMHaD1+lAEuGXBP48dK1IV8xVJ69DiqeP3aE5GBjNaOn7XGPbOfegDRtOuDV6TlRVGLIIwavIdyc0AedeIUEOqzJjq+Rj0PNefeIvhb4T1+7uL25sJ7W9nkMstxaXLIzseScHcvPsK9S8YW4S9jlAOHX07isVVyvOc0ASeFoBYW8FmZZJhDCsQklI3OFGAzYwCeOeK6cR4jGec1zVq5SYHHB46V0+n7bm2AP3h3FAFaeBTEw6bge+c1nxwYk2EEAjINbE0Z+4foDUEcOHG7k8jPpQBmoiKrpIR854pbuPCBtuQxwP6VcurT97GQT8nIxUjws8JOAM4PHagDnNUgBtJopyNrtgAn7uR/k15brdq6b1IO5eDXtV7Yh7ZmKnqp474rzrxfZqrb8ZBHIHrQB8+/Ee2FveW1yeEkjIYn1BrI8SeHtS8Nvp8GsQtbXd5aC9+zvw0UZdlTd6E7ScduM819U+DfhvCLqz1nxNaB57djJZ2coDKhI4kkU9WHYdup56Q/Fez+Gtp4ssNe+JFy73klssFvaOJXiZUZjvKxrluX7nHtQB8t+HNA1bxLdNbeHdLutTmT5mFvGWCj/AGm6D8TT9f0LVfDWrSaXr9lJZXyqH8tyDuU9GVhkMPcGvo+6+PngbRLNLPw9pmqXNopO2Oxs0tYFHqASOv8Au15b8Sfi8PHulDTp/BttCkbE293NdF57cnHKkBce68g0AeaBMEbiB+NIoYg9gP1pFHzdOT0yKcuOAMe+aAE2js1FIVJOQwA9M0UAdNNkAkn26VAw/EDoamlIVQ+Mmq+/GOP1oAjdCByDjpyKqzhh2JHtV1iN2CM8ZqB8Y5A9aAK2OcYyO31pjYDDdn6U9jt/A1G2OrZIx0zQBHIoAHGT35qJ1JGRx6ZqViCw46Cqyy/N939aAFfI46Z9BSeoOBnofSjzDhmHXFNDfOCRknjmgAwdvfBHUU0hg2MA0iyDGCtR+bhgdozzQBKuDxk59MUHnccHimxyY5CjNOD5Xp6UACHayuOqnP0rv9DujMkbZH3RXBFlxwuDjrmuj8NXDRpsA4VuOaAPovwLMkunQqmAdpx7Eda7C3lY7JF6AgNx+FeXfD26cRBABw+QT716bEwPOOMZxmgDftXMiZIAOcVbtWZZMnnmqVkMQEdhg/WrsON+McDpQBrDpweTVu3PHvVOHtnvVqA80AY3jC38zT1mUZMTZP0NckoIRWBDZ569K9B1RQ9ncIwyChrzwjbx1waAFIIXHTPvWtol6YpNjHBPqKys7uvcUkLYl4H3WoA7sxJMof17ig2yop3HPSmaU5a2+bnbVmQ/IFI60AULlHMGIQGOec+lV1glV8MQMjIGelW5HKHC8dqSNQRubkqcigB9zFvsXBXkKfzrzXxZblIgxBUscjt2r1dR5kLK3cV5B4juJZ7+4R2OyJiqL2FAHDX2ra9ZSTPpev6rZzEFgROZEJHTKPuUj8K868V/FLXPF2if2T4rstNvo4nMkFzBGbaeGboGDDKkYyCu0Z9RgV6NrChZfxI/SvCfEMS2+uXUaD5fMyPxoAz8sR1GQevrQCcc43DnFAYBDhR1xS5G4cD2oAcD3Dcnv0qT5e5x9KYjZPI4HapsgDge9AERU5/iooacZPyn/vqigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several small osteochondromas (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12849=[""].join("\n");
var outline_f12_35_12849=null;
var title_f12_35_12850="Dx chronic diarrhea II";
var content_f12_35_12850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to chronic diarrhea - part II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 661px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12850=[""].join("\n");
var outline_f12_35_12850=null;
var title_f12_35_12851="Chiari type II malformation and associated lesions";
var content_f12_35_12851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chiari type II malformation and associated lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, R, Strayer, DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12851=[""].join("\n");
var outline_f12_35_12851=null;
var title_f12_35_12852="Belladonna and opium: Patient drug information";
var content_f12_35_12852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Belladonna and opium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/41/26261?source=see_link\">",
"     see \"Belladonna and opium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/42/41636?source=see_link\">",
"     see \"Belladonna and opium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atropine, belladonna, morphine, opium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, drink too much alcohol, early labor, glaucoma, kidney disease, liver disease, lung disease, or seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet suppository before putting in rectum.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put in a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11170 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12852=[""].join("\n");
var outline_f12_35_12852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012757\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012756\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012761\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012762\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012764\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012759\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012760\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012765\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012766\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/41/26261?source=related_link\">",
"      Belladonna and opium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/42/41636?source=related_link\">",
"      Belladonna and opium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12853="Mitochondrial structure, function, and genetics";
var content_f12_35_12853=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitochondrial structure, function, and genetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Angela Genge, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Rami Massie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12853/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12853/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/35/12853/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial diseases are a group of disorders caused by pathologic dysfunction of the mitochondrial respiratory chain. They present with a wide range of clinical expression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/1\">",
"     1",
"    </a>",
"    ]. Although neurologic impairment is a common manifestation (eg, in the mitochondrial encephalomyopathies), mitochondrial disorders can also affect other organ systems, either exclusively or in combination.",
"   </p>",
"   <p>",
"    In this topic, we will review the mitochondrial structure and its unique genetic attributes. Clinical aspects of mitochondrial disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link\">",
"     \"Renal involvement in the mitochondrial cytopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondria are intracellular organelles found in almost all human cells. They are responsible for aerobic metabolism through oxidative phosphorylation, which leads to energy production in the form of adenosine triphosphate (ATP).",
"   </p>",
"   <p>",
"    Mitochondria are thought to be derived from aerobic bacteria that invaded the proto eukaryotic cell more than a billion years ago and lived in a symbiotic relationship with it, exchanging energy in the form of ATP for residence. However, this \"endosymbiotic hypothesis\" is not universally accepted and has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each human cell contains on average hundreds to thousands of mitochondria. The exception is mature red blood cells, which rely exclusively on anaerobic metabolism and contain no mitochondria.",
"   </p>",
"   <p>",
"    Mitochondria have four main compartments (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outer membrane, which is permeable to certain ions and small molecules",
"     </li>",
"     <li>",
"      The intermembrane space, which has a composition similar to that of the cytosol",
"     </li>",
"     <li>",
"      The inner membrane, which is folded in multiple cristae in order to increase its surface area and which contains the respiratory chain proteins",
"     </li>",
"     <li>",
"      The matrix or the inner part of the mitochondrion, where most of the metabolic reactions take place",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to ATP generation through the respiratory chain, mitochondria perform multiple other metabolic functions, including pyruvate oxidation, the Krebs cycle, fatty acid oxidation, and amino acid metabolism. All of these tasks take place in the matrix. Although any abnormality in the above pathways could be technically designated as a mitochondrial disorder, only defects in the respiratory chain are traditionally referred to as primary mitochondrial diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respiratory chain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory chain is composed of five enzyme complexes (",
"    <a class=\"graphic graphic_figure graphicRef82715 \" href=\"UTD.htm?9/48/9990\">",
"     figure 2",
"    </a>",
"    ). Their polypeptides originate partially from the 13 encoded by mitochondrial DNA. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Mitochondrial DNA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex I (NADH dehydrogenase-ubiquinone oxidoreductase) is composed of approximately 46 subunits, seven of which are of mitochondrial origin (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6). Complex I receives electrons from NADH.",
"     </li>",
"     <li>",
"      Complex II (succinate dehydrogenase-ubiquinone oxidoreductase) is composed of only four subunits, all of nuclear DNA origin. It receives electrons from succinate.",
"      <br/>",
"      <br/>",
"      Both succinate and NADH are products of the Krebs cycle. Their electrons are transferred horizontally from complex I and II to a mobile lipid carrier in the inner membrane, co-enzyme Q10, which in turn transfers them to complex III.",
"     </li>",
"     <li>",
"      Complex III (ubiquinone-cytochrome c oxidoreductase) is composed of 11 subunits. Only one of them, cytochrome b, is encoded by mitochondrial DNA.",
"      <br/>",
"      <br/>",
"      The electrons are transferred from complex III to complex IV by cytochrome c, another protein mobile carrier, in the intermembrane space.",
"     </li>",
"     <li>",
"      Complex IV (cytochrome c oxidase) is composed of 13 subunits, three of them (COXI, COXII and COXIII) of mitochondrial origin. Complex IV uses oxygen as the final electron acceptor to produce water molecules.",
"     </li>",
"     <li>",
"      Complex V (ATP synthase) is composed of 16 subunits, two of them (ATP6 and ATP8) from mitochondrial DNA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using the energy released by the electron transfers, complexes I, III, and IV pump hydrogen molecules (H+) from the matrix to the intermembrane space, creating an electrochemical proton gradient across the inner membrane. ATP is then generated, in a mechanism comparable to a small rotary motor, when hydrogen protons flow back to the mitochondrial matrix through complex V.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MITOCHONDRIAL GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondria are under the dual control of nuclear DNA and mitochondrial DNA. It was once believed that nuclear DNA disorders tended to present in childhood while mitochondrial DNA disorders (whether primary or secondary to nuclear DNA abnormalities) tended to present in late childhood or adulthood. However, mounting evidence suggests that many nuclear DNA mutations that cause mitochondrial disorders present in adulthood, while many mitochondrial DNA disorders present in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mitochondrial DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the nuclear genome is diploid, harboring only two homologous copies of each chromosome (one from the father and one from the mother), the mitochondrial genome is polyploid, containing 1 to 10 identical molecules of mitochondrial DNA within its matrix. This variable copy number, combined with the variable number of mitochondria in each cell, has important implications for the phenotypic expression of a mutation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Heteroplasmy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mitochondrial DNA is a double-stranded closed circular molecule, composed of 16,569 base pairs, that codes for 13 polypeptide units, all of which are components of the respiratory chain. However, each mitochondrion has approximately 900 gene products, including 85 to 90 respiratory chain proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the great majority of these are encoded by nuclear DNA. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Nuclear DNA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mitochondria have their own machinery for DNA transcription and then RNA translation. In addition to 13 polypeptide genes, mitochondrial DNA encodes for 22 transfer RNAs and 2 ribosomal RNAs, giving a total of 37 mitochondrial genes. The genetic code of mitochondrial DNA differs slightly from the universal genetic code of nuclear DNA in that certain mitochondrial trinucleotides encode different amino acids or stop codons than those in the universal genetic code.",
"   </p>",
"   <p>",
"    In addition to a different genetic code, mitochondrial DNA have several characteristics that distinguish them from their nuclear counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/5\">",
"     5",
"    </a>",
"    ]. They are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mutation rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial DNA has a high mutation rate due to the lack of histones and to damage from oxygen radical species. More than 200 mitochondrial DNA mutations have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Maternal inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most distinctive features of mitochondrial DNA is that of maternal inheritance. During oocyte fertilization, the sperm brings only a small quantity of mitochondria, approximately 100 times less than the oocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the paternal mitochondria are diluted with subsequent cell divisions and mitotic segregation. Furthermore, some paternal mitochondria are targeted and destroyed, possibly through ubiquitination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a fertilized egg possesses mitochondria derived predominantly from the mother, so that the mitochondrial genotype is essentially only transmitted through the mother. While paternal mitochondria transmission in animals does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/9\">",
"     9",
"    </a>",
"    ], there has been only one reported human case of paternal transmission in muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of events can complicate the mitochondrial inheritance pattern, including the high mitochondrial mutation rate and the fact that de novo mutations in maternal germ cell lines may affect one but not other maternal offspring. Thus, while most mitochondrial DNA disorders are maternally inherited, some are sporadic (eg, giant deletions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Heteroplasmy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each mitochondrion has several DNA molecules and each cell has several hundred mitochondria. In a normal state, all these mitochondrial DNAs are identical (homoplasmy). When a pathogenic mutation ensues, it is generally present in some but not all of these mitochondrial DNA copies (heteroplasmy).",
"   </p>",
"   <p>",
"    Heteroplasmy can apply to a single mitochondrion (ie, some pathologic DNA copies mixed with normal ones within one mitochondrion), to the cell (ie, healthy mitochondria mixed with mitochondria harboring mutated DNA) or to specific tissues (ie, some pathologic cells mixed with healthy ones).",
"   </p>",
"   <p>",
"    It was once believed that all pathogenic mutations are heteroplasmic. This view is no longer accepted, as rare homoplasmic mutations have been found to cause disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/11\">",
"     11",
"    </a>",
"    ]. Similarly, nonpathogenic haplotype differences are usually but not always homoplasmic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Threshold effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given variable heteroplasmy, not all cells in a tissue are abnormal. As a consequence, a minimal number of mutated DNAs must be present before respiratory chain failure and cellular dysfunction occur. Clinical signs do not become apparent until enough cells are affected. This is known as the threshold effect.",
"   </p>",
"   <p>",
"    The threshold varies between different body tissues but is lower in tissues mainly relying on oxidative phosphorylation for energy production, such as the brain, the retina, the skeletal muscles, and the heart. This explains why systemic mitochondrial defects often manifest clinically in these organs. Furthermore, the amount of heteroplasmy (or \"mutation load\") in a specific tissue often correlates with severity of the illness in that tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mitotic segregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organelles are randomly distributed at the time of cell division, which can lead to a change in the amount of mutant DNA in a cell and surpass its threshold. The clinical phenotype can then change in a previously unaffected tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postmitotic replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial DNA replication is not linked to the cell cycle. This allows for postmitotic mitochondrial DNA replication in terminally differentiated cells such as neurons or muscle in response to specific stimuli (exercise, increased metabolic demand). This explains how the symptomatic threshold can be exceeded later in life in previously asymptomatic tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nuclear DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each mitochondrion has approximately 900 gene products, including 85 to 90 respiratory chain proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/4\">",
"     4",
"    </a>",
"    ]. The great majority of these are encoded by nuclear DNA and synthesized in the cytosol, then imported to the mitochondrion. The only exceptions are the 13 polypeptide components of the respiratory chain encoded by mitochondrial DNA. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Mitochondrial DNA'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast to mitochondrial DNA, nuclear DNA mutations affecting the mitochondria follow mendelian genetics and are inherited in an autosomal dominant, autosomal recessive, or X-linked pattern.",
"   </p>",
"   <p>",
"    Most of the nuclear genes that are important in mitochondrial control are only starting to be recognized. Thus, in many patients with a suspected nuclear DNA-based mitochondrial disorder, no specific genetic mutation can be identified. Nevertheless, nuclear gene mutations are thought to be the major cause of mitochondrial disease in children and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic classification of mitochondrial disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial disorders can be classified according to whether the causative mutations affect mitochondrial DNA or nuclear DNA (",
"    <a class=\"graphic graphic_table graphicRef55067 \" href=\"UTD.htm?16/14/16621\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12853/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each group (mitochondrial and nuclear DNA mutations) can be further subdivided into:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations of genes that directly encode respiratory chain proteins.",
"     </li>",
"     <li>",
"      Mutations of genes that encode the ancillary machinery required for the synthesis of the respiratory chain proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For mitochondrial DNA, this involves mutations in mitochondrial transfer RNA or ribosomal RNA, or large-scale deletions affecting the synthesis of multiple mitochondrial DNA genes.",
"     </li>",
"     <li>",
"      For nuclear DNA, this involves mutations in ancillary proteins needed for the proper assembly or function of the respiratory chain proteins, or mutations affecting either the lipid milieu or intergenomic signaling between mitochondrial DNA and nuclear DNA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although essential for understanding the pathophysiology of these disorders (and perhaps important as a basis for future therapies), this genetic classification of mitochondrial disorders has limited clinical relevance at the present time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitochondria are intracellular organelles that are specialized for aerobic metabolism and energy production through oxidative phosphorylation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Structure and function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondria have four main compartments (",
"      <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"       figure 1",
"      </a>",
"      ). Oxidative phosphorylation takes place along the inner mitochondrial membrane, which contains the respiratory chain proteins. The respiratory chain is composed of five enzyme complexes (",
"      <a class=\"graphic graphic_figure graphicRef82715 \" href=\"UTD.htm?9/48/9990\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Structure and function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Respiratory chain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondria are under the dual control of mitochondrial DNA and nuclear DNA. Mitochondrial DNA codes for 13 polypeptide units, all of which are components of the respiratory chain. However, there are 85 to 90 respiratory chain proteins. Thus, most of these are encoded by nuclear DNA and synthesized in the cytosol, then imported to the mitochondrion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mitochondrial genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mitochondrial DNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondrial DNA have several characteristics that distinguish them from their nuclear counterparts. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maternal inheritance (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Maternal inheritance'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Heteroplasmy (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Heteroplasmy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The threshold effect (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Threshold effect'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Mitotic segregation (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Mitotic segregation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Postmitotic replication (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Postmitotic replication'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to mitochondrial DNA, nuclear DNA mutations affecting the mitochondria follow mendelian genetics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nuclear DNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondrial disorders can be classified according to whether the causative mutations affect mitochondrial DNA or nuclear DNA (",
"      <a class=\"graphic graphic_table graphicRef55067 \" href=\"UTD.htm?16/14/16621\">",
"       table 1",
"      </a>",
"      ). However, this classification has limited clinical utility. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic classification of mitochondrial disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/1\">",
"      Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med 2012; 366:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/2\">",
"      Martin W, M&uuml;ller M. The hydrogen hypothesis for the first eukaryote. Nature 1998; 392:37.",
"     </a>",
"    </li>",
"    <li>",
"     Chinnery, PF. Mitochondrial disorders overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1224/ (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/4\">",
"      DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/5\">",
"      Wallace DC. The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene 2005; 354:169.",
"     </a>",
"    </li>",
"    <li>",
"     MITOMAP: A human mitochondrial genome database. file://mitomap.org/MITOMAP (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/7\">",
"      Schwartz M, Vissing J. New patterns of inheritance in mitochondrial disease. Biochem Biophys Res Commun 2003; 310:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/8\">",
"      Sutovsky P, Moreno RD, Ramalho-Santos J, et al. Ubiquitin tag for sperm mitochondria. Nature 1999; 402:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/9\">",
"      Kvist L, Martens J, Nazarenko AA, Orell M. Paternal leakage of mitochondrial DNA in the great tit (Parus major). Mol Biol Evol 2003; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/10\">",
"      Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med 2002; 347:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/11\">",
"      McFarland R, Clark KM, Morris AA, et al. Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation. Nat Genet 2002; 30:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/12\">",
"      Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. MELAS and MERRF. The relationship between maternal mutation load and the frequency of clinically affected offspring. Brain 1998; 121 ( Pt 10):1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/13\">",
"      DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 2005; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12853/abstract/14\">",
"      DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006; 18:636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5148 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12853=[""].join("\n");
var outline_f12_35_12853=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respiratory chain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MITOCHONDRIAL GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mitochondrial DNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mutation rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Maternal inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Heteroplasmy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Threshold effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mitotic segregation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postmitotic replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nuclear DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic classification of mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5148|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/55/12148\" title=\"figure 1\">",
"      Mitochondrial pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/48/9990\" title=\"figure 2\">",
"      Respiratory chain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/14/16621\" title=\"table 1\">",
"      Genetics of mitochondrial myopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12854="Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones";
var content_f12_35_12854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Isaac Raijman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Susana Escalante-Glorsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12854/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/35/12854/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrohydraulic lithotripsy (EHL) is primarily used in the endoscopic fragmentation of difficult bile [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/1-15\">",
"     1-15",
"    </a>",
"    ] and pancreatic duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. It was originally used in the Soviet Union as an industrial tool for fragmentation of rocks. It was first used to treat bile duct stones in 1975 when it was performed through a T-tube tract using fluoroscopic guidance.",
"   </p>",
"   <p>",
"    An advantage of EHL compared with other methods for treating difficult stones is that it is portable, rapid, efficient, and relatively inexpensive. EHL is typically used during peroral or percutaneous choledochoscopy or peroral pancreatoscopy. Because these techniques are not widely available, EHL is mostly used in tertiary centers with expertise in the endoscopic management of biliary tract disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EHL has also been used for treatment of urinary tract stones, a setting where it has largely been replaced by other methods to achieve stone fragmentation (particularly Holmium laser lithotripsy). Laser lithotripsy for bile duct stones has not been widely adopted in part because of the costs and limited availability of equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/18\">",
"     18",
"    </a>",
"    ], but Holmium laser lithotripsy has been used successfully at various endoscopy centers, including ours, for the management of biliary and pancreatic stones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the technical aspects and efficacy of EHL in the management of bile duct and pancreatic duct stones. Other methods for treating bile and pancreatic duct stones, including laser lithotripsy, extracorporeal shock wave lithotripsy, and standard mechanical lithotripsy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10168?source=see_link\">",
"     \"Extracorporeal shock wave lithotripsy for pancreatic stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THEORETICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle of EHL is the creation of an electric high-voltage spark between two isolated electrodes located at the tip of a fiber. The electric sparks are delivered in short pulses that create an immediate expansion of the surrounding liquid, inducing a spherical shock wave. The shock wave oscillates, generating sufficient pressure to fragment the stone. In vitro studies using chalk to simulate a stone and a 3.3 Fr probe have demonstrated that short pulses of high peak pressure provided by a low capacity and a high voltage have a greater impact on fragmentation than the corresponding broader shock waves of lower peak pressure carrying the same energy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/20\">",
"     20",
"    </a>",
"    ]. Application of EHL is best achieved under direct visualization, since shock waves can also injure normal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EQUIPMENT AND TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most endoscopists use the peroral route to perform EHL on bile duct stones, while the peroral or intraoperative approach is used for pancreatic duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/1-17\">",
"     1-17",
"    </a>",
"    ]. The percutaneous approach is usually reserved for peripheral or pre-stricture intrahepatic stones. Percutaneous choledochoscopy and EHL can be used in patients after surgery that precludes reaching the bile duct perorally (eg, after pancreatoduodenectomy). EHL can also be performed laparoscopically or intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Intracorporeal lithotripsy can be used in conjunction with extracorporeal lithotripsy in patients with stones that are difficult to remove [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/3,4,6,8\">",
"     3,4,6,8",
"    </a>",
"    ]. This approach increases the success rate and decreases the need for surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We currently use a catheter-based system (SpyGlass, Boston Scientific Corporation, Natick, MA, USA), which uses a 10 Fr scope mini-endoscope (also known as a \"daughter scope\") that is passed through the accessory channel of a therapeutic duodenoscope. It has a separate channel for the fiberoptic wire and a channel for therapeutic intervention. In addition, it has a separate irrigation channel. An important feature of this scope is that it has four-way tip deflection, in contrast with standard choledochoscopes, which have two-way deflection. We have used this system for per-oral treatment of biliary and pancreatic stones, and also percutaneously in patients after pancreatoduodenectomy who developed a biliojejunal anastomotic stricture and formed a stone proximal to it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EHL fiber measures approximately 1.9 to 3.3 Fr, or 0.66 to 1.1 mm. Current mini-endoscopes have a working channel of 1.2 mm. Thus, space around the EHL fiber within the channel is almost nonexistent when larger probes are used. As a result, great care must be taken when advancing the EHL fiber through the channel of the choledochoscope to avoid bending or breaking. Because the EHL fiber is rigid and can easily damage the inside aspect of the bending part of the mini-endoscope, it is best to attempt to straighten the mini-endoscope when advancing the EHL fiber. We lubricate the accessory channel of the mini-endoscope with liquid silicone before inserting the EHL fiber. The EHL fiber is not advanced into the bile duct unless the stone is well visualized. Once the EHL fiber is advanced, the mini-endoscope is usually pushed forward to achieve a \"long\" position, a maneuver that permits straightening of the bending portion of the mini-endoscope. It is usually necessary to gently \"jiggle\" the EHL probe before it comes out of the mini-endoscope. Another useful tip is advancing the fiber while simultaneously pushing water through the channel. If the above steps fail to advance the fiber, pushing the mini-endoscope up into the proximal bile duct can facilitate fiber advancement.",
"   </p>",
"   <p>",
"    Once outside the mini-endoscope, the EHL fiber tip can be seen both endoscopically and fluoroscopically (",
"    <a class=\"graphic graphic_figure graphicRef56346 \" href=\"UTD.htm?32/56/33670\">",
"     figure 1",
"    </a>",
"    ). Whenever possible, the EHL fiber is pushed against the center of the stone. An approach using a balloon to help center the fiber has been described. However, this technique is too risky since it can cause epithelial injury with potential secondary perforation. If there is no other option, we fire the probe tangentially, but avoid any contact with the bile duct wall. This may permit \"chipping\" of the stone, which may then allow for better accommodation against the probe. The tip of the fiber should be as close to the stone as possible. The stone can be touched if needed. However, touching the stone may reduce the probe functional lifespan. EHL is delivered according to a preset power wattage (usually in the range of 70 to 100 watts) via 1 to 2 seconds or continuous pulsations. We start at a power of 70 Watts and increase it by 10 Watts as needed to a maximum of 100 Watts. Continuous saline irrigation into the bile duct is used to generate a fluid medium and magnify the EHL power (approximately 10-fold). The probe will not work unless it is in a fluid medium. Thus both the probe tip and stone surface need to be in an aqueous environment for fragmentation to occur. It also aids in flushing out debris and facilitates visualization.",
"   </p>",
"   <p>",
"    Once fragmentation of the stones is complete, the mini-endoscope is withdrawn and the stones are removed using standard methods (",
"    <a class=\"graphic graphic_figure graphicRef56346 \" href=\"UTD.htm?32/56/33670\">",
"     figure 1",
"    </a>",
"    ). EHL can also be successfully performed on stones located above a bile duct stricture or when, upon attempting stone removal with a basket, the basket-stone complex becomes impacted in the distal bile duct and cannot be removed or dislodged (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77303 \" href=\"UTD.htm?8/26/8623\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall success rate for biliary EHL exceeds 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/1-15,21,22\">",
"     1-15,21,22",
"    </a>",
"    ] when considering reports using varied routes to access the biliary tree and including reports in which EHL was used in conjunction with other methods such as extracorporeal lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report focused on 65 of 108 patients with difficult stones who underwent EHL via peroral choledochoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/3\">",
"       3",
"      </a>",
"      ]. Stone removal was successful in all patients except for one in whom the choledochoscope could not be introduced.",
"     </li>",
"     <li>",
"      Another report described the long-term experience in 55 patients with intrahepatic stones that were not accessible to routine endoscopic extraction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/6\">",
"       6",
"      </a>",
"      ]. Extracorporeal shock wave lithotripsy (ESWL) was used in 27, EHL in 12, and laser lithotripsy in 16. Stone fragmentation was achieved in 33, 42, and 75 percent, respectively. The success rate increased to more than 90 percent when the different methods were combined.",
"     </li>",
"     <li>",
"      A third study included 125 patients with common bile duct stones in whom conventional endoscopic treatment failed. EHL was used in 46 patients and ESWL was used in 79 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/8\">",
"       8",
"      </a>",
"      ]. ESWL could fragment stones in 68 patients and the bile duct was cleared of stones in 62 patients, for a success rate of 79 percent. EHL successfully fragmented and cleared the stones in 38 patients, for a success rate of 77 percent. When the treatment modalities were combined, the overall success rate was 94 percent.",
"     </li>",
"     <li>",
"      Another study described the use of EHL without cholangioscopy in a total of 19 patients with bile duct stones that could not be removed with standard methods [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/23\">",
"       23",
"      </a>",
"      ]. The authors advanced a 3.0 F radio opaque EHL probe through a balloon catheter. EHL was performed under fluoroscopic guidance until the stone was fragmented small enough to be captured with a mechanical lithotripsy basket. The bile duct was cleared in 16 patients (84 percent). However, additional mechanical lithotripsy was required in 9 of the 16 patients. Complications included hemobilia in two, pancreatitis in one, and cholangitis in one. While this may be the only alternative in some patients, the overall success rate was lower than expected for standard EHL and not using direct endoscopic visualization may increase risk. Thus, we continue to recommend that EHL should be performed only under cholangioscopic guidance.",
"     </li>",
"     <li>",
"      A fifth study compared biliary stenting with EHL in 36 high-risk patients with retained common bile duct stones [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/24\">",
"       24",
"      </a>",
"      ]. Nineteen patients underwent double pigtail stenting and 17 underwent EHL with an attempt at complete stone removal. Only 77 percent of the patients undergoing EHL achieved stone clearance, whereas the success rate of stent introduction was 95 percent. During follow-up, there was a significant increase in recurrent cholangitis and mortality due to recurrent cholangitis in the stent group compared with the EHL group (63 versus 8 percent and 21 versus 0 percent, respectively). This study further emphasizes that achieving complete stone clearance even in the high-risk patients is the better option [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pancreatic stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;EHL has also been used in the treatment of difficult pancreatic stones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. Most reports focused on patients with impacted stones in the setting of chronic calcific pancreatitis. One report, for example, included five patients who had failed extracorporeal shock wave lithotripsy and one patient who developed recurrent pancreatic stones after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients were treated with a total of nine intraductal EHL procedures. Complete or partial pancreatic duct clearance was achieved in all but one patient. The five patients in whom the duct was partially or completely cleared experienced complete relief of abdominal pain for at least six months. No complications were observed.",
"   </p>",
"   <p>",
"    Fragmentation of an impacted pancreatic duct stone that failed ESWL has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/25\">",
"     25",
"    </a>",
"    ]. The EHL probe was advanced to the stone housed in a balloon under fluoroscopic control without direct visualization. Although the intervention was successful, EHL should be performed under direct visualization to avoid ductal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;EHL has been successfully used in patients with duodenal obstruction secondary to biliary stone, in patients with gallstone ileus, and in patients with stones after orthotopic liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12854/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main risk of EHL is perforation of the bile duct, which can occur if the EHL probe touches the bile duct wall. Perforation can also occur due to extreme elevation of the surface temperature of the stone and surrounding ductal tissues, which is usually caused by prolonged application of EHL. The overall risk is probably less than 1 percent; in our own experience with over 43 patients, we have not encountered any perforations. Bleeding can also occur from touching the wall of the bile duct with the probe. The overall risk is also probably less than 1 percent. We encountered two patients with self limited bleeding among 43 treated patients.",
"   </p>",
"   <p>",
"    Other risks are mostly related to endoscopic retrograde cholangiopancreatography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81454084\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrohydraulic lithotripsy (EHL) is primarily used in the endoscopic fragmentation of difficult bile and pancreatic duct stones. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principle of EHL is the creation of an electric high-voltage spark between two isolated electrodes located at the tip of a fiber. The electric sparks are delivered in short pulses that create an immediate expansion of the surrounding liquid, inducing a spherical shock wave. The shock wave oscillates, generating sufficient pressure to fragment the stone. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Theoretical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall success rate for biliary EHL exceeds 90 percent when using varied routes to access the biliary tree and when using EHL in conjunction with other methods, such as extracorporeal lithotripsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main risk of EHL is perforation of the bile duct. The overall risk is probably less than 1 percent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/1\">",
"      Siegel JH, Ben-Zvi JS, Pullano WE. Endoscopic electrohydraulic lithotripsy. Gastrointest Endosc 1990; 36:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/2\">",
"      Seitz U, Bapaye A, Bohnacker S, et al. Advances in therapeutic endoscopic treatment of common bile duct stones. World J Surg 1998; 22:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/3\">",
"      Binmoeller KF, Br&uuml;ckner M, Thonke F, Soehendra N. Treatment of difficult bile duct stones using mechanical, electrohydraulic and extracorporeal shock wave lithotripsy. Endoscopy 1993; 25:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/4\">",
"      Lee JG, Leung JW. Endoscopic management of difficult common bile duct stones. Gastrointest Endosc Clin N Am 1996; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/5\">",
"      Craigie JE, Adams DB, Byme TK, et al. Endoscopic electrohydraulic lithotripsy in the management of pancreatobiliary lithiasis. Surg Endosc 1998; 12:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/6\">",
"      Adamek HE, Schneider AR, Adamek MU, et al. Treatment of difficult intrahepatic stones by using extracorporeal and intracorporeal lithotripsy techniques: 10 years' experience in 55 patients. Scand J Gastroenterol 1999; 34:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/7\">",
"      Raijman I, Ankoma-Sey V, Monsour H, et al. The role of choledochoscopy in the diagnosis and management of non-transplant biliary tract disease. Hepatology 1997; 26:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/8\">",
"      Adamek HE, Maier M, Jakobs R, et al. Management of retained bile duct stones: a prospective open trial comparing extracorporeal and intracorporeal lithotripsy. Gastrointest Endosc 1996; 44:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/9\">",
"      De Masi E, Lamazza A, Fiori E, et al. [Electrohydraulic intracorporeal lithotripsy in the treatment of \"difficult\" calculi of the common bile duct. Report of a caseload]. G Chir 1995; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/10\">",
"      Blind PJ, Lundmark M. Management of bile duct stones: lithotripsy by laser, electrohydraulic, and ultrasonic techniques. Report of a series and clinical review. Eur J Surg 1998; 164:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/11\">",
"      Schumacher B, Frieling T, Haussinger D, Niederau C. Endoscopic treatment of symptomatic choledocholithiasis. Hepatogastroenterology 1998; 45:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/12\">",
"      Hixson LJ, Fennerty MB, Jaffee PE, et al. Peroral cholangioscopy with intracorporeal electrohydraulic lithotripsy for choledocholithiasis. Am J Gastroenterol 1992; 87:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/13\">",
"      Josephs LG, Birkett DH. Electrohydraulic lithotripsy (EHL) for the treatment of large retained common duct stones. Am Surg 1990; 56:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/14\">",
"      Yucel O, Arregui ME. Electrohydraulic lithotripsy combined with laparoscopy and endoscopy for managing difficult biliary stones. Surg Laparosc Endosc 1993; 3:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/15\">",
"      Sheen-Chen SM, Chou FF. Intraoperative choledochoscopic electrohydraulic lithotripsy for difficulty retrieved impacted common bile duct stones. Arch Surg 1995; 130:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/16\">",
"      Tanaka M, Yokohata K, Kimura H, et al. Intraoperative endoscopic electrohydraulic lithotripsy of pancreatic stones. Int J Pancreatol 1992; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/17\">",
"      Howell DA, Dy RM, Hanson BL, et al. Endoscopic treatment of pancreatic duct stones using a 10F pancreatoscope and electrohydraulic lithotripsy. Gastrointest Endosc 1999; 50:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/18\">",
"      DiSario J, Chuttani R, Croffie J, et al. Biliary and pancreatic lithotripsy devices. Gastrointest Endosc 2007; 65:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/19\">",
"      Fishman DS, Tarnasky PR, Patel SN, Raijman I. Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience. World J Gastroenterol 2009; 15:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/20\">",
"      Vorreuther R, Engelmann Y. Evaluation of the shock-wave pattern for endoscopic electrohydraulic lithotripsy. Surg Endosc 1995; 9:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/21\">",
"      Arya N, Nelles SE, Haber GB, et al. Electrohydraulic lithotripsy in 111 patients: a safe and effective therapy for difficult bile duct stones. Am J Gastroenterol 2004; 99:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/22\">",
"      Piraka C, Shah RJ, Awadallah NS, et al. Transpapillary cholangioscopy-directed lithotripsy in patients with difficult bile duct stones. Clin Gastroenterol Hepatol 2007; 5:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/23\">",
"      Moon JH, Cha SW, Ryu CB, et al. Endoscopic treatment of retained bile-duct stones by using a balloon catheter for electrohydraulic lithotripsy without cholangioscopy. Gastrointest Endosc 2004; 60:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/24\">",
"      Hui CK, Lai KC, Ng M, et al. Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. Aliment Pharmacol Ther 2003; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/25\">",
"      Papachristou GI, Baron TH. Endoscopic treatment of an impacted pancreatic duct stone using a balloon catheter for electrohydraulic lithotripsy without pancreatoscopy. J Clin Gastroenterol 2006; 40:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/26\">",
"      Silver RI, Daniels MA, Rollins NK, et al. Percutaneous transhepatic endoscopic electrohydraulic lithotripsy of biliary tract calculi after orthotopic liver transplantation. J Laparoendosc Surg 1996; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/27\">",
"      Bourke MJ, Schneider DM, Haber GB. Electrohydraulic lithotripsy of a gallstone causing gallstone ileus. Gastrointest Endosc 1997; 45:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12854/abstract/28\">",
"      Apel D, Jakobs R, Benz C, et al. Electrohydraulic lithotripsy treatment of gallstone after disimpaction of the stone from the duodenal bulb (Bouveret's syndrome). Ital J Gastroenterol Hepatol 1999; 31:876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 639 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12854=[""].join("\n");
var outline_f12_35_12854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H81454084\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THEORETICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EQUIPMENT AND TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pancreatic stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other uses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81454084\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/639|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/26/8623\" title=\"diagnostic image 1\">",
"      EHL for entrapped basket",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/639|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/56/33670\" title=\"figure 1\">",
"      EHL sequential views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10168?source=related_link\">",
"      Extracorporeal shock wave lithotripsy for pancreatic stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12855="Tizanidine: Drug information";
var content_f12_35_12855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tizanidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/36/4677?source=see_link\">",
"    see \"Tizanidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zanaflex Capsules&reg;;",
"     </li>",
"     <li>",
"      Zanaflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tizanidine&reg;;",
"     </li>",
"     <li>",
"      Gen-Tizanidine;",
"     </li>",
"     <li>",
"      Mylan-Tizanidine;",
"     </li>",
"     <li>",
"      Zanaflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Spasticity:",
"     </b>",
"     Oral:  Initial: 4 mg up to 3 times daily (at 6- to 8-hour intervals); may titrate to optimal effect in 2-4 mg increments as needed to a maximum of 3 doses in 24 hours (at 6- to 8-hour intervals); maximum: 36 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     Limited experience with single doses &gt;8 mg and daily doses &gt;24 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; clearance is decreased. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;25 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, caution may be needed as creatinine clearance decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute: Use with caution; clearance reduced &gt;50%. During initial dose titration, use reduced doses. If higher doses are necessary, increase dose instead of increasing dosing frequency.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in hepatic impairment; if used, lowest possible dose should be used initially with close monitoring for adverse effects (eg, hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 2 mg, 4 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zanaflex Capsules&reg;: 2 mg, 4 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zanaflex&reg;: 4 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F518407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Capsules may be opened and contents sprinkled on food; however, extent of absorption is increased up to 20% relative to administration of the capsule under fasted conditions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skeletal muscle relaxant used for treatment of muscle spasticity",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F228435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tension headaches, acute low back pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TiZANidine may be confused with tiaGABine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zanaflex&reg; may be confused with Xiaflex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zanaflex&reg; capsules and Zanaflex&reg; tablets (or generic tizanidine tablets) are not interchangeable in the fed state",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency percentages below reported during multiple-dose studies, unless specified otherwise.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension (16% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Somnolence (48%), dizziness (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (49%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (12% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Nervousness (3%), speech disorder (3%), visual hallucinations/delusions (3%), anxiety (1%), depression (1%), fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (1%), skin ulcer (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4%), vomiting (3%), abdominal pain (1%), diarrhea (1%), dyspepsia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: UTI (10%), urinary frequency (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (3%), back pain (1%), myasthenia (1%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pharyngitis (3%), rhinitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection (6%), flu-like syndrome (3%), diaphoresis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, frequency not defined, and postmarketing experience (limited to important or life-threatening): Abnormal dreams, abnormal thinking, abscess, adrenal insufficiency, allergic reaction, anemia, angina pectoris, arrhythmia, carcinoma (including skin), cholelithiasis, deafness, dementia, depersonalization, dyslipidemia, gastrointestinal hemorrhage, glaucoma, heart failure, hepatomegaly, hemiplegia, hepatic failure, hepatitis, hepatoma, herpes infections, hypercholesterolemia, hyperglycemia, hypokalemia, hyponatremia, hypoproteinemia, hypothyroidism, intestinal obstruction, jaundice, leukopenia, leukocytosis, MI, migraine, neuralgia, optic neuritis, orthostatic hypotension, palpitation, paralysis, psychotic-like symptoms, pulmonary embolus, purpura, respiratory acidosis, retinal hemorrhage, seizure, sepsis, suicide attempt, syncope, thrombocythemia, thrombocytopenia, ventricular extrasystoles, ventricular tachycardia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tizanidine or any component of the formulation; concomitant therapy with ciprofloxacin or fluvoxamine (potent CYP1A2 inhibitors)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Potential for hepatotoxicity; AST/ALT elevations (&gt;3 times ULN) and hepatic failure have occurred; monitor aminotransferases prior to and during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Dose-related significant hypotension (possibly with bradycardia or orthostatic hypotension) may occur; use with caution in patients with cardiac disease or those at risk for severe hypotensive effects (eg, patients taking concurrent medications which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Dose-related sedation common with use; significant and severe sedation may also occur; use with caution in patients at risk for sedative effects; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual hallucinations: Use has been associated with visual hallucinations or delusions, generally in first 6 weeks of therapy; use caution in patients with psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid or use extreme caution in patients with hepatic impairment; potential for effects likely due to extensive hepatic metabolism of tizanidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Clearance decreased significantly in patients with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute); dose reductions recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Hypotensive effects may be potentiated when used with antihypertensives. Should not be used with other alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Sedative effects may be potentiated when used with other CNS depressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: In general, avoid use in patients taking other CYP1A2 inhibitors; if taken concomitantly, use with caution and monitor for increased hypotensive and sedative effects of tizanidine. Concomitant use of ciprofloxacin or fluvoxamine is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral contraceptives: In general, avoid concomitant use with tizanidine. Clearance of tizanidine may be decreased by 50%; if taken concomitantly, decrease initial tizanidine dose and titration rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). Use with caution; clearance decreased fourfold in the elderly; may increase risk of adverse effects and/or duration of effects. Elderly with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute) may have clearance reduced by &gt;50% compared to healthy elderly subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Withdrawal resulting in rebound hypertension, tachycardia, and hypertonia may occur upon discontinuation; doses should be decreased slowly, particularly in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Food: Food alters absorption profile relative to administration under fasting conditions. In addition, bioequivalence between capsules and tablets is altered by food; capsules and tablets are bioequivalent under fasting conditions, but not under nonfasting conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Limited data exist for chronic use of single doses &gt;8 mg and multiple doses &gt;24 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3015415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: TiZANidine may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lisinopril: TiZANidine may enhance the hypotensive effect of Lisinopril.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F228404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: The tablet and capsule dosage forms are not bioequivalent when administered with food. Food increases both the time to peak concentration and the extent of absorption for both the tablet and capsule. However, maximal concentrations of tizanidine achieved when administered with food were increased by 30% for the tablet, but decreased by 20% for the capsule. Under fed conditions, the capsule is approximately 80% bioavailable relative to the tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may increase hypotensive effects).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13206218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13206219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown, but expected due to lipid solubility.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4591382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food compared to administration in the fasting state results in clinically-significant differences in absorption and other pharmacokinetic parameters. Patients should be consistent and should not switch administration of the tablets or the capsules between the fasting and nonfasting state. In addition, switching between the capsules and the tablets in the fed state will also result in significant differences. Opening capsule contents to sprinkle on applesauce compared to swallowing intact capsules whole will also result in significant absorption differences. Patients should be consistent with regards to administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F228397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (TiZANidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (150): $406.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (150): $515.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (150): $773.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zanaflex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (150): $451.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (150): $572.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (150): $859.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TiZANidine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (150): $183.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (150): $219.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zanaflex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (150): $426.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor liver function (aminotransferases) at baseline, 1, 3, 6 months and periodically thereafter; blood pressure; renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      KaiLaiTong (CL);",
"     </li>",
"     <li>",
"      Mio-Relax (CO);",
"     </li>",
"     <li>",
"      Musant (BG);",
"     </li>",
"     <li>",
"      Myores (ID);",
"     </li>",
"     <li>",
"      Myos-Nor (CO);",
"     </li>",
"     <li>",
"      Phardex (ID);",
"     </li>",
"     <li>",
"      Sirdalud (AE, AR, AT, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GH, GM, GN, GR, GY, HN, IL, IN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PE, PH, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Sirdalud MR (CH, NL);",
"     </li>",
"     <li>",
"      Sirdalud Retard (DK, FI);",
"     </li>",
"     <li>",
"      Sirdalum (UY);",
"     </li>",
"     <li>",
"      Spaslax (TW);",
"     </li>",
"     <li>",
"      Stidine (TW);",
"     </li>",
"     <li>",
"      Ternelax (PH);",
"     </li>",
"     <li>",
"      Ternelin (JP);",
"     </li>",
"     <li>",
"      Tizalin (TW);",
"     </li>",
"     <li>",
"      Tizan (TH);",
"     </li>",
"     <li>",
"      Zanaflex (GB, IE);",
"     </li>",
"     <li>",
"      Zita (PK);",
"     </li>",
"     <li>",
"      Zitanid (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonist agent which decreases excitatory input to alpha motor neurons; an imidazole derivative chemically-related to clonidine, is a centrally acting muscle relaxant with alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonist properties; acts on the level of the spinal cord",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: Single dose (8 mg): Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Single dose (8 mg): 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Tablets and capsules are bioequivalent under fasting conditions, but not under nonfasting conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets administered with food: Peak plasma concentration is increased by ~30%; time to peak increased by 25 minutes; extent of absorption increased by ~30%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules administered with food: Peak plasma concentration decreased by 20%; time to peak increased by 2 hours; extent of absorption increased by ~10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules opened and sprinkled on applesauce are not bioequivalent to administration of intact capsules under fasting conditions. Peak plasma concentration and AUC are increased by 15% to 20%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP1A2 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~40% (extensive first-pass metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Fasting state: Capsule, tablet: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Fed state: Capsule: 3-4 hours, Tablet: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%); feces (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delgado MR, Hirtz D, Aisen M, et al, &ldquo;Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 74(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/20101040/pubmed\" id=\"20101040\" target=\"_blank\">",
"        20101040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fromm GH, Aumentado D, and Terrence CF, &ldquo;A Clinical and Experimental Investigation of the Effects of Tizanidine in Trigeminal Neuralgia,&rdquo;",
"      <i>",
"       Pain",
"      </i>",
"      , 1993, 53(3):265-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/8351156/pubmed\" id=\"8351156\" target=\"_blank\">",
"        8351156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gronseth G, Cruccu G, Alksne J, et al, \"Practice Parameter: The Diagnostic Evaluation and Treatment of Trigeminal Neuralgia (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2008, 71(15):1183-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/18716236/pubmed\" id=\"18716236\" target=\"_blank\">",
"        18716236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malanga G, Reiter RD, and Garay E, &ldquo;Update on Tizanidine for Muscle Spasticity and Emerging Indications,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2008 9(12):2209-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/18671474/pubmed\" id=\"18671474\" target=\"_blank\">",
"        18671474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saper JR, Lake AE 3rd, Cantrell DT, et al, &ldquo;Chronic Daily Headache Prophylaxis With Tizanidine: A Double-Blind, Placebo-Controlled, Multicenter Outcome Study,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(6):470-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/35/12855/abstract-text/12167135/pubmed\" id=\"12167135\" target=\"_blank\">",
"        12167135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9999 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12855=[""].join("\n");
var outline_f12_35_12855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228406\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228439\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228409\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228410\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228411\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228412\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228392\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228378\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518407\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228393\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228435\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228445\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228437\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228396\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228382\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3015415\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228387\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228404\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228388\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206218\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228414\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206219\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4591382\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228397\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228390\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228398\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228381\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228395\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9999|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/36/4677?source=related_link\">",
"      Tizanidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12856="Tuberculous pleural effusions in HIV-negative patients";
var content_f12_35_12856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberculous pleural effusions in HIV-negative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Michael D Frye, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12856/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12856/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/35/12856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous pleural effusion accounts for approximately 5 percent of disease due to Mycobacterium tuberculosis and is the second most common form of extrapulmonary tuberculosis (TB) after lymphatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the diagnosis and treatment of tuberculous pleural effusions in HIV-negative patients will be reviewed here. Issues related to tuberculous pleural effusions in HIV-infected patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3576576\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous pleural effusions are thought to result from a delayed hypersensitivity reaction to mycobacteria and mycobacterial antigens in the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/3\">",
"     3",
"    </a>",
"    ]. These organisms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their antigens probably enter the pleural space due to leakage or rupture of a subpleural focus of disease. In one study of 24 patients with tuberculous pleural effusions who underwent thoracotomy, for example, a caseous focus in the lung contiguous with the diseased pleura was found in half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/4\">",
"     4",
"    </a>",
"    ]. Development of pleural effusion occurs largely as a result of hypersensitivity reaction, but tuberculous pleurisy must be considered to be due to infection since culture of the fluid grows mycobacteria in some cases and culture of the pleural tissue usually grows mycobacteria. Tuberculous pleural effusions are usually self-limited and resolve spontaneously with or without treatment in most cases. However, the condition can potentially progress and worsen and become a tuberculous empyema.",
"   </p>",
"   <p>",
"    A tuberculous empyema represents chronic active infection of the pleural space and can occur in the setting of a large pleural effusion which progresses, usually leading to an unexpandable lung [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/5\">",
"     5",
"    </a>",
"    ]. Simple tuberculous pleural effusion and tuberculous empyema can be considered a continuum of the same process. Tuberculous empyema can also develop via extension of infection from thoracic lymph nodes or subdiaphragmatic focus, via hematogenous spread, or in the setting of therapeutic pneumothorax therapy leading to an unexpandable lung.",
"   </p>",
"   <p>",
"    In an experimental model of tuberculous effusion in which Bacille Calmette-Guerin (BCG) was injected into the pleural space of rabbits that had been previously sensitized with intradermal BCG, a sequential influx of cells into the pleural space was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/6\">",
"     6",
"    </a>",
"    ]. An initial neutrophilic response is necessary for the subsequent mononuclear influx [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/7\">",
"     7",
"    </a>",
"    ]. Macrophages are the predominant mononuclear cells until day four, with lymphocytes predominating thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/6\">",
"     6",
"    </a>",
"    ]. The local release of cytokines probably induces the sequential expression of specific cell adhesion molecules in vascular endothelium that direct the influx of the different inflammatory cells.",
"   </p>",
"   <p>",
"    In patients with tuberculous pleural effusion, the proportion of T-lymphocytes is higher in pleural fluid than in blood. This is due to selective enrichment of cells with the",
"    <span class=\"nowrap\">",
"     helper/inducer",
"    </span>",
"    (CD4) phenotype via local proliferation and probable selective influx. Those pleural helper T-cells with a \"memory\" phenotype (CD4+, CDw29+) are the cells that proliferate and produce gamma interferon when stimulated with purified protein derivative (PPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3576050\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous pleural effusions can occur in association with either reactivation disease or primary tuberculosis (TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Most often they are due to reactivation disease in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and to primary disease in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/12\">",
"     12",
"    </a>",
"    ]. TB pleural effusions are typically unilateral and small to moderate in size [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with tuberculous pleural effusion usually have acute febrile illness with nonproductive cough (94 percent) and pleuritic chest pain (78 percent), without an elevation in the peripheral white blood cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/13\">",
"     13",
"    </a>",
"    ]. Night sweats, chills, weakness, dyspnea, and weight loss can also occur. The average age in one series from the United States was 47 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases pleural scarring can lead to a \"trapped lung\" and pleural fluid fills the void created by the nonexpandable lung. Less commonly, tuberculous pleural effusion can develop when a cavity ruptures into the pleural space, resulting in a chronic suppurative effusion, called a chronic tuberculous empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. Chronic tuberculous empyema is characterized by purulent fluid containing numerous tuberculous organisms, and results in thickened, scarred, and calcified pleura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5532142\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous pleural effusions are unilateral in almost all cases and occur slightly more frequently on the right side than the left (55 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The effusions are typically small to moderate in size; they occupy less than one-third of the hemithorax in 82 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/15\">",
"     15",
"    </a>",
"    ]. The size or side of the effusion has no bearing on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parenchymal disease has been observed in association with pleural effusion on chest radiography in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1\">",
"     1",
"    </a>",
"    ]. These findings are located in the upper lobe in approximately three-fourths of cases, suggestive of reactivation TB. In the remaining patients, parenchymal disease is located in the lower lobe and resembles primary disease. The effusion virtually always occurs on the same side as the parenchymal infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/13\">",
"     13",
"    </a>",
"    ]. Computed tomography (CT) is more sensitive than chest radiography; it demonstrates parenchymal disease in over 80 percent of cases, supporting the theory of spread to the pleura from a subpleural focus of infection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63772 \" href=\"UTD.htm?19/29/19920\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/18\">",
"     18",
"    </a>",
"    ]. In patients without apparent parenchymal involvement, pleural disease may develop via hematogenous spread following primary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3577153\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation of pleural effusion in the setting of suspected tuberculous begins with thoracentesis; fluid should be sent for routine studies and additional assays as discussed below. In the setting of moderate to high suspicion for tuberculosis (TB) with nondiagnostic pleural fluid evaluation, pleural biopsy is warranted.",
"   </p>",
"   <p>",
"    In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail separately. Evaluation for concurrent HIV infection should also be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3577801\">",
"    <span class=\"h2\">",
"     Pleural fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of pleural fluid consists of routine studies as outlined below. The additional assays described are not required for routine evaluation but can be helpful in some cases if the diagnosis is difficult to establish based on routine pleural studies and pleural biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21729436\">",
"    <span class=\"h3\">",
"     Routine studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pleural fluid in tuberculous pleural effusion is straw-colored in more than 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/19\">",
"     19",
"    </a>",
"    ]. It is uniformly exudative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/15\">",
"     15",
"    </a>",
"    ]; the protein concentration is invariably &gt;3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    and &gt;5.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    in 50 to 77 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. The pleural fluid lactate dehydrogenase (LDH) level is elevated in approximately 75 percent of cases, with levels commonly exceeding 500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1,13,15,20\">",
"     1,13,15,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low pH and low glucose concentration may be observed; these findings are more characteristic of chronic tuberculous empyema than tuberculous pleural effusion. The pleural fluid pH is virtually always &lt;7.40; pH &lt;7.30 is observed in about 20 percent of cases. The pleural fluid glucose concentration in tuberculous pleural effusion is usually between 60 and 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3 and 5.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Glucose levels below 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are observed in 7 to 20 percent of effusions. Extremely low glucose concentrations (&lt;30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    can occur occasionally [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3576576\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pleural fluid nucleated cell count is usually between 1000 and 6000",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/15\">",
"     15",
"    </a>",
"    ]. It is lymphocyte-predominant in 60 to 90 percent of cases; the remaining cases have neutrophil predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1,13,20\">",
"     1,13,20",
"    </a>",
"    ]. Timing is important in the type of nucleated cells that are seen; neutrophils predominate in the first few days of a tuberculous pleural effusion and lymphocytes predominate thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/6,7,19\">",
"     6,7,19",
"    </a>",
"    ]. The pleural fluid rarely contains more than 5 percent mesothelial cells. Eosinophil infiltration is uncommon. The presence of more than 10 percent eosinophils usually excludes the diagnosis of tuberculous pleuritis unless the patient has had a pneumothorax or hemothorax near the time of pleural analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29527?source=see_link\">",
"     \"Pleural fluid eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural fluid cultures are positive in 12 to 80 percent of patients; most series note positive cultures in less than 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9\">",
"     9",
"    </a>",
"    ]. The addition of pleural biopsy culture may increase the yield to &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5532816\">",
"     'Pleural biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nucleic acid amplification (NAA) techniques for evaluation of tuberculous pleural effusion in HIV-negative patients appear to have high specificity but relatively low sensitivity. In a meta-analysis of HIV-negative patients published in 2004, NAA tests had relatively low sensitivity (62 percent) but high specificity (98 percent) for diagnosis of tuberculous pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/22\">",
"     22",
"    </a>",
"    ]. Subsequently use of the Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    NAA assay was described in a series of 20 cases of confirmed tuberculous pleuritis; the sensitivity and specificity of the Xpert assay were 25 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8017262\">",
"    <span class=\"h3\">",
"     Additional assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional assays for evaluation of pleural fluid in the setting of suspected TB include measurement of pleural fluid adenosine deaminase (ADA) level, lysozyme concentration, and interferon-gamma (IFN-gamma) concentration. Of these tests, the pleural fluid ADA level is most clinically useful and accessible. An ADA level should be sent along with the routine pleural fluid studies whenever TB is the suspected cause of the effusion. Even when the AFB smear and culture are negative, compatible routine studies along with an elevated ADA level may establish a presumptive diagnosis of tuberculous pleuritis in the right clinical setting.",
"   </p>",
"   <p>",
"    Adenosine deaminase (ADA) levels are most useful in patients with moderate to high suspicion for TB with negative pleural histology and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/24\">",
"     24",
"    </a>",
"    ]. Some large series suggest that a value &gt;45 to 60",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    is 100 percent sensitive and up to 97 percent specific for tuberculous pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/15,24-27\">",
"     15,24-27",
"    </a>",
"    ]. However, one report of 87 cases found levels &gt;43",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    in only 78 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/28\">",
"     28",
"    </a>",
"    ]; other series have documented specificities of 85 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Pleural effusions with an ADA level &lt;40",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    are rarely caused by TB [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/31\">",
"     31",
"    </a>",
"    ]. Specificity is diminished by elevated ADA levels that can occur in other conditions, including rheumatoid effusion, empyema, mesothelioma, lung cancer, parapneumonic effusion, and hematologic malignancies. These findings in part reflect failure to distinguish between the two principal isoenzymes, ADA-1 and ADA-2; most assays report the total level only. ADA-2 is increased in tuberculous effusions, while ADA-1 is increased in empyemas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural fluid lysozyme concentrations are &gt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in over 80 percent of tuberculous pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. The highest concentrations are found in empyemas, which can be tuberculous or bacterial. Lysozyme concentrations can also be elevated in the setting of malignant effusions. The pleural fluid-to-serum lysozyme ratio may be more useful than the absolute value. Excluding empyemas, a ratio above 1.2 has been reported to have 100 percent sensitivity for tuberculous effusions and 95 percent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/33\">",
"     33",
"    </a>",
"    ]. In a heterogeneous group of 276 effusions, however, a threshold ratio of 1.1 was associated with a sensitivity of only 67 percent; the specificity was 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of pleural fluid interferon-gamma (IFN-gamma) concentration by commercially available enzyme-linked immunosorbent assay kits may be a useful diagnostic tool [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In one study including 145 patients with tuberculous pleural effusion, an IFN-gamma concentration &gt;140",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    had sensitivity and specificity of 94 percent and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/27\">",
"     27",
"    </a>",
"    ]. Another study including 66 patients with exudative, lymphocytic pleural effusions with cut-off value of 240",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    noted sensitivity and specificity of 95 and 96 percent (",
"    <a class=\"graphic graphic_figure graphicRef72138 \" href=\"UTD.htm?42/7/43133\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/36\">",
"     36",
"    </a>",
"    ]. A meta-analysis including 22 studies to estimate the accuracy of interferon-gamma in the diagnosis of tuberculous pleural effusion were 89 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/37\">",
"     37",
"    </a>",
"    ]; other series have described lower sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural fluid tuberculous antigens and antituberculous antibodies have also been studied and appear to be elevated in tuberculous pleuritis. However, these immunologic tests are not useful diagnostically due to lack of specificity for TB.",
"   </p>",
"   <p>",
"    Nucleic acid amplification (NAA) testing on respiratory secretions can be used for rapid diagnosis of TB; further study is needed to establish the accuracy of NAA tests in other clinical specimens. Pleural fluid may contain inhibitors that diminish the sensitivity of the test [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/30,38\">",
"     30,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5532816\">",
"    <span class=\"h2\">",
"     Pleural biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is not diagnostic. A definitive diagnosis should be pursued in most cases when tuberculous pleurisy is suspected. Pleural biopsy offers the highest likelihood of a certain diagnosis, and a positive culture also provides information pertaining to drug sensitivities of the organism. Pleural biopsy for confirmation of the diagnosis may also be necessary when use of antituberculous medications poses a particularly high risk of complications, such as in patients with pre-existing liver disease.",
"   </p>",
"   <p>",
"    Histologic examination and culture of pleural tissue is the most sensitive evaluation for pleural TB; this approach yields a diagnosis in 60 to 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9,19,39,40\">",
"     9,19,39,40",
"    </a>",
"    ]. Pleural biopsy demonstrates granulomas in 50 to 97 percent of cases and culture of biopsy material is positive in 40 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/9\">",
"     9",
"    </a>",
"    ]. Sensitivity generally increases with the number of biopsies taken.",
"   </p>",
"   <p>",
"    The presence of pleural caseating granulomas on histologic examination is virtually diagnostic of TB pleural effusion. Caseation and demonstration of acid-fast bacilli are not required. Noncaseating pleural granulomas can occasionally be seen in other disorders, such as sarcoidosis, fungal disease, and rheumatoid pleuritis.",
"   </p>",
"   <p>",
"    Pleural tissue can be obtained via thoracoscopy or closed percutaneous needle biopsy. Sensitivities are comparable; needle biopsy is generally preferred in areas where tuberculous pleuritis is common [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8017296\">",
"    <span class=\"h2\">",
"     Other evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail separately. Evaluation for concurrent HIV infection should also be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sputum culture is positive in 20 to 50 percent of patients with pleural effusion; positive sputum culture is more likely in the setting of concomitant parenchymal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1,4,13,20,43\">",
"     1,4,13,20,43",
"    </a>",
"    ]. In one report of 70 patients with tuberculous pleural effusions, sputum culture was positive in 89 percent of patients with parenchymal changes but only 11 percent of patients without parenchymal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/43\">",
"     43",
"    </a>",
"    ]. The yields for induced sputum and pleural biopsy were 52 and 62 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     Tuberculin skin test",
"    </a>",
"    (TST) and interferon-gamma release assays (IGRAs) can be useful components of the evaluation of suspected tuberculous pleural effusions, although neither can distinguish between latent tuberculosis infection and active tuberculosis disease. Older series reported almost uniformly positive TST results in patients with tuberculous pleural effusions; subsequent reports have observed false-negative tests in 7 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Almost all patients with tuberculous pleural effusion and an initially negative TST have a positive TST if retested two months later. One possible explanation for the initial negative TST is suppression of sensitized T-cells in the peripheral circulation and skin by circulating adherent mononuclear cells (chiefly monocytes, not classic CD8 suppressor cells). These monocytes are known to suppress antigen-induced lymphocyte blastogenesis and the production of interleukin-2.",
"   </p>",
"   <p>",
"    Interferon-gamma release assays (IGRAs) can be used in place of TST and are discussed further separately. The use of IGRAs on pleural fluid for the diagnosis of tuberculous pleuritis has been investigated and thus far appears to lack sufficient sensitivity and specificity for clinical use. A meta-analysis reported that IGRAs used on pleural fluid in patients with tuberculous pleuritis has a sensitivity and specificity of 75 and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of tuberculous pleural effusion is similar to treatment of pulmonary tuberculosis (TB). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases the diagnosis rests on clinical rather than microbiologic or histologic criteria. Presumptive therapy is warranted for patients with lymphocytic exudate and a positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or interferon-gamma release assay, even in the absence of definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/45\">",
"     45",
"    </a>",
"    ]. In the absence of treatment for tuberculous pleuritis, patients have a 65 percent risk of developing pulmonary or extrapulmonary TB within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine complete drainage of pleural fluid at the time of diagnosis does not appear to improve long-term outcomes. This was demonstrated in a randomized trial including 61 patients with newly diagnosed tuberculous pleural effusion treated with anti-TB therapy with or without pigtail drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/47\">",
"     47",
"    </a>",
"    ]. Drainage was associated with significantly more rapid resolution of dyspnea (four versus eight days), although after the first week there were no differences in symptoms between groups during the 24-week follow-up period. Pulmonary function and the degree of residual pleural thickening on chest radiography were the same in both groups at the conclusion of the trial.",
"   </p>",
"   <p>",
"    With appropriate therapy, most patients defervesce within two weeks; in most cases, pleural fluid is resorbed within six weeks. However, some patients take up to two months to defervesce, and fluid resorption may take up to four months. In selected patients, administration of corticosteroids can shorten the duration of fever and time to fluid resorption, although the precise risks and benefits of corticosteroids in this setting have not been well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Data are insufficient to support routine adjunctive use of corticosteroids for tuberculous pleuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual pleural thickening can occur in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/52\">",
"     52",
"    </a>",
"    ]. Among 56 patients with 10 mm of residual pleural thickening following completion of medical therapy, the pleural fluid had a significantly lower pH, lower glucose concentration, higher lysozyme concentration, and higher TNF-alpha levels; the adenosine deaminase (ADA) level was elevated to a similar degree in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12856/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695691\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculous pleural effusions can occur in association with either primary tuberculosis (TB) or reactivation disease. Patients with tuberculous pleural effusion usually have acute febrile illness with nonproductive cough and pleuritic chest pain. Night sweats, chills, weakness, dyspnea, and weight loss can also occur. (See",
"      <a class=\"local\" href=\"#H3576050\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculous pleural effusions are usually small to moderate in size, unilateral, and occur slightly more frequently on the right side than the left. Parenchymal disease may be observed in association with pleural effusion. Most often parenchymal disease is in the upper lobe, suggestive of reactivation TB; in some cases parenchymal disease is in the lower lobe and resembles primary disease. (See",
"      <a class=\"local\" href=\"#H5532142\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation of pleural effusion in the setting of suspected tuberculous pleuritis begins with thoracentesis. The pleural fluid is generally exudative with protein concentration &gt;3.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and lactate dehydrogenase level commonly exceeding 500",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      Low pH and low glucose concentration may be observed; these findings are more characteristic of chronic tuberculous empyema than tuberculous pleural effusion. The pleural fluid nucleated cell count is usually lymphocyte-predominant. Cultures are positive in &lt;30 percent of cases. (See",
"      <a class=\"local\" href=\"#H21729436\">",
"       'Routine studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is suggestive of TB pleuritis but not diagnostic. Histologic examination and culture of pleural tissue is the most sensitive evaluation for pleural TB. The presence of pleural caseating granulomas on histologic examination is virtually diagnostic of TB pleural effusion. (See",
"      <a class=\"local\" href=\"#H5532816\">",
"       'Pleural biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional assays for evaluation of pleural fluid in the setting of suspected TB (such as pleural fluid adenosine deaminase level, lysozyme concentration, and interferon-gamma concentration) can be helpful to establish a presumptive diagnosis of tuberculous pleuritis. The pleural fluid adenosine deaminase level is the most clinically useful of these assays. However, a definitive diagnosis made with AFB smear, culture, and sensitivities should be pursued whenever possible. (See",
"      <a class=\"local\" href=\"#H8017262\">",
"       'Additional assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail separately. Evaluation for concurrent HIV infection should also be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"       \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of tuberculous pleural effusion is similar to treatment of pulmonary TB. Presumptive therapy is warranted for patients with lymphocytic exudate and a positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or serum interferon-gamma release assay, even in the absence of definitive diagnosis. With appropriate therapy most patients defervesce within two weeks; in most cases, pleural fluid is resorbed within six weeks. Residual pleural thickening can occur. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management and outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/1\">",
"      Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/2\">",
"      Baumann MH, Nolan R, Petrini M, et al. Pleural tuberculosis in the United States: incidence and drug resistance. Chest 2007; 131:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/3\">",
"      Leibowitz S, Kennedy L, Lessof MH. The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum. Br J Exp Pathol 1973; 54:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/4\">",
"      STEAD WW, EICHENHOLZ A, STAUSS HK. Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous. Am Rev Tuberc 1955; 71:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/5\">",
"      Sahn SA, Iseman MD. Tuberculous empyema. Semin Respir Infect 1999; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/6\">",
"      Antony VB, Repine JE, Harada RN, et al. Inflammatory responses in experimental tuberculosis pleurisy. Acta Cytol 1983; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/7\">",
"      Antony VB, Sahn SA, Antony AC, Repine JE. Bacillus Calmette-Gu&eacute;rin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 1985; 76:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/8\">",
"      Ellner JJ, Barnes PF, Wallis RS, Modlin RL. The immunology of tuberculous pleurisy. Semin Respir Infect 1988; 3:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/9\">",
"      Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/10\">",
"      Torgersen J, Dorman SE, Baruch N, et al. Molecular epidemiology of pleural and other extrapulmonary tuberculosis: a Maryland state review. Clin Infect Dis 2006; 42:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/11\">",
"      Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest 2006; 129:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/12\">",
"      Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural effusion in children. Chest 1999; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/13\">",
"      Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/14\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/15\">",
"      Vald&eacute;s L, Alvarez D, San Jos&eacute; E, et al. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 1998; 158:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/16\">",
"      Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997; 112:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/17\">",
"      SIBLEY JC. A study of 200 cases of tuberculous pleurisy with effusion. Am Rev Tuberc 1950; 62:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/18\">",
"      Hulnick DH, Naidich DP, McCauley DI. Pleural tuberculosis evaluated by computed tomography. Radiology 1983; 149:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/19\">",
"      Levine H, Metzger W, Lacera D, Kay L. Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen. Arch Intern Med 1970; 126:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/20\">",
"      Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987; 91:106.",
"     </a>",
"    </li>",
"    <li>",
"     Light RW. Chapter 10. In: Pleural Diseases, 2d ed, Lea &amp; Febiger, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/22\">",
"      Pai M, Flores LL, Hubbard A, et al. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis 2004; 4:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/23\">",
"      Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol 2011; 49:4341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/24\">",
"      Piras MA, Gakis C, Budroni M, Andreoni G. Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis. Br Med J 1978; 2:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/25\">",
"      Riantawan P, Chaowalit P, Wongsangiem M, Rojanaraweewong P. Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis. Chest 1999; 116:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/26\">",
"      Oca&ntilde;a I, Martinez-Vazquez JM, Segura RM, et al. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest 1983; 84:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/27\">",
"      Vald&eacute;s L, San Jos&eacute; E, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. Chest 1993; 103:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/28\">",
"      Orriols R, Coloma R, Ferrer J, et al. Adenosine deaminase in tuberculous pleural effusion. Chest 1994; 106:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/29\">",
"      Ba&ntilde;ales JL, Pineda PR, Fitzgerald JM, et al. Adenosine deaminase in the diagnosis of tuberculous pleural effusions. A report of 218 patients and review of the literature. Chest 1991; 99:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/30\">",
"      Villegas MV, Labrada LA, Saravia NG. Evaluation of polymerase chain reaction, adenosine deaminase, and interferon-gamma in pleural fluid for the differential diagnosis of pleural tuberculosis. Chest 2000; 118:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/31\">",
"      Jim&eacute;nez Castro D, D&iacute;az Nuevo G, P&eacute;rez-Rodr&iacute;guez E, Light RW. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. Eur Respir J 2003; 21:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/32\">",
"      Gakis C. Adenosine deaminase in pleural effusions. Chest 1995; 107:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/33\">",
"      Verea Hernando HR, Masa Jimenez JF, Dominguez Juncal L, et al. Meaning and diagnostic value of determining the lysozyme level of pleural fluid. Chest 1987; 91:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/34\">",
"      Hiraki A, Aoe K, Eda R, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest 2004; 125:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/35\">",
"      Aoe K, Hiraki A, Murakami T, et al. Diagnostic significance of interferon-gamma in tuberculous pleural effusions. Chest 2003; 123:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/36\">",
"      Wongtim S, Silachamroon U, Ruxrungtham K, et al. Interferon gamma for diagnosing tuberculous pleural effusions. Thorax 1999; 54:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/37\">",
"      Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest 2007; 131:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/38\">",
"      Villena V, Rebollo MJ, Aguado JM, et al. Polymerase chain reaction for the diagnosis of pleural tuberculosis in immunocompromised and immunocompetent patients. Clin Infect Dis 1998; 26:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/39\">",
"      Kirsch CM, Kroe DM, Azzi RL, et al. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest 1997; 112:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/40\">",
"      Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/41\">",
"      Diacon AH, Van de Wal BW, Wyser C, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J 2003; 22:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/42\">",
"      Emad A, Rezaian GR. Diagnostic value of closed percutaneous pleural biopsy vs pleuroscopy in suspected malignant pleural effusion or tuberculous pleurisy in a region with a high incidence of tuberculosis: a comparative, age-dependent study. Respir Med 1998; 92:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/43\">",
"      Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med 2003; 167:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/44\">",
"      Zhou Q, Chen YQ, Qin SM, et al. Diagnostic accuracy of T-cell interferon-&gamma; release assays in tuberculous pleurisy: a meta-analysis. Respirology 2011; 16:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/45\">",
"      Losi M, Bossink A, Codecasa L, et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 2007; 30:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/46\">",
"      ROPER WH, WARING JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Tuberc 1955; 71:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/47\">",
"      Lai YF, Chao TY, Wang YH, Lin AS. Pigtail drainage in the treatment of tuberculous pleural effusions: a randomised study. Thorax 2003; 58:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/48\">",
"      Lee CH, Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 1988; 94:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/49\">",
"      Matchaba PT, Volmink J. Steroids for treating tuberculous pleurisy. Cochrane Database Syst Rev 2000; :CD001876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/50\">",
"      Light RW. Update on tuberculous pleural effusion. Respirology 2010; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/51\">",
"      Engel ME, Matchaba PT, Volmink J. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 2007; :CD001876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/52\">",
"      Barbas CS, Cukier A, de Varvalho CR, et al. The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis. Chest 1991; 100:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12856/abstract/53\">",
"      de Pablo A, Villena V, Echave-Sustaeta J, Encuentra AL. Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis? Chest 1997; 112:1293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8012 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12856=[""].join("\n");
var outline_f12_35_12856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4695691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3576576\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3576050\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5532142\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3577153\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3577801\">",
"      Pleural fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21729436\">",
"      - Routine studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8017262\">",
"      - Additional assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5532816\">",
"      Pleural biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8017296\">",
"      Other evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695691\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8012\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8012|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/29/19920\" title=\"diagnostic image 1\">",
"      TB pleural effusion CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8012|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/7/43133\" title=\"figure 1\">",
"      Interferon gamma in TB effusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29527?source=related_link\">",
"      Pleural fluid eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12857="Approach to flushing in adults";
var content_f12_35_12857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to flushing in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Sara B Fazio, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12857/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/35/12857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing, a common problem encountered in the practice of medicine, has a broad differential diagnosis. A vigilant history of associated symptoms, duration, tempo, and environmental exposure is important to determine the underlying etiology and to formulate a management plan.",
"   </p>",
"   <p>",
"    This topic reviews the pathogenesis, differential diagnosis, evaluation, and treatment of flushing. The management of benign excessive sweating as well as the approach to the patient with night sweats are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1257?source=see_link\">",
"     \"Primary focal hyperhidrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=see_link\">",
"     \"Approach to the patient with night sweats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing is a sensation of warmth accompanied by transient erythema that most commonly occurs on the face, but also may involve the neck, ears, chest, epigastrium, and arms or other areas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. The predilection for specific anatomical areas is likely to relate to the volume of visible superficial vessels and differences in the relative amount of cutaneous blood flow compared to other body areas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to differentiate \"true flushing\" from other disorders that lead to facial erythema, such as the butterfly rash associated with systemic lupus erythematosus or photosensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/3\">",
"     3",
"    </a>",
"    ]. It is also important to distinguish flushing from excess sweating alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing is a consequence of increased cutaneous blood flow secondary to vasodilation and represents part of a synchronized physiologic response of cutaneous vascular smooth muscle to a variety of autonomic or vasodilator stimuli. Flushing may be episodic, transient, or constant, depending on the etiology.",
"   </p>",
"   <p>",
"    The appearance of a patient with flushing varies depending on the skin color, temperature, visibility of blood vessels beneath the skin, and capacitance of those vessels for erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. A fixed degree of facial erythema and telangiectasias may be seen in patients who have experienced flushing over many years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular smooth muscle responds to both autonomic innervation and circulating vasoactive agents; changes in either of these factors can lead to a flushing response. Autonomic nerves also innervate eccrine sweat glands. Thus disorders of the autonomic nervous system tend to cause vasodilation accompanied by sweating, whereas vasoactive substances, either endogenous or exogenous, tend to cause flushing reactions alone. Autonomic-mediated flushing is often referred to as a \"wet\" flush, whereas vasoactive-mediated flushing is referred to as a \"dry\" flush [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasomotor innervation of specific cutaneous vessels involves either vasoconstrictor or vasodilator fibers; in most areas of the body, one will predominate over the other. Cutaneous vessels in the face are primarily innervated by vasodilator fibers that originate in the brainstem and exit with the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of flushing is broad (",
"    <a class=\"graphic graphic_table graphicRef53013 \" href=\"UTD.htm?41/27/42428\">",
"     table 1",
"    </a>",
"    ). Neural (autonomic) mediated flushing syndromes can be classified as thermoregulatory flushing, emotional flushing, and flushing related to a disorder of the central nervous system. Direct vasodilator-mediated flushing syndromes result from exposure to a variety of exogenous substances that have a direct effect on the vascular smooth muscle or a number of systemic disorders associated with overproduction of vasoactive agents.",
"   </p>",
"   <p>",
"    An approach to the evaluation of patients with flushing is shown in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef68454 \" href=\"UTD.htm?20/32/20992\">",
"     algorithm 1",
"    </a>",
"    ) and discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most common etiologies for which a patient will present with flushing are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Hyperthermia",
"     </li>",
"     <li>",
"      Menopause",
"     </li>",
"     <li>",
"      Emotional blushing",
"     </li>",
"     <li>",
"      Rosacea",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autonomic mediated flushing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Thermoregulatory flushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of thermoregulatory flushing are associated with diaphoresis, which is the body's attempt to bring the core body temperature back to baseline. Thermoregulatory flushing can be caused by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Heat exposure: ambient or ingested hot beverage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever is readily diagnosed by an elevated temperature and may be caused by a variety of infectious and non-infectious etiologies. An increase in body temperature, either by exposure (ie, a very hot day) or exercise will induce a similar response.",
"   </p>",
"   <p>",
"    The ingestion of a hot beverage appears to induce flushing by a countercurrent heat exchange between the internal jugular vein and the carotid artery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/6\">",
"     6",
"    </a>",
"    ]. Transmission of heat via the carotid to the anterior hypothalamus, which is exquisitely sensitive to temperature, causes a rapid flushing and sweating response. Thermoregulatory flushing can typically be avoided by allowing a hot drink to cool slightly prior to ingestion and mitigated by consuming a cold beverage or ice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;A particularly common and uncomfortable form of thermoregulatory flushing is seen around the time of menopause and is secondary to decreasing levels of circulating estrogen. The flushing reaction is best known as a \"hot flash.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms related to hot flashes characteristically consist of episodic sensations of heat, intense sweating, and flushing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/7\">",
"     7",
"    </a>",
"    ]. An estimated 50 to 80 percent of women over the age of 45 suffer from these symptoms. Surgically-induced menopause tends to cause more severe symptoms, particularly in the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/8\">",
"     8",
"    </a>",
"    ]. Typical episodes last from 3 to 5 minutes and may occur up to 20 times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/9\">",
"     9",
"    </a>",
"    ]. They are often very uncomfortable, anxiety-provoking, and can interfere with sleep as well as normal daily functioning.",
"   </p>",
"   <p>",
"    The decrease in circulating estrogen appears to stimulate a sudden downward resetting of the body's thermostat in the hypothalamus that precedes the hot flash via unclear mechanisms. The alternation in set point causes a sensation of extreme heat and concomitant activation of both physiologic and behavioral heat loss responses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/8\">",
"     8",
"    </a>",
"    ]. Central adrenergic pathways may contribute to the reaction, as evidenced by the relief that many women gain from use of an alpha-2 agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Emotional flushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional flushing may be a significant source of discomfort for a patient and is more common in women than men. The exact etiology of the heightened vascular response has not been determined.",
"   </p>",
"   <p>",
"    It has been suggested that blushers are particularly concerned with how others perceive them [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/10\">",
"     10",
"    </a>",
"    ]. These patients often exhibit other heightened physiological reactions to stress, including palpitations, dry mouth, and a sense of cognitive dysfunction. The flushing reaction may be triggered by even minor healthy emotional responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions that disturb autonomic function anywhere along the nervous system can lead to flushing. Neurologic disorders that may cause autonomic instability and flushing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors or masses that compress the third ventricle",
"     </li>",
"     <li>",
"      Diencephalic autonomic epilepsy &mdash; Generalized seizures accompanied by sympathetic and parasympathetic discharge that results in sweating, flushing, piloerection, salivation, tachycardia, and hypertension",
"     </li>",
"     <li>",
"      Cluster headache &mdash; Characterized by hemifacial sweating, lacrimation, rhinorrhea, and Horner's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/11\">",
"       11",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal cord injuries &mdash; Cause autonomic hyperreflexia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H31#H31\">",
"       \"Chronic complications of spinal cord injury\", section on 'Thermoregulatory dysfunction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parkinson disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical manifestations of Parkinson disease\", section on 'Autonomic dysfunction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multiple sclerosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H13#H13\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Sensory symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autonomic hyperreflexia and orthostatic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"       2",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link&amp;anchor=H6#H6\">",
"       \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\", section on 'Autonomic failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Auriculotemporal (Frey) syndrome &mdash; Recurrent episodes of gustatory flushing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sweating in the cutaneous distribution of the auriculotemporal nerve. This is believed to result from misdirection of regenerated parasympathetic nerve fibers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"       2",
"      </a>",
"      ] and can occur after parotid surgery or injury, perinatal birth injury, or facial trauma in childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1257?source=see_link\">",
"       \"Primary focal hyperhidrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trigeminal neuralgia and migraine headache &mdash; May cause unilateral flushing, described as \"antidromic sensorineural flushing\" [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"       1",
"      </a>",
"      ]. This is mediated by a non-classic autonomic vasodilator system that originates in the brainstem and is not associated with eccrine sweat gland activation.",
"     </li>",
"     <li>",
"      Harlequin syndrome &ndash; Rare autonomic disorder involving unilateral hyperhydrosis and flushing of the head and neck. It is felt to be secondary to compression or a lesion of the sympathetic regulatory neurons. Flushing is often brought on by exercise or heat [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vasodilator mediated flushing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne rosacea is a common inflammatory dermatologic disorder primarily affecting the face. The typical age of onset is between age 40 and 60, though earlier onset is not uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rosacea characteristically is associated with telangiectasias as well as papules and pustules. Flushing is one of the earliest reported symptoms, and some have suggested that frequent flushing may be part of the pathogenesis of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/5\">",
"     5",
"    </a>",
"    ]. Flushing may be stimulated by emotion, heat or cold, exercise, spicy or hot foods, and alcohol. Patients often complain of a burning sensation. Xerosis, edema, and plaque formation may all occur.",
"   </p>",
"   <p>",
"    Diagnosis is purely clinical, with persistent facial erythema lasting greater than three months and frequent flushing episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medications cause flushing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]. The mechanisms responsible include vasodilation, increased prostacyclin synthesis, release of mast cell mediators, and release of other vasoactive mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19868329\">",
"    <span class=\"h4\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilators, including calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , and phosphodiesterase 5 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ), are the most common medications associated with flushing.",
"   </p>",
"   <p>",
"    Among calcium channel blockers, dihydropyridine agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ) are more commonly associated with flushing than non-dihydropyridine agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ). Flushing caused by dihydropyridine calcium channel blockers occurs with the following frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      &mdash; 10.5 to 25.0 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"       Nisoldipine",
"      </a>",
"      &mdash; 7 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       Amlodipine",
"      </a>",
"      &mdash; 1.2 to 2.0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Nicotinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing associated with nicotinic acid therapy is caused by an increase in prostacyclin, which is a potent vasodilator. The flushing response is antagonized by concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    administration. Newer slow-release formulations tend to mitigate this effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selective prostaglandin D2 receptor antagonist laropiprant has been shown to decrease flushing associated with extended-release niacin, but long-term safety data are absent, and it is not clear that the benefit is greater than that achieved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/15\">",
"     15",
"    </a>",
"    ]. This medication is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other medications that may produce flushing include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antihypertensives: Beta-blockers and ACE inhibitors",
"     </li>",
"     <li>",
"      Hormonal therapies: Calcitonin, calcitonin gene-related peptide, thyrotropin-releasing hormone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone acetate",
"      </a>",
"     </li>",
"     <li>",
"      Glucocorticoids: High-dose intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      , intrasynovial triamcinolone",
"     </li>",
"     <li>",
"      Antimicrobials:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link&amp;anchor=H2#H2\">",
"       \"Vancomycin hypersensitivity\", section on 'Red man syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chemotherapy agents:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , interferon alfa-2,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , mithramycin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"     </li>",
"     <li>",
"      Opiates and related drugs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      and other narcotics, enkephalin analogs",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"     </li>",
"     <li>",
"      Gold (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"       \"Major side effects of gold\"",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Induction of anesthesia (especially the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"       isoflurane",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Contrast media",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"     </li>",
"     <li>",
"      Catecholamines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also several medications that can cause flushing when taken in combination with alcohol. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Alcohol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Food ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of foods or their additives may be responsible for flushing. Spicy foods are often implicated, particularly those containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , which is derived from red peppers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. Other examples include foods containing sodium nitrate (eg, cured meats) and sulfites (used to maintain freshness).",
"   </p>",
"   <p>",
"    Certain toxins can produce a flushing reaction, believed to be mediated by histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. Scombroid fish poisoning is commonly associated with flushing and also causes headache, nausea, oral burning, sweating, and diarrhea. Ciguatera fish poisoning is characterized by abdominal pain, nausea and vomiting, diarrhea, flushing, pruritus, dysesthesias, and muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monosodium glutamate (MSG) in Chinese food has long been purported to cause a flushing reaction as part of the \"MSG syndrome.\" However, randomized placebo controlled studies raise questions whether MSG reproducibly causes symptoms in most individuals who believe they react to this additive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. When MSG is ingested in large doses, however, it causes an increase in an acetylcholine like substance that may result in flushing in susceptible individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"     \"Allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol ingestion can cause flushing by direct vasodilation of the skin, related either to alcohol directly or its metabolite, acetaldehyde. Alcohol is oxidized to acetaldehyde in the liver by alcohol dehydrogenase (ADH). The rate of this reaction is a key factor in determining whether flushing will occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/19\">",
"     19",
"    </a>",
"    ]. The enzyme aldehyde dehydrogenase (ALDH) is also involved in alcohol metabolism and deficiency of ALDH-2, seen frequently in individuals of Asian descent, results in severe flushing after alcohol ingestion due to buildup of acetaldehyde, a potent trigger of the flushing response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/20\">",
"     20",
"    </a>",
"    ]. Acetaldehyde triggers catecholamine release from the adrenal medulla and sympathetic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/21\">",
"     21",
"    </a>",
"    ]. Several studies have suggested that such polymorphisms in alcohol dehydrogenase activity may increase an individual&rsquo;s susceptibility to esophageal cancer as well as oropharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, fermented alcoholic beverages such as wine contain vasoactive substances (such as tyramine, histamine. and sulfites) that contribute to the flushing response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many medications, when combined with alcohol, can intensify the flushing response.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     Disulfiram",
"    </a>",
"    inhibits aldehyde dehydrogenase and may cause severe flushing, nausea, vomiting, and hypotension. Co-administration of sulfonylurea medication (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ) with alcohol is well known to cause flushing that typically begins around the eyes and spreads to the forehead [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/23\">",
"     23",
"    </a>",
"    ]. Other medications that may cause flushing with concomitant alcohol administration include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    , cephalosporins, antimalarials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ], and topical calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Carcinoid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic carcinoid syndrome is characterized by flushing and secretory diarrhea; additional symptoms may include profuse sweating, abdominal pain, and bronchospasm. Patients with longstanding carcinoid syndrome may develop valvular heart disease (especially right-sided) and facial telangiectasias. However, only a small subset of patients with carcinoid tumors will experience symptoms of carcinoid syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The carcinoid syndrome is primarily associated with metastatic tumors originating in the distal small intestine and proximal colon (midgut). Since the liver normally inactivates these hormones, there needs to be enough tumor burden downstream of normally functioning hepatic tissue for the mediators to enter the systemic circulation and cause symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The typical flush associated with midgut carcinoids (jejunum, ileum, cecum, appendix) begins suddenly and lasts from 30 seconds to as long as 30 minutes. It primarily involves the face, neck, and upper chest, which become red to violaceous or purple, and is associated with a mild burning sensation (",
"      <a class=\"graphic graphic_picture graphicRef55493 \" href=\"UTD.htm?15/40/16000\">",
"       picture 1",
"      </a>",
"      ). Patients often develop a drop in blood pressure as well as tachycardia during a typical flushing episode.",
"     </li>",
"     <li>",
"      In contrast, bronchial, gastric, appendiceal and rectal carcinoid tumors (ie, those arising from the foregut and hindgut) can produce the carcinoid syndrome in the absence of metastatic disease because of their direct access to the systemic circulation; but this is rare overall (",
"      <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      When they occur, the flushes associated with gastric carcinoid tumors are atypical, and tend to be red-brown hue, patchy, sharply demarcated, serpiginous; they are also intensely pruritic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features of the carcinoid syndrome\", section on 'Gastric carcinoid variant syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with the bronchial carcinoid variant, the flushes can be very severe and prolonged, lasting hours to days [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/25\">",
"       25",
"      </a>",
"      ]. They may be associated with disorientation, anxiety, and tremor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical features of the carcinoid syndrome\", section on 'Bronchial carcinoid variant syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of stimuli may trigger flushing in patients with carcinoid syndrome, including alcohol, chocolate, and ingestion of beef. It is postulated that alcohol and chocolate may release a catecholamine with direct activity on the tumor. The secretion of gastrin may also play a role, particularly in tumors of stomach or foregut origin. Alcohol and beef consumption are known to enhance gastrin secretion, which is one proposed mechanism for their mediating a carcinoid flush [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential flushing mediators include substance P, histamine, kallikrein, and kinins, although it is not absolutely clear which vasoactive hormone is responsible for symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of carcinoid syndrome may be made by measurement of 24 hour urine 5-hydroxyindoleoacetic acid (5-HIAA), a metabolite of serotonin. Diagnosis and tumor localization are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis is a rare disorder of mast cell proliferation leading to tissue infiltration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mastocytosis in the pediatric population is typically associated with a skin rash characterized by red-brown papules, macules, or plaques that become urticarial with topical pressure (Darier sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/26\">",
"     26",
"    </a>",
"    ]. Systemic symptoms and abnormalities in the peripheral blood smear are more common in adults. Systemic symptoms are caused by the release of mast cell mediators such as histamine and prostaglandin, which cause vasodilation, flushing, hypotension, tachycardia, and anaphylaxis. Patients may also have abdominal cramping, diarrhea, nausea, vomiting, and fever.",
"   </p>",
"   <p>",
"    Systemic symptoms may be triggered by narcotic analgesics, as well as by agents that trigger allergic reactions such as intravenous contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/4\">",
"     4",
"    </a>",
"    ]. Other known precipitants include anesthetic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and nonsteroidal antiinflammatory medications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    A disorder of mast cell activation syndrome felt to be distinct from mastocytosis has been described that typically presents with abdominal pain, dermatographism, and flushing and may also be associated with headache, diarrhea, and memory or concentration difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma is a neoplasia of chromaffin cells. The tumor is typically derived from the adrenal medulla, and is associated with a release of catecholamines episodically into the systemic circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Headaches, sweating, and tachycardia and hypertension are common; 60 percent of patients have sustained hypertension or labile blood pressure, and 40 percent experience blood pressure elevation only during attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients may experience either pallor or flushing, though flushing characteristically occurs following, rather than during, a typical attack. A feeling of apprehension is not uncommon, and patients often experience nausea, vomiting, and chest or abdominal pain. Episodes are paroxysmal in nature and last between minutes to hours.",
"   </p>",
"   <p>",
"    Catecholamine-induced flushing is felt to be regulated by innervation of sympathetic vasodilator fibers of the face, as well as related to increased cardiac output. Diagnosis is made by measuring urinary catecholamine and fractionated metanephrine levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Medullary thyroid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary thyroid carcinoma is a malignant tumor of parafollicular thyroid cells. Tumor cells produce calcitonin, as well as biogenic amines, ACTH, and corticotropin-releasing hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/7\">",
"     7",
"    </a>",
"    ]. Presentation typically involves facial and upper-extremity flushing, as well as telangiectasias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor may occur in an autosomal dominant fashion as part of the Multiple Endocrine Neoplasia (MEN) syndrome or may be sporadic. Diagnosis is typically made via fine needle aspiration of a thyroid nodule and by calcitonin radioimmunoassay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Serotonin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serotonin syndrome, associated with increased serotonergic activity in the central nervous system, is most often related to medication side effects and interactions. It is characterized by mental status changes, autonomic hyperreactivity, and neuromuscular hyperreactivity. Diaphoresis and hyperthermia are characteristic autonomic manifestations that may present as flushing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to consider anaphylaxis in the differential diagnosis. Flushing occurs commonly with anaphylaxis but generally in conjunction with other symptoms such as hypotension, stridor, hives, and abdominal pain. Flushing in isolation is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]. Flushing is seen in almost 50 percent of anaphylactic allergic reactions to medications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flushing is caused by the release of mast cell as well as basophil vasoactive substances into the circulation. Diagnosis is typically based on clinical presentation, and prompt treatment with intramuscular epinephrine is imperative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pancreatic tumor/VIPoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoactive intestinal polypeptide (VIP) tumors are non-beta islet cell neoplasms that secrete VIP, prostaglandins, gastric inhibitory peptides, and pancreatic peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ]. Typical presentation includes watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/7\">",
"     7",
"    </a>",
"    ]. Flushing occurs in 20 percent of patients and is attributable to the vasodilator action of VIP. Nausea, vomiting, abdominal pain, and weakness are also common symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Renal cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinoma most often presents with hematuria. The classic triad of gross hematuria, palpable abdominal mass, and flank pain is present in less than 10 percent of cases. Patients may also have fatigue, weight loss, fever, and anemia. Flushing, when it occurs, is felt to be due to the production of gonadotropin-like hormones from the tumor that cause a down regulation of the pituitary gland. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of less-common causes of flushing should be considered in a broad differential diagnosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dumping syndrome or short-gut syndrome &mdash; tachycardia, flushing, sweating, dizziness, and hypotension related to rapid gut transit",
"     </li>",
"     <li>",
"      Sarcoidosis &mdash; associated with facial flushing due to vasodilation caused by granuloma infiltration of blood vessels in the skin, especially in the lupus pernio variant (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperthyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Skin'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bronchogenic carcinoma",
"     </li>",
"     <li>",
"      Androgen deficiency in men",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, other conditions that cause facial erythema may be mistaken for a flushing reaction. Conditions to be considered are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral stenosis &mdash; can cause a chronic malar flush associated with cyanosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus &mdash; the classic malar or \"butterfly rash\" over the cheeks and nose may be confused with flushing",
"     </li>",
"     <li>",
"      Photosensitivity reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of an approach to evaluating a patient with flushing is presented in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef68454 \" href=\"UTD.htm?20/32/20992\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A detailed history and physical exam are important in evaluating the patient with flushing. The presence of sweating associated with flushing suggests an autonomic mediated etiology of flushing and distinguishes this from a direct vasodilator etiology.",
"   </p>",
"   <p>",
"    Patients should be advised to keep a diary of flushing reactions for two weeks, recording associations with food or medication, exertion, or emotional stress, as well as symptoms including headache, bronchospasm, abdominal pain, diarrhea, and urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most systemic disorders that include flushing are distinguished by typical and evident associated symptoms. When history and physical do not yield a probable diagnosis, the patient should undergo initial evaluation for carcinoid syndrome, mastocytosis, and pheochromocytoma, as these are the most common systemic disorders to cause flushing. Initial laboratory evaluation should include a complete blood count and liver function tests, a 24 hour urine for 5-HIAA (carcinoid syndrome), histamine and prostaglandin D2 (systemic mastocytosis), and catecholamines as well as fractionated metanephrines (pheochromocytoma). Serum tryptase may also be helpful in diagnosing systemic mastocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If initial studies are negative, referral to an endocrinologist is warranted to continue evaluation for etiologies such as a VIPoma, medullary thyroid carcinoma, and other conditions as noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is typically tailored to the underlying condition or predisposing factor. Flushing that is a consequence of an exogenous agent is readily treated by removal of the identified offending agent.",
"   </p>",
"   <p>",
"    Anaphylaxis must be immediately recognized and treated with subcutaneous epinephrine. Patients with flushing as a consequence of a systemic illness should be treated appropriately for the underlying condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link\">",
"     \"Treatment and prognosis of systemic mastocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other specific conditions may respond to tailored treatment for flushing. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menopausal related hot flashes respond to a variety of agents, including estrogen, selective serotonin and norepinephrine reuptake inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Flushing related to nicotinic acid can be prevented by administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      prior to a dose of nicotinic acid and by use of longer-acting formulations of nicotinic acid.",
"     </li>",
"     <li>",
"      Alcohol-induced flushing can be ameliorated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      taken together with an antihistamine in many individuals.",
"     </li>",
"     <li>",
"      Patients may develop tolerance to calcium channel blocker flushing over time.",
"     </li>",
"     <li>",
"      Flushing associated with rosacea has been treated with only minimal success [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29066?source=see_link&amp;anchor=H2324141#H2324141\">",
"       \"Management of rosacea\", section on 'Avoidance of flushing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most benign etiologies, there are no agents that easily and readily eliminate the flushing response. Emotional flushing or blushing may respond to the use of a non-selective beta blocker, particularly when associated with other prominent sympathetic nervous system features such as tachycardia, palpitations, and dry mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ]. Individuals who are predisposed to blushing secondary to skin type may find that use of cosmetics with a green tint can offset the redness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Botulinum toxin A has been used with success to treat neck and anterior chest wall flushing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/33\">",
"     33",
"    </a>",
"    ]. Endoscopic transthoracic sympathectomy has been reported to have short-term effectiveness for severe cases of flushing associated with social phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12857/abstract/34\">",
"     34",
"    </a>",
"    ]. The potential side effects of such procedures must be weighed against possible benefits, and in general we do not recommend either botulinum toxin or sympathectomy for management of flushing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/14/40161?source=see_link\">",
"       \"Patient information: Rosacea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common etiologies of flushing are fever, hyperthermia, menopause, emotional blushing, or rosacea. Flushing may be categorized as autonomic-mediated or vasodilator-mediated flushing. Autonomic flushing syndromes include thermoregulatory flushing, emotional flushing, and flushing related to a central nervous system disorder. Vasodilator flushing may be caused by exogenous agents (drugs, alcohol, food) or endogenous hormones resulting from systemic disease (",
"      <a class=\"graphic graphic_table graphicRef53013 \" href=\"UTD.htm?41/27/42428\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough history and physical is important. Patients should maintain a diary for at least two weeks that documents each flushing episode along with associated activity, food intake, emotional state, and medication use. Although many conditions that are associated with flushing have non-specific or no physical exam findings, the presence of other skin lesions, hypertension, thyroid nodule, or abdominal mass may suggest specific etiologies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Vasodilator mediated flushing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When an etiology is not identified by history and physical examination, initial laboratory evaluation includes a complete blood count and liver function tests, a 24-hour urine for 5-HIAA (carcinoid syndrome), histamine and prostaglandin D2 (systemic mastocytosis), and catecholamines, as well as fractionated metanephrines (pheochromocytoma) (",
"      <a class=\"graphic graphic_algorithm graphicRef68454 \" href=\"UTD.htm?20/32/20992\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is tailored to the underlying condition or predisposing factor. Avoidance of hot beverages, spicy foods, cured meats, and alcohol may be helpful for those individuals who are predisposed to flushing episodes. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/1\">",
"      Wilkin JK. The red face: flushing disorders. Clin Dermatol 1993; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/2\">",
"      Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/3\">",
"      Robson KJ, Piette WW. Cutaneous manifestations of systemic diseases. Med Clin North Am 1998; 82:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/4\">",
"      Ray D, Williams G. Pathophysiological causes and clinical significance of flushing. Br J Hosp Med 1993; 50:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/5\">",
"      Wilkin JK. Flushing reactions: consequences and mechanisms. Ann Intern Med 1981; 95:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/6\">",
"      Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol 1981; 76:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/7\">",
"      Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/8\">",
"      Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/9\">",
"      Aldrich LB, Moattari AR, Vinik AI. Distinguishing features of idiopathic flushing and carcinoid syndrome. Arch Intern Med 1988; 148:2614.",
"     </a>",
"    </li>",
"    <li>",
"     Edelmann R. Coping with blushing, Sheldon Press, London 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/11\">",
"      Freeman R, Waldorf HA, Dover JS. Autonomic neurodermatology (Part II): Disorders of sweating and flushing. Semin Neurol 1992; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/12\">",
"      Kaddu S, Smolle J, Komericki P, Kerl H. Auriculotemporal (Frey) syndrome in late childhood: an unusual variant presenting as gustatory flushing mimicking food allergy. Pediatr Dermatol 2000; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/13\">",
"      Tascilar N, Tekin NS, Erdem Z, et al. Unnoticed dysautonomic syndrome of the face: Harlequin syndrome. Auton Neurosci 2007; 137:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/14\">",
"      Ioulios P, Charalampos M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J 2003; 9:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/15\">",
"      Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/16\">",
"      Olday J, Currie E, Drummond GB. The incidence of flushing on induction of anaesthesia in patients who blush easily. Anaesthesia 2003; 58:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/17\">",
"      Wilkin JK. Does monosodium glutamate cause flushing (or merely \"glutamania\")? J Am Acad Dermatol 1986; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/18\">",
"      Geha RS, Beiser A, Ren C, et al. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. J Nutr 2000; 130:1058S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/19\">",
"      Eriksson CJ, Fukunaga T, Sarkola T, et al. Functional relevance of human adh polymorphism. Alcohol Clin Exp Res 2001; 25:157S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/20\">",
"      Oroszi G, Goldman D. Alcoholism: genes and mechanisms. Pharmacogenomics 2004; 5:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/21\">",
"      Chao HM. Alcohol and the mystique of flushing. Alcohol Clin Exp Res 1995; 19:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/22\">",
"      Morita M, Kumashiro R, Kubo N, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol 2010; 15:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/23\">",
"      Fellner MJ, Ledesma GN. The red face: drugs, chemicals and other causes. Clin Dermatol 1993; 11:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/24\">",
"      Ogunleye T, James WD. Ethanol-induced flushing with topical pimecrolimus use. Dermatitis 2008; 19:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/25\">",
"      Melmon KL, Sjoerdsma A, Mason DT. Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors. Am J Med 1965; 39:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/26\">",
"      Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000; 14:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/27\">",
"      Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011; 128:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/28\">",
"      Aaronson DW. Flushing as a symptom of anaphylaxis. J Allergy Clin Immunol 1999; 103:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/29\">",
"      Hammar M, Berg G. Clonidine in the treatment of menopausal flushing. A review of clinical studies. Acta Obstet Gynecol Scand Suppl 1985; 132:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/30\">",
"      Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/31\">",
"      Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/32\">",
"      Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/33\">",
"      Sterodimas A, Nicolaou M, Paes TR. Successful use of Botulinum toxin-A for the treatment of neck and anterior chest wall flushing. Clin Exp Dermatol 2003; 28:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12857/abstract/34\">",
"      Drummond PD. A caution about surgical treatment for facial blushing. Br J Dermatol 2000; 142:194.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2782 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12857=[""].join("\n");
var outline_f12_35_12857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autonomic mediated flushing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Thermoregulatory flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Emotional flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vasodilator mediated flushing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rosacea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19868329\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nicotinic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Food ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Medullary thyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pancreatic tumor/VIPoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2782|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/32/20992\" title=\"algorithm 1\">",
"      Algorithm for the evaluation of flushing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2782|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16000\" title=\"picture 1\">",
"      Carcinoid flush",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/27/42428\" title=\"table 1\">",
"      Differential dx flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 2\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=related_link\">",
"      Approach to the patient with night sweats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29066?source=related_link\">",
"      Management of rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/14/40161?source=related_link\">",
"      Patient information: Rosacea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1257?source=related_link\">",
"      Primary focal hyperhidrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12858="Assessing surgical risk in patients with liver disease";
var content_f12_35_12858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessing surgical risk in patients with liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/35/12858/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/35/12858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with liver disease who require surgery are at greater risk for surgical and anesthesia related complications than those with a healthy liver [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The magnitude of the risk depends upon the type of liver disease and its severity, the surgical procedure, and the type of anesthesia.",
"   </p>",
"   <p>",
"    The assessment of surgical risk in patients with liver disease will be reviewed here. Patients with liver disease may have concomitant disorders (such as cardiovascular disease) that influence surgical outcomes; these issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING FOR LIVER DISEASE BEFORE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing surgery should undergo a history and physical examination to exclude findings or risk factors for liver disease. This may include asking about prior blood transfusions, tattoos, illicit drug use, sexual promiscuity, a family history of jaundice or liver disease, a history of jaundice or fever following anesthesia, alcohol use (current, prior and quantity), and a complete review of current medications. Clinical features suggestive of liver disease (such as fatigue, pruritus, increased abdominal girth, jaundice, palmar erythema, spider telangiectasias, splenomegaly, and gynecomastia and testicular atrophy in men) should be evaluated.",
"   </p>",
"   <p>",
"    Whether otherwise healthy surgical candidates should undergo biochemical screening for liver disease is controversial. The vast majority of patients found to have abnormal liver biochemical test results do not have advanced liver disease. Thus, it is unlikely that routinely obtaining a liver biochemical profile in otherwise healthy patients without risk factors for liver disease would lead to improved outcomes; thus, such testing is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS OF ANESTHESIA AND SURGERY ON THE LIVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of anesthesia and surgery on the liver depend upon the type of anesthesia used, the specific surgical procedures, and the severity of liver disease. In addition, perioperative events, such as hypotension, sepsis, or the administration of hepatotoxic drugs, can compound injury to the liver occurring during the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40805?source=see_link\">",
"     \"Effects of anesthesia and surgery on the liver\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESTIMATING SURGICAL RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of surgical risk in patients with liver disease includes an appraisal of the severity of liver disease, the urgency of surgery (and alternatives to surgery), and coexisting medical illness. Surgical risk assessment is less relevant if immediate surgery is required to prevent death. On the other hand, the vast majority of decisions are made in the setting of semi-urgent or elective procedures for which there is time for risk assessment, optimization of the patient's medical status, and consideration of alternative approaches.",
"   </p>",
"   <p>",
"    The majority of studies examining the risk of surgery in patients with liver disease have focused on patients with cirrhosis from which a number of risk factors have been identified (",
"    <a class=\"graphic graphic_table graphicRef61787 \" href=\"UTD.htm?23/14/23787\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/5-17\">",
"     5-17",
"    </a>",
"    ]. Much less information has been published on the risk of surgery in patients with milder forms of liver disease. The available evidence is derived mostly from small retrospective studies and clinical experience. Furthermore, many of the studies were published prior to the availability of a number of serologic tests for specific types of liver disease, and modern hepatobiliary imaging. Thus, there is relatively little information on the risk of surgery in patients with specific types of liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patients in whom surgery is contraindicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of settings have been identified that are associated with unacceptable surgical mortality. As a result, these conditions are usually considered to be contraindications to elective surgery (",
"    <a class=\"graphic graphic_table graphicRef64509 \" href=\"UTD.htm?10/29/10715\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute or fulminant hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatitis is a contraindication to elective surgery. This recommendation is based upon older studies, in which operative mortality rates of 10 to 13 percent were reported among icteric patients who underwent laparotomy as part of a diagnostic evaluation that ultimately led to a diagnosis of acute viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, patients with fulminant hepatitis are gravely ill and are unlikely to withstand surgery other than liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective surgery is contraindicated in patients with histologic evidence of alcoholic hepatitis. Mortality rates as high as 55 to 100 percent have been observed in such patients undergoing open liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/19\">",
"     19",
"    </a>",
"    ], portosystemic shunt surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], or exploratory laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is possible that advances in surgical technique and postoperative care may have improved the outcome in such patients compared to the above studies, some of which were conducted more than 20 to 30 years ago. This was illustrated in a report from 1984, in which operative liver biopsy findings were reviewed in 164 patients with alcoholic cirrhosis and bleeding varices who underwent emergency portacaval shunt surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/24\">",
"     24",
"    </a>",
"    ]. Of these patients, 49 (30 percent) had histologic evidence of alcoholic hepatitis, but had survival rates similar to those without alcoholic hepatitis. These results have not been duplicated.",
"   </p>",
"   <p>",
"    We recommend that elective surgery should be delayed for at least 12 weeks, or that a repeat liver biopsy should be considered to confirm resolution. The severity of underlying liver disease should be reassessed prior to making a final recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Severe chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical risk in patients with chronic hepatitis correlates with the clinical, biochemical, and histologic severity of disease. Patients with symptomatic and histologically severe chronic hepatitis have increased surgical risk, particularly in those with impaired hepatic synthetic or excretory function, portal hypertension, or bridging or multilobular necrosis on liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients at variable increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of surgery in patients with cirrhosis depends upon the severity of disease, the clinical setting and type of surgical procedure. For over 30 years, the principal predictor of operative risk in patients with cirrhosis has been the Child's classification, but newer studies suggest that the Model for End-Stage Liver Disease (MELD) score may be superior [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Child's classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of retrospective studies have demonstrated that perioperative mortality and morbidity in patients with cirrhosis correlate well with the Child-Turcotte (",
"    <a class=\"graphic graphic_table graphicRef56436 \" href=\"UTD.htm?13/0/13323\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/28\">",
"     28",
"    </a>",
"    ] or Child-Pugh [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/17,29\">",
"     17,29",
"    </a>",
"    ] classification of cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study from 1984, perioperative mortality rates of 10, 31, and 76 percent were observed in 100 patients with predominantly alcoholic cirrhosis undergoing abdominal surgery who were Child-Pugh class A, B, and C, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/16\">",
"       16",
"      </a>",
"      ]. On multivariate analysis, the Child-Pugh classification was the best predictor of surgical mortality and morbidity.",
"     </li>",
"     <li>",
"      Nearly identical results were observed in a similarly designed study published in 1997 of 92 patients with cirrhosis (approximately 50 percent alcoholic) undergoing abdominal surgery (mortality rates of 10, 30, and 82 percent in patients with Child-Pugh class A, B, and C, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study published in 2010, however, showed lower mortality rates of 2, 12, and 12 percent for patients with Child-Pugh class A, B, and C cirrhosis, respectively, undergoing abdominal surgery.",
"     </li>",
"     <li>",
"      A study of 138 patients undergoing intra-abdominal or abdominal wall surgery published in 2011 showed rates of 10, 17, and 63 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality rates declined in the 2000s, presumably because of improvements in the overall care of critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 261 patients (45 with cirrhosis and 216 matched controls without cirrhosis) undergoing cardiac surgery between 1992 and 2009, patients with a Child-Pugh score of less than 8 had a higher survival rate at 90 days compared with patients whose score was 8 or greater (95 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, patients with a Child-Pugh score of less than 8 had survival rates similar to control patients without cirrhosis (95 versus 97 percent).",
"   </p>",
"   <p>",
"    Patients with Child's class A cirrhosis and portal hypertension are at increased risk of postoperative ascites, jaundice, and encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/34\">",
"     34",
"    </a>",
"    ]. Limited observations suggest that postoperative morbidity may be reduced by preoperative placement of a transjugular intrahepatic portosystemic shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Measures of hepatic function and the APACHE score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of measures of hepatic function have been proposed as predictors of perioperative morbidity and mortality in patients with cirrhosis. Examples include quantitative assessment of liver function with dynamic tests such as galactose elimination capacity, aminopyrine breath testing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    clearance, and the rate of metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to monoethylglycinexylidide (MEGX). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .) However, none has been shown convincingly to provide additional prognostic information compared to the Child-Pugh classification, and, as a result, they are not used widely [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Acute Physiology, Age, and Chronic Health Evaluation System (APACHE III) score can predict survival in cirrhotic patients admitted to an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/37\">",
"     37",
"    </a>",
"    ]. However, it has not been studied specifically in cirrhotic patients undergoing surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MELD score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MELD score is a statistical model predicting survival in patients with cirrhosis (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). It has been evaluated principally for selecting patients for liver transplantation. Use of this model for predicting surgical risk in the nontransplant setting has been promising and thus it may ultimately supplant the Child's classification as the principal method for determining surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. However, more studies involving diverse groups of surgical patients with a wide range of MELD scores are needed to understand its performance as a predictive model for surgery. The following summarizes representative studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MELD score, American Society of Anesthesiologists class, and age predicted mortality in a study of 772 patients with cirrhosis who underwent major digestive, orthopedic, or cardiovascular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/38\">",
"       38",
"      </a>",
"      ]. The MELD score was the best predictor of 30 and 90 day mortality. Mortality at 30 days ranged from 6 percent (MELD score, &lt;8) to more than 50 percent (MELD score, &gt;20) and correlated linearly with the MELD score.",
"     </li>",
"     <li>",
"      Another study compared the MELD score with the Child-Turcotte-Pugh classification in 40 cirrhotic patients who required either elective or emergency surgery with general anesthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/40\">",
"       40",
"      </a>",
"      ]. Emergency surgery was associated with significantly higher one- and three-month mortality rates. There was good correlation between the Child-Turcotte-Pugh classification and the MELD scores in predicting mortality, especially in the emergency surgery group.",
"     </li>",
"     <li>",
"      In other reports in selected settings, a MELD score &ge;8 was useful for predicting morbidity in 33 patients undergoing cholecystectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/41\">",
"       41",
"      </a>",
"      ], a MELD score &gt;14 was a better predictor of poor outcomes than the Child-Pugh classification in a series of 53 cirrhotic patients undergoing abdominal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/42\">",
"       42",
"      </a>",
"      ], a MELD score &ge;15 with an albumin &le;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      predicted significantly increased mortality in a series of 100 patients undergoing abdominal surgery (60 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/32\">",
"       32",
"      </a>",
"      ], and a MELD score &ge;11 predicted a high risk for postoperative liver failure in 154 patients with cirrhosis undergoing hepatectomy for hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that patients with a MELD score below 10 can undergo elective surgery, those with a MELD score of 10 to 15 may undergo elective surgery with caution, and those with a MELD score &gt;15 should not undergo elective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/44\">",
"     44",
"    </a>",
"    ]. A calculator is available (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?31/26/32162?source=see_link\">",
"     calculator 3",
"    </a>",
"    )to calculate the estimated 7-day, 30-day, 90-day, 1-year, and 5-year mortality rates after surgery based on the patient's age, ASA class, INR, serum bilirubin and creatinine. The model is based on the original MELD score, not the one currently being used for organ transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Obstructive jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructive jaundice are at increased risk for several perioperative complications including infections (which result in part from bacterial colonization of the biliary tree, impaired Kupffer cell function, defective neutrophil function, and a high rate of endotoxemia), stress ulceration, disseminated intravascular coagulation, wound dehiscence, and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Perioperative mortality ranged from 8 to 28 percent in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. As an example, an overall mortality rate of 9 percent was found in a large retrospective study that included 373 patients undergoing surgery for obstructive jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/50\">",
"     50",
"    </a>",
"    ]. Multivariate analysis identified three predictors of postoperative mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An initial hematocrit value &lt;30 percent",
"     </li>",
"     <li>",
"      An initial serum bilirubin level &gt;11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       micromoles/L)",
"      </span>",
"     </li>",
"     <li>",
"      A malignant cause of obstruction (eg, pancreatic carcinoma or cholangiocarcinoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When all three factors were present, mortality approached 60 percent; when none was present, mortality was only 5 percent. Several other preoperative predictors of poor surgical outcome have been observed in other studies including azotemia, hypoalbuminemia, and cholangitis (",
"    <a class=\"graphic graphic_table graphicRef72637 \" href=\"UTD.htm?0/60/971\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/49-54\">",
"     49-54",
"    </a>",
"    ]. The presence of portal hypertension can also be presumed to increase the surgical risk.",
"   </p>",
"   <p>",
"    A number of interventions have been attempted to reduce morbidity and mortality in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioperative administration of broad-spectrum intravenous antibiotics reduces the frequency of postoperative infections but does not influence mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      External biliary drainage via a transhepatic approach has not been proven to improve morbidity or mortality in controlled studies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/56-59\">",
"       56-59",
"      </a>",
"      ]. In one report, it increased overall and infectious postoperative complication rates when used before resection for hilar cholangiocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoscopic biliary drainage has the advantage of restoring enterohepatic circulation of bile acids while avoiding the complications of percutaneous puncture. However, as for external biliary drainage, it also has not been shown to improve surgical mortality in patients with a malignant cause of biliary obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/61,62\">",
"       61,62",
"      </a>",
"      ], although preoperative biliary drainage has been recommended in patients undergoing extended hepatic resection [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/63\">",
"       63",
"      </a>",
"      ] or with cholangitis or pruritus when surgery is delayed [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/64\">",
"       64",
"      </a>",
"      ]. In patients with cholangitis and choledocholithiasis, broad spectrum intravenous antibiotics and endoscopic drainage have been associated with lower mortality and morbidity rates compared to surgical decompression [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]. Although endoscopic sphincterotomy is associated with an increased rate of complications in patients with cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/68\">",
"       68",
"      </a>",
"      ], morbidity and mortality rates are low even in patients with Child's class C cirrhosis when biliary decompression can be achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"       \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A major cause of morbidity in patients with obstructive jaundice is postoperative renal failure, which is usually due to acute tubular necrosis; the average frequency was approximately 8 percent in several reports [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/47,70,71\">",
"       47,70,71",
"      </a>",
"      ]. The high incidence may be related to the absorption of endotoxin from the gut [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/72\">",
"       72",
"      </a>",
"      ]. In normal subjects, endotoxin absorption is limited by the detergent effect of bile salts on the lipopolysaccharide endotoxin molecule; this protection is lost with obstructive jaundice, since bile salt secretion is minimal. As a result, patients may develop exaggerated renal vasoconstriction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"       \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence suggests that the administration of bile salts or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    to patients with obstructive jaundice can prevent both the endotoxemia and the exaggerated renal vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/55,72-74\">",
"     55,72-74",
"    </a>",
"    ]. In one report, for example, 102 patients with obstructive jaundice who had a serum bilirubin concentration &gt;5.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     micromoles/liter)",
"    </span>",
"    were randomly assigned to receive lactulose, sodium deoxycholate (a bile salt) or no specific treatment prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/73\">",
"     73",
"    </a>",
"    ]. Postoperative deterioration in renal function in patients with normal preoperative function was significantly more common in patients who had received no specific treatment.",
"   </p>",
"   <p>",
"    Another approach that has been attempted to reduce the incidence of renal failure is the postoperative administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/55,75\">",
"     55,75",
"    </a>",
"    ]. Despite its theoretical benefit, maintenance of intravascular volume, and the avoidance of nephrotoxic drugs, such as aminoglycosides, are probably more critical elements in management [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic oral antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , have also been proposed as a means to reduce adverse effects of endotoxemia but a benefit has not yet been demonstrated. Furthermore, it is possible that oral antibiotics could increase endotoxemia because they may lead to increased release of endotoxin caused by destruction gram-negative organisms. On the other hand, intravenous broad-spectrum antibiotics should generally be given perioperatively to reduce the incidence of postoperative infection, although a benefit on mortality has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patients with cholestatic liver disease (such as primary biliary cirrhosis and primary sclerosing cholangitis) also have an increased risk of acute tubular necrosis following surgery has not been well studied. An interesting clinical observation is that patients with primary biliary cirrhosis appear to be at decreased risk for developing hepatorenal syndrome after surgery compared to patients with other forms of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/79\">",
"     79",
"    </a>",
"    ]. A possible explanation is the natriuretic and renal vasodilator actions of retained bile salts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery is associated with increased mortality in patients with cirrhosis compared to other surgical procedures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest series included 44 patients with cirrhosis of whom 12 developed hepatic decompensation and 7 died [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/39\">",
"       39",
"      </a>",
"      ]. The Child's class was a significant predictor of decompensation and mortality. For mortality, a CPT score of &gt;7 had sensitivity, specificity, positive, and negative predictive values of 86, 92, 67, and 97 percent, respectively. The authors concluded that cardiopulmonary bypass can be conducted safely in patients with a CPT score of &lt;7. However, in other reports, major complications have been described in patients with lower scores [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series included 27 patients with cirrhosis (10 with Child class A, 11 with Child class B and 6 with Child class C, with an overall mean MELD score of 14.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/81\">",
"       81",
"      </a>",
"      ]. Operative mortality was 11, 18, and 67 percent for Child class A, B, and C, respectively (26 percent overall), and the Child classification was a better predictor or mortality than the MELD score (using an arbitrary MELD classification of 0-12 and &ge;13).",
"     </li>",
"     <li>",
"      A third report included 13 patients with predominantly alcoholic cirrhosis (eight with Child class A, and five with Child class B) who required coronary artery bypass grafting, valve replacement or both [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/82\">",
"       82",
"      </a>",
"      ]. All patients who were Child class B experienced major complications and only one patient survived. All patients who were Child class A survived despite a complication rate of 25 percent. The high mortality rate in patients with Child class B was attributed to postoperative infections and bleeding, rather than cardiac dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of risk factors for hepatic decompensation following cardiac surgery have been identified including the total time of cardiopulmonary bypass, use of nonpulsatile as opposed to pulsatile cardiopulmonary bypass, and need for perioperative pressor support [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/83\">",
"     83",
"    </a>",
"    ]. Cardiopulmonary bypass can exacerbate underlying coagulopathy by inducing platelet dysfunction, fibrinolysis, and hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the least invasive options, such as angioplasty, valvuloplasty, or minimally invasive revascularization techniques, should be considered in patients with advanced cirrhosis who require invasive intervention for cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    .) Cardiac surgery followed by liver transplantation has been performed in rare instances [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/83,86,87\">",
"     83,86,87",
"    </a>",
"    ]. Even more rarely, liver transplantation has been undertaken before cardiac surgery in patients with left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/84\">",
"     84",
"    </a>",
"    ]. This approach is hazardous because of the risk of hemodynamic instability resulting from reduced venous return and reperfusion of the graft during liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hepatic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis undergoing resection for hepatocellular carcinoma or other liver tumors are at increased risk for hepatic decompensation compared to those undergoing other types of operations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition to having severe underlying disease, a significant portion of functional hepatocellular mass may be removed in a setting in which patients already have severely compromised hepatic reserve. In the past, cirrhosis was considered to be a contraindication to resection of hepatic tumors since mortality rates exceeded 50 percent.",
"   </p>",
"   <p>",
"    More recently, the perioperative mortality rate for hepatic resection has decreased to 3 to 16 percent, although postoperative morbidity rates are still as high as 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/89-97\">",
"     89-97",
"    </a>",
"    ]. The improvement in outcomes has been attributed to better patient selection (including earlier detection of tumors), meticulous preoperative preparation, intensive intra- and postoperative monitoring, and improved surgical techniques. Postresectional liver failure is defined as an INR &gt;1.7 (prothrombin time index &lt;50 percent) and serum bilirubin greater than 2.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the so-called 50-50 criteria, and is associated with a mortality rate of about 60 percent compared with 1.2 percent when the criteria are not met [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/98\">",
"     98",
"    </a>",
"    ]. Options for treating hepatocellular carcinoma, including surgical resection, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several systems for risk stratification of patients undergoing hepatic resection have been proposed, although none has been validated extensively. A database study of 587 patients who underwent hepatic resection concluded that the Child-Pugh Score and American Society of Anesthesiologists (ASA) physical status classification were better predictors of morbidity and mortality than the MELD score [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/99\">",
"     99",
"    </a>",
"    ]. The ASA score was the only significant predictor of 30-day mortality (area under the receiver operating curve {ROC} of 0.63) while the ASA and Charlson Index of Comorbidity were the only significant predictors of morbidity (ROC of 0.56 and 0.40, respectively). However, the low ROC areas indicate that none of these models was an accurate predictor of outcomes. Moderate to severe hepatic steatosis (&gt;30 percent of liver volume) is a risk factor for postoperative complications after major hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma patients found to have cirrhosis at laparotomy are at increased risk for morbidity and mortality. In one study, the overall mortality rate was 45 percent, significantly higher than of a matched control population (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/101\">",
"     101",
"    </a>",
"    ]. Mortality and morbidity rates were increased even for patients considered to have relatively minor trauma. The authors recommended that trauma patients found to have cirrhosis at laparotomy be admitted to the intensive care unit for close monitoring and aggressive management irrespective of the severity of their injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patients with minimally increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild to moderate chronic liver disease without cirrhosis usually tolerate surgery well. However, medical therapy should be optimized prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mild chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with mild chronic hepatitis are at low risk for complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/102\">",
"     102",
"    </a>",
"    ]. In one report, for example, no major complications were noted during 34 surgical procedures in 24 patients with mild to moderate chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/102\">",
"     102",
"    </a>",
"    ]. Two patients developed sustained hyperbilirubinemia, both of whom had preoperative bilirubin levels of 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35.91",
"    <span class=\"nowrap\">",
"     micromoles/liter)",
"    </span>",
"    or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Fatty liver and nonalcoholic steatohepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the histologic appearance of nonalcoholic steatohepatitis (NASH) is similar to alcoholic hepatitis, patients with NASH do not appear to have excessive mortality following elective surgery. However, a trend toward increased mortality following hepatic resection has been observed in those with moderate to severe steatosis (&gt;30 percent of hepatocytes containing fat) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NASH is relatively common in patients with morbid obesity who undergo gastric bypass surgery. Cirrhosis, due presumably to NASH, has been found unexpectedly in up to 6 percent of such patients, in whom a perioperative mortality rate of 4 percent has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be difficult to distinguish NASH from alcoholic hepatitis since the histologic features can be identical, and patients do not always admit to alcohol ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .) Thus, recommending a period of abstinence from alcohol prior to surgery is advisable for all patients with the histologic appearance of steatohepatitis, or those who are suspected of excessive alcohol consumption, since alcoholics are at increased risk for perioperative complications, such as alcohol withdrawal and hepatotoxicity with therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (often used for analgesia in the postoperative period) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/104\">",
"     104",
"    </a>",
"    ], even if they do not have liver disease. Furthermore, alcohol may potentiate the toxicity of halothane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective surgery is usually well-tolerated in patients with autoimmune hepatitis who have compensated liver disease. Perioperative \"stress\" doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    should be given to patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemochromatosis should be evaluated for complications such as diabetes and cardiomyopathy, which could influence perioperative care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .) In the past, a relatively poor outcome of liver transplantation in these patients compared to other types of liver disease was attributed to underlying cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/107\">",
"     107",
"    </a>",
"    ], but outcomes have improved with careful patient selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Wilson disease who have neuropsychiatric involvement may not be able to provide informed consent. Furthermore, surgery can precipitate or aggravate neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .) D-penicillamine (a copper chelator commonly used for treatment), interferes with the crosslinking of collagen and may impair wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. As a result, the dose should be decreased prior to surgery and during the first one to two postoperative weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OPTIMIZING MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to assessing surgical risk, all patients with known liver disease should be assessed for the presence of jaundice, coagulopathy, ascites, electrolyte abnormalities, renal dysfunction and encephalopathy, all of which may require specific treatment prior to surgery. The basic principles involved in the evaluation of patients with specific forms of liver disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with an elevated prothrombin time, a reasonable goal is to attempt correction with vitamin K and fresh frozen plasma to achieve a prothrombin time within three seconds of normal prior to surgery. Experience is also accumulating with recombinant factor VIIA, which can temporarily correct the prothrombin time, but its use is limited by its high cost, transient effect, an absence of data showing improved outcomes, and the associated risk of thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A prolonged bleeding time can be treated with diamino-8-D-arginine vasopressin (DDAVP). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of von Willebrand disease\", section on 'Desmopressin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optimal surgical technique and maintenance of low central venous pressure may reduce blood loss [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ascites should be treated aggressively to reduce the chance of wound dehiscence and abdominal wall herniation. This can be achieved safely with diuretics in patients who also have peripheral edema. In patients without edema or those in whom there is not enough time for a course of diuretic therapy, ascites can be drained completely during laparotomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolyte abnormalities, particularly hypokalemia and metabolic alkalosis, should be corrected to reduce the chance of cardiac arrhythmias and hepatic encephalopathy.",
"     </li>",
"     <li>",
"      Conditions known to exacerbate hepatic encephalopathy should be corrected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"       \"Hepatic encephalopathy: Pathogenesis\"",
"      </a>",
"      .) However, there is no evidence that prophylactic therapy can prevent encephalopathy after surgery.",
"     </li>",
"     <li>",
"      Renal function should be evaluated. For most patients, assessment of the blood urea nitrogen and creatinine is sufficient. However, these measures often overestimate renal function in patients with advanced liver disease because of the reduction in urea and creatinine synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H4#H4\">",
"       \"Hepatorenal syndrome\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H17253448#H17253448\">",
"       \"Hepatorenal syndrome\", section on 'Problems with estimating kidney function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with known gastroesophageal varices should receive the appropriate prophylactic treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"       \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"      </a>",
"      .) Although surgery has not been associated with an increased risk of variceal bleeding, fluid overload should be avoided postoperatively.",
"     </li>",
"     <li>",
"      TIPS may be considered before surgery in patients with portal hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/111-114\">",
"       111-114",
"      </a>",
"      ], but the role of preoperative TIPS has not been well-studied.",
"     </li>",
"     <li>",
"      Patients with cirrhosis are often malnourished. Perioperative nutritional support can reduce the frequency of postoperative complications and short-term mortality; its benefit on long-term survival is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/115-119\">",
"       115-119",
"      </a>",
"      ]. A reasonable approach is to provide total calories equal to 1.2 times the estimated resting energy expenditure and a 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day of protein. Approximately 30 to 35 percent of total energy should be given as fat and the remainder (typically 50 to 55 percent) as carbohydrates. Supplementation of the fat soluble vitamins A, D, E, and K, may also be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?12/35/12858/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percutaneous gastrostomy (PEG) is contraindicated in patients with ascites, and should usually be avoided in patients with portal hypertension due to the possibility of lacerating an abdominal wall varix during PEG insertion.",
"   </p>",
"   <p>",
"    Following surgery, patients with liver disease should be observed closely for hepatic decompensation, which often presents with worsening jaundice, encephalopathy, and ascites. The best biochemical measures of liver function are probably the prothrombin time and serum bilirubin concentration. However, the serum bilirubin concentration usually rises, particularly after complicated surgery, multiple blood transfusions, excessive bleeding, hemodynamic instability, or systemic infection. Renal function, serum electrolytes, and glucose should also be monitored carefully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering the available data and clinical experience, guidelines for assessing the risk of elective or semi-urgent surgery in patients with liver disease can be suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy should be optimized in all patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Optimizing medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Operative mortality can be estimated based upon the Child classification and the MELD score (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?31/26/32162?source=see_link\">",
"       calculator 3",
"      </a>",
"      ) taking into consideration other factors such as the patient's age, ASA score, and additional comorbidities.",
"     </li>",
"     <li>",
"      We recommend elective or semi-urgent surgery",
"      <strong>",
"       not",
"      </strong>",
"      be performed in patients with acute or fulminant hepatitis, alcoholic hepatitis, severe chronic hepatitis, Child class C or MELD &gt;15 cirrhosis, severe coagulopathy, or severe extrahepatic manifestations of liver disease (such as hypoxia, cardiomyopathy, or acute renal failure) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For other patients, the risk of surgery should be considered individually depending upon the clinical setting and the type of procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is generally well-tolerated in patients with Child's class A or MELD &lt;10 cirrhosis and those with mild chronic liver disease without cirrhosis.",
"     </li>",
"     <li>",
"      Surgery is generally permissible in patients with Child's class B or MELD 10-15 cirrhosis (except those undergoing extensive hepatic resection or cardiac surgery) who have undergone thorough preoperative preparation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consideration should also be given as to whether surgery can be deferred until after liver transplantation (either orthotopic or live donor) in appropriate candidates.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/1\">",
"      Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/2\">",
"      O'Leary JG, Yachimski PS, Friedman LS. Surgery in the patient with liver disease. Clin Liver Dis 2009; 13:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/3\">",
"      Patel T. Surgery in the patient with liver disease. Mayo Clin Proc 1999; 74:593.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman LS. Preoperative evaluation of the patient with liver disease. In: Schiff's Diseases of the Liver, 11th ed, Schiff ER, Maddrey WC, Sorrell MF.  (Eds), Wiley-Blackwell, Oxford, UK 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/5\">",
"      Bloch RS, Allaben RD, Walt AJ. Cholecystectomy in patients with cirrhosis. A surgical challenge. Arch Surg 1985; 120:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/6\">",
"      Aranha GV, Sontag SJ, Greenlee HB. Cholecystectomy in cirrhotic patients: a formidable operation. Am J Surg 1982; 143:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/7\">",
"      Aranha GV, Kruss D, Greenlee HB. Therapeutic options for biliary tract disease in advanced cirrhosis. Am J Surg 1988; 155:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/8\">",
"      Castaing D, Houssin D, Lemoine J, Bismuth H. Surgical management of gallstones in cirrhotic patients. Am J Surg 1983; 146:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/9\">",
"      Schwartz SI. Biliary tract surgery and cirrhosis: a critical combination. Surgery 1981; 90:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/10\">",
"      McSherry CK, Glenn F. The incidence and causes of death following surgery for nonmalignant biliary tract disease. Ann Surg 1980; 191:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/11\">",
"      Pitt HA, Cameron JL, Postier RG, Gadacz TR. Factors affecting mortality in biliary tract surgery. Am J Surg 1981; 141:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/12\">",
"      Lehnert T, Herfarth C. Peptic ulcer surgery in patients with liver cirrhosis. Ann Surg 1993; 217:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/13\">",
"      Metcalf AM, Dozois RR, Wolff BG, Beart RW Jr. The surgical risk of colectomy in patients with cirrhosis. Dis Colon Rectum 1987; 30:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/14\">",
"      Sleeman D, Namias N, Levi D, et al. Laparoscopic cholecystectomy in cirrhotic patients. J Am Coll Surg 1998; 187:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/15\">",
"      Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 1998; 133:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/16\">",
"      Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984; 199:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/17\">",
"      Ziser A, Plevak DJ, Wiesner RH, et al. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology 1999; 90:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/18\">",
"      HARVILLE DD, SUMMERSKILL WH. Surgery in acute hepatitis. Causes and effects. JAMA 1963; 184:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/19\">",
"      Greenwood SM, Leffler CT, Minkowitz S. The increased mortality rate of open liver biopsy in alcoholic hepatitis. Surg Gynecol Obstet 1972; 134:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/20\">",
"      Mikkelsen WP. Therapeutic portacaval shunt. Preliminary data on controlled trial and morbid effects of acute hyaline necrosis. Arch Surg 1974; 108:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/21\">",
"      Mikkelsen WP, Kern WH. The influence of acute hyaline necrosis on survival after emergency and elective portacaval shunt. Major Probl Clin Surg 1974; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/22\">",
"      Mikkelsen WP, Turrill FL, Kern WH. Acute hyaline necrosis of the liver. A surgical trap. Am J Surg 1968; 116:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/23\">",
"      Powell-Jackson P, Greenway B, Williams R. Adverse effects of exploratory laparotomy in patients with unsuspected liver disease. Br J Surg 1982; 69:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/24\">",
"      Bell RH Jr, Miyai K, Orloff MJ. Outcome in cirrhotic patients with acute alcoholic hepatitis after emergency portacaval shunt for bleeding esophageal varices. Am J Surg 1984; 147:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/25\">",
"      Hargrove MD Jr. Chronic active hepatitis: possible adverse effect of exploratory laparotomy. Surgery 1970; 68:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/26\">",
"      Higashi H, Matsumata T, Adachi E, et al. Influence of viral hepatitis status on operative morbidity and mortality in patients with primary hepatocellular carcinoma. Br J Surg 1994; 81:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/27\">",
"      O'Leary JG, Friedman LS. Predicting surgical risk in patients with cirrhosis: from art to science. Gastroenterology 2007; 132:1609.",
"     </a>",
"    </li>",
"    <li>",
"     Child CG, Turcotte JG. Surgery and portal hypertension. In: The Liver and Portal Hypertension, Child CG (Ed), Saunders, Philadelphia 1964. p.50.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/29\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/30\">",
"      Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997; 122:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/31\">",
"      Neeff H, Mariaskin D, Spangenberg HC, et al. Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores. J Gastrointest Surg 2011; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/32\">",
"      Telem DA, Schiano T, Goldstone R, et al. Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. Clin Gastroenterol Hepatol 2010; 8:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/33\">",
"      Macaron C, Hanouneh IA, Suman A, et al. Safety of cardiac surgery for patients with cirrhosis and Child-Pugh scores less than 8. Clin Gastroenterol Hepatol 2012; 10:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/34\">",
"      Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/35\">",
"      Azoulay D, Buabse F, Damiano I, et al. Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J Am Coll Surg 2001; 193:46.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman LS, Martin P, Mu&ntilde;oz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Hepatology: A Textbook of Liver Disease, 4th ed, Zakim D, Boyer TD (Eds), Saunders, Philadelphia 2003. p.661.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/37\">",
"      Zimmerman JE, Wagner DP, Seneff MG, et al. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 1996; 23:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/38\">",
"      Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007; 132:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/39\">",
"      Suman A, Barnes DS, Zein NN, et al. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004; 2:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/40\">",
"      Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004; 188:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/41\">",
"      Perkins L, Jeffries M, Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol 2004; 2:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/42\">",
"      Befeler AS, Palmer DE, Hoffman M, et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg 2005; 140:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/43\">",
"      Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006; 12:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/44\">",
"      Hanje AJ, Patel T. Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/45\">",
"      Greve JW, Gouma DJ, Soeters PB, Buurman WA. Suppression of cellular immunity in obstructive jaundice is caused by endotoxins: a study with germ-free rats. Gastroenterology 1990; 98:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/46\">",
"      Plusa S, Webster N, Primrose J. Obstructive jaundice causes reduced expression of polymorphonuclear leucocyte adhesion molecules and a depressed response to bacterial wall products in vitro. Gut 1996; 38:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/47\">",
"      Wait RB, Kahng KU. Renal failure complicating obstructive jaundice. Am J Surg 1989; 157:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/48\">",
"      Grande L, Garcia-Valdecasas JC, Fuster J, et al. Obstructive jaundice and wound healing. Br J Surg 1990; 77:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/49\">",
"      Shirahatti RG, Alphonso N, Joshi RM, et al. Palliative surgery in malignant obstructive jaundice: prognostic indicators of early mortality. J R Coll Surg Edinb 1997; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/50\">",
"      Dixon JM, Armstrong CP, Duffy SW, Davies GC. Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut 1983; 24:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/51\">",
"      Greig JD, Krukowski ZH, Matheson NA. Surgical morbidity and mortality in one hundred and twenty-nine patients with obstructive jaundice. Br J Surg 1988; 75:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/52\">",
"      Pain JA, Cahill CJ, Bailey ME. Perioperative complications in obstructive jaundice: therapeutic considerations. Br J Surg 1985; 72:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/53\">",
"      Blamey SL, Fearon KC, Gilmour WH, et al. Prediction of risk in biliary surgery. Br J Surg 1983; 70:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/54\">",
"      Lai EC, Chu KM, Lo CY, et al. Surgery for malignant obstructive jaundice: analysis of mortality. Surgery 1992; 112:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/55\">",
"      Diamond T, Parks RW. Perioperative management of obstructive jaundice. Br J Surg 1997; 84:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/56\">",
"      Hatfield AR, Tobias R, Terblanche J, et al. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982; 2:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/57\">",
"      McPherson GA, Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/58\">",
"      Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985; 201:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/59\">",
"      Clements WD, Diamond T, McCrory DC, Rowlands BJ. Biliary drainage in obstructive jaundice: experimental and clinical aspects. Br J Surg 1993; 80:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/60\">",
"      Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/61\">",
"      Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994; 81:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/62\">",
"      van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/63\">",
"      Khan AZ, Makuuchi M. Trends in the surgical management of Klatskin tumours. Br J Surg 2007; 94:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/64\">",
"      Baron TH, Kozarek RA. Preoperative biliary stents in pancreatic cancer--proceed with caution. N Engl J Med 2010; 362:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/65\">",
"      Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med 1992; 326:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/66\">",
"      Jacyna MR, Summerfield JA. Endoscopic management of biliary tract obstruction in the 1990s. J Hepatol 1992; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/67\">",
"      Chijiiwa K, Kozaki N, Naito T, et al. Treatment of choice for choledocholithiasis in patients with acute obstructive suppurative cholangitis and liver cirrhosis. Am J Surg 1995; 170:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/68\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/69\">",
"      Prat F, Tennenbaum R, Ponsot P, et al. Endoscopic sphincterotomy in patients with liver cirrhosis. Gastrointest Endosc 1996; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/70\">",
"      Fogarty BJ, Parks RW, Rowlands BJ, Diamond T. Renal dysfunction in obstructive jaundice. Br J Surg 1995; 82:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/71\">",
"      Kimmings AN, van Deventer SJ, Obertop H, et al. Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. J Am Coll Surg 1995; 181:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/72\">",
"      Cahill CJ. Prevention of postoperative renal failure in patients with obstructive jaundice--the role of bile salts. Br J Surg 1983; 70:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/73\">",
"      Pain JA, Cahill CJ, Gilbert JM, et al. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991; 78:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/74\">",
"      Greve JW, Gouma DJ, von Leeuwen PA, Buurman WA. Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study. Gut 1990; 31:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/75\">",
"      Gubern JM, Sancho JJ, Sim&oacute; J, Sitges-Serra A. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988; 103:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/76\">",
"      Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/77\">",
"      Lucena MI, Andrade RJ, Cabello MR, et al. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol 1995; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/78\">",
"      Gentilini P. Cirrhosis, renal function and NSAIDs. J Hepatol 1993; 19:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/79\">",
"      Better OS. Renal and cardiovascular dysfunction in liver disease. Kidney Int 1986; 29:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/80\">",
"      Bizouarn P, Ausseur A, Desseigne P, et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg 1999; 67:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/81\">",
"      Filsoufi F, Salzberg SP, Rahmanian PB, et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 2007; 13:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/82\">",
"      Klemperer JD, Ko W, Krieger KH, et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 1998; 65:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/83\">",
"      Morris JJ, Hellman CL, Gawey BJ, et al. Case 3-1995. Three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 1995; 9:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/84\">",
"      Pollard RJ, Sidi A, Gibby GL, et al. Aortic stenosis with end-stage liver disease: prioritizing surgical and anesthetic therapies. J Clin Anesth 1998; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/85\">",
"      Gaudino M, Santarelli P, Bruno P, et al. Palliative coronary artery surgery in patients with severe noncardiac diseases. Am J Cardiol 1997; 80:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/86\">",
"      Eckhoff DE, Frenette L, Sellers MT, et al. Combined cardiac surgery and liver transplantation. Liver Transpl 2001; 7:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/87\">",
"      Ehtisham J, Altieri M, Salam&eacute; E, et al. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/88\">",
"      Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/89\">",
"      Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/90\">",
"      Mor E, Tur-Kaspa R, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/91\">",
"      MacIntosh EL, Minuk GY. Hepatic resection in patients with cirrhosis and hepatocellular carcinoma. Surg Gynecol Obstet 1992; 174:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/92\">",
"      Wu CC, Ho WL, Yeh DC, et al. Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery 1996; 120:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/93\">",
"      Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/94\">",
"      Capussotti L, Polastri R. Operative risks of major hepatic resections. Hepatogastroenterology 1998; 45:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/95\">",
"      Cohnert TU, Rau HG, Buttler E, et al. Preoperative risk assessment of hepatic resection for malignant disease. World J Surg 1997; 21:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/96\">",
"      Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001; 234:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/97\">",
"      Wu CC, Yeh DC, Lin MC, et al. Improving operative safety for cirrhotic liver resection. Br J Surg 2001; 88:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/98\">",
"      van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008; 28:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/99\">",
"      Schroeder RA, Marroquin CE, Bute BP, et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/100\">",
"      McCormack L, Petrowsky H, Jochum W, et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007; 245:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/101\">",
"      Demetriades D, Constantinou C, Salim A, et al. Liver cirrhosis in patients undergoing laparotomy for trauma: effect on outcomes. J Am Coll Surg 2004; 199:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/102\">",
"      Runyon BA. Surgical procedures are well tolerated by patients with asymptomatic chronic hepatitis. J Clin Gastroenterol 1986; 8:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/103\">",
"      Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/104\">",
"      Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/105\">",
"      Takagi T, Ishii H, Takahashi H, et al. Potentiation of halothane hepatotoxicity by chronic ethanol administration in rat: an animal model of halothane hepatitis. Pharmacol Biochem Behav 1983; 18 Suppl 1:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/106\">",
"      Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res 1986; 10:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/107\">",
"      Farrell FJ, Nguyen M, Woodley S, et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994; 20:404.",
"     </a>",
"    </li>",
"    <li>",
"     Scheinberg IH, Sternlieb I. Wilson's disease. In: Major Problems in Internal Medicine, Smith LH (Ed), Saunders, Philadelphia 1984. Vol 23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/109\">",
"      Yarze JC, Martin P, Mu&ntilde;oz SJ, Friedman LS. Wilson's disease: current status. Am J Med 1992; 92:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/110\">",
"      Alkozai EM, Lisman T, Porte RJ. Bleeding in liver surgery: prevention and treatment. Clin Liver Dis 2009; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/111\">",
"      Semiz-Oysu A, Moustafa T, Cho KJ. Transjugular intrahepatic portosystemic shunt prior to cardiac surgery with cardiopulmonary bypass in patients with cirrhosis and portal hypertension. Heart Lung Circ 2007; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/112\">",
"      Vinet E, Perreault P, Bouchard L, et al. Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study. Can J Gastroenterol 2006; 20:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/113\">",
"      Saad WE, Saad NE, Davies MG, et al. Elective transjugular intrahepatic portosystemic shunt creation for portal decompression in the immediate pretransplantation period in adult living related liver transplant recipient candidates: preliminary results. J Vasc Interv Radiol 2006; 17:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/114\">",
"      Norton SA, Vickers J, Callaway MP, Alderson D. The role of preoperative TIPSS to facilitate curative gastric surgery. Cardiovasc Intervent Radiol 2003; 26:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/115\">",
"      Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/116\">",
"      Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994; 19:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/117\">",
"      Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997; 84:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/118\">",
"      Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990; 98:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/35/12858/abstract/119\">",
"      Hirsch S, Bunout D, de la Maza P, et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. JPEN J Parenter Enteral Nutr 1993; 17:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1234 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12858=[""].join("\n");
var outline_f12_35_12858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING FOR LIVER DISEASE BEFORE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS OF ANESTHESIA AND SURGERY ON THE LIVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESTIMATING SURGICAL RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patients in whom surgery is contraindicated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute or fulminant hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Severe chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients at variable increased risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Child's classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Measures of hepatic function and the APACHE score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MELD score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Obstructive jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patients with minimally increased risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mild chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Fatty liver and nonalcoholic steatohepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OPTIMIZING MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/14/23787\" title=\"table 1\">",
"      Risk factors surgery in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/29/10715\" title=\"table 2\">",
"      Contraindications elective surgery in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/0/13323\" title=\"table 3\">",
"      Child Turcotte classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 4\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/60/971\" title=\"table 5\">",
"      Risk factors surgery obstructive jaundice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?31/26/32162?source=related_link\" title=\"calculator 3\">",
"      Calculator: Mortality risk in post-operative patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40805?source=related_link\">",
"      Effects of anesthesia and surgery on the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_35_12859="Risk neuraxis involvement NHL";
var content_f12_35_12859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for neuraxis involvement by non-Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Stage III/IV disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of B symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal lymph node involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Involvement of &gt;1 extranodal site*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated serum lactate dehydrogenase level*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low serum albumin concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age &gt;60 years*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggressive or highly aggressive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High- or high-intermediate risk disease by the IPI#",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testicular involvement (see text for other primary sites)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IPI: International Prognostic Index.",
"     <br>",
"      * Components of the IPI.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12859=[""].join("\n");
var outline_f12_35_12859=null;
var title_f12_35_12860="Upper extremity splints";
var content_f12_35_12860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Upper extremity splints",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Splint",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Figure-of-eight splint",
"       </td>",
"       <td>",
"        Medial clavical fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sling and swathe",
"       </td>",
"       <td>",
"        Shoulder injuries, humeral injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Velpeau bandage",
"       </td>",
"       <td>",
"        Shoulder injuries, humeral injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Sugar tong splints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proximal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Humeral fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Distal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Wrist fractures, distal forearm fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Double",
"       </td>",
"       <td class=\"sublist_other\">",
"        Elbow fractures, forearm fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reverse",
"       </td>",
"       <td class=\"sublist_other\">",
"        Distal forearm fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior arm splint",
"       </td>",
"       <td>",
"        Stable elbow and forearm injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colles splint",
"       </td>",
"       <td>",
"        Distal forearm and wrist fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal or volar splint",
"       </td>",
"       <td>",
"        Wrist fractures or injuries, fractures of 2nd to 5th metacarpals, soft tissue injuries of the hand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gutter splint",
"       </td>",
"       <td>",
"        Phalangeal and metacarpal fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thumb spica splint",
"       </td>",
"       <td>",
"        Scaphoid fractures, extra-articular fractures of the thumb metacarpal, ulnar collateral ligament injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volar finger splint",
"       </td>",
"       <td>",
"        Fractures of distal phalanges and interphalangeal joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulky hand compression dressing",
"       </td>",
"       <td>",
"        Closed hand fractures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12860=[""].join("\n");
var outline_f12_35_12860=null;
var title_f12_35_12861="Proposed GIST management algorithm";
var content_f12_35_12861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proposed algorithm for the management of localized gastrointestinal stromal cell tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 263px; background-image: url(data:image/gif;base64,R0lGODlhUAEHAcQAAP///wAAALu7u4iIiCIiIkRERGZmZt3d3TMzM5mZme7u7hEREVVVVczMzHd3d6qqqqCgoLCwsODg4ICAgGBgYPDw8CAgIBAQEDAwMFBQUMDAwJCQkNDQ0AAAAAAAAAAAACH5BAAAAAAALAAAAABQAQcBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lg8Fajb7/i8fs/v+/96c4KCAXOFg4hvh3GLiY5pjYqPk2iRbpaUmV6YbJyan1ieaqKgpVKkMQECMgUDQaimsUyRBgY1qgKwI60lCQh1BK52Bw2/AQgJBngFJLqyz0a0tjSqrK4judcDzADVCA4iA9PdqyXO0OivJbUkBXUFCgAMdQsABMAN5Ln2drbzx/H+BbgmgsG4ZqsQcDNXrlm6h7PWjRtAQIECBAMoHjBBAByuRQIWNBiAIB5GjQB4/40IBiBXAAIiqjVQFqBAvpgNR5yDyBOHtBHsAIgLCkABzQC2PopIQCDfUaRBVRYcxxTnOgQ6c8bsyZXIz3AVFQRDCSBBAJNJBexjulFoyREULbIc8SAAOKEwyQFAJsLAwmrmugoGQuuOAHc14yFecMAYgbT77jATmOBigAVzR/gCJqzOAQd2ELTVG3iw6R07xaQ+zdrEajCvW8uOvUm2bRm0u+S+LXj3Ft+8ewLPMjz4w+JXkBuHBqi58+fQ+yyfDkU59euhsGuXY3279yfdv4tXEn68+SLlz6snvL59bffwrUDAsyG+fSgS8HC4z7+JBTsX9CegEhTYkcGACBoRgf8dECTooBAV2CHBgxT+gEEAFlSoIQ8TBEDBhiDioEEAEYRo4i0VnKhiDBOs6OKLMMYo44wrRmfjjTgGQqMhPO7IXY8+wpFedUEyAmSRbQwJHpKS/Mhkkkc+CYkJCixGEDVaybBPS5bQ1JRrUnZiggNYlbUQljdsuQIDDIAZ5ihjiqbZAvGQ1M09SNWBVS6/NHXUAQPomc9LddCE1QGhiQXMPo3V0WZfB2315pQlGLXAMQnYkykBmQ4EgAEEHICoWgHkw6ZeDZT6KTOegioqYAAg+sCW+zBwZgMFvFXapGeIYpYC2zyQVzXb4LQlRXpV1RJMxHKjCq52JEBrIZySoKz/m7yaYQkD1yRApwILYGRVsfocgkBSDwCQqqmsrkKuKgZgpUAA0p7FpTxnqqBktkJYQtGiIjhA57jOkqrnRjQBKqhe76p16T2V9cmoMW1euyu/Y+giVQpqnoJxGbDUFc8KHUex78c+nBwRyqpFybJuLr/8W8wyE0dzzcnlqPPOzuF8nM8Cqgz0z0PfJ3TRzCFt39FKx8J006U8DfUnUk+dSdVWxynCuqnw7PXXYPdsQqCPZsakWK58g1twmAywwAKbXslkSA5U1ChSZV3qKba2tR0MnSwFesxNQSqzikGxilTAXShgTWkJcS0A6gBc+4XklnjWIe0vNp3geCUnICv4/wDKCpBXkFsiboLqF88Wel73UK6qrZcfcncAByD2Jd+uj52XWa4IjgDhQH/ea9YrzHdHfacpbwfzyJeQ3x37nTa9HdVHX8J/dQTYGvcBeK99CQXWcWBr5Qdw/vgkLFhHg625HwD87I8QYR0TtnZ/APnXP8KFGbINAP1Xgg59yDYGJCAJRlQi2zBQgc1I0W0CIEEIAqBFvMGgBTfIwQ56cDxhiw54QkjCEuoIPlLDmvFMtrQmqFAWK5xECpfktBauzIUwtOESXljD+MzQCTGkIQpxCMQc+rAELnlJlmJQMocUkQSBypRQ6KUDWNGgSnoaWQy8RLxu6FAEudgImdLkCf8ewuUYIoDYEg4gOS3GCh5os8GpnDhEEoRRHm26my28VQdX/KMkd2MAnk5HxxuChQACeIA7NoUPLF4GAKCpA+EcWQ942QEmgtvdCIxCgAJIkQTiGkEgc3GPBfyDcZ+KVBAdEYkkFmAjiGMjrhhHEpMMgHZgLKMQwSIOBpjlk/ZwQC60GIB0IdFeVokVpxogEkg+amwvgWKZRoBLLq2ik2U5BK50pZMvcukA3tpI5uglAM7N5A6g+mQTu/lEuITqkfQySj8geZng3cMAbgTNAoSxCmZmyiyXrBSoPEmCeLlRU9g4BC+2ZDF21jGhYiwJ60hgkFpScyHDbNwu8SIPYST/4Fd7GUeqRgM3E4z0WQsoBzO7KAI24pMEjYlUQTCqUFess5DtaSXuRFCAVxoDd7ozVbQCaRlCOtSQHNVJAu72mCTiU2/cdCo5EFOHKRYKpniACUCBAVOKbWmhh2iopB5Kno1SzZtIMGPU0HoEtYJilYn4IRFNAVdEyBWpZz0iXpNQ1x2yNRpm1URfCWFCQIywsIgN4QdBttgJNrZvj+1dZE8z2Mlmx7KmqSxmq6DZzU6hs55lYWhxoDa8HJQFiU2tav1gAlLGw3JhWhcbjQkD0GrBEqS0BWzDRJJTmU5z9JSk59jWWnrBixkhuQwwfUSAgZX0AZWk7XB5g1ugPoYZ//vM22lnVCxE3QFQ99yubW12TGK8A1Ft2WmRyFVSE7S3da2pLsJqAoDsum27MiLXb18CrixO17HljRV9k/veoY33sgp0Xh2gNxgFB4DB47teHbI3GAkHgMLsA5/4TqNhCKZvfaf5MATlR7/TkBiC++vfaVJswQEKEEMbTCACPbTBBzqQRBykIHUrCEENInC0QA4yv1a7h1MQ+ch8SNBd22lXJc81sE4a0JKfPIgD38wrHmOlk/fqVy0jaMpcNtKXqUzmK7unugCzwU2Nt5pIIgW/KiBXO+T2AytHGaKQnCYN1pxlGEB3I8UYDczGHOBT6TFvfZRHFgM5SN6VeQXQzf+JWSBFyZQYwxbF2u82grcwlqCXj3ur7ZbtaIdXysMWslwcXN6CkWryWbQxIEk9swmpjPK0TesqVnZ5KjunMMPTQEVlKkYN0XDyI1rlrMk5+1GtXGoU1jNg5gMmnUp6Zlcl9NoGendBuryYzh6uQG+yOzdsQpM6ogqYKDUNYNGZJlS8fX6BOOLBTFKJ6lwjGCkv6gIo7BKkFVyjXQEwrd5Tr83ceE6JT4cRVEVrjqh9cnSYOfbTa7gjXAaQKlWDh1y9bdqqw+PSMYCKj4NL+dFlJcLGmNwfMHd5CCtHOVn5Gu8qE5vm0LY5wnFOJB8Irgmke/bJJ55WE3iXq4CpCiX/rzSvJZog5jE4ui0egACDyAm+RpN50Uuw7awsBSZjNBMJUuUCqEdbVd4VetCQfIeaC1jQSQf71UuAp4zjKVNH+Wi0gN3vQB3gjwoohqNEiTuq22ruRxXyCixx9GjGvSgGuBRfEiqC59YDKFhRCd8p4i5WZ0TPQnlv0P+r+MUbveCksZO1kHmvxuPObVzVfLhfz42nGODvmErjculQ+hYwHvUKKQq+ubWUgTm7vp+UFSRhouqUELzf4eCmO03ee95z/Q4wEXxi8JLm4++X+cDQquZc8gvoFyRagqMiQn1ffdN7uf1q1zn8SS//+WP9zvZPPCHyL3H889/ONgCAb8J2/wTYdvyXcwf4CAKYgD7BgFfjgJSwgBBIDROogBX4fhe4fxlYfxdYWnFRWwUYgor1dJ4yKm8iWwsgXexHXSdQAPfwKk4XJL3VJvuVKW7GUhKIgM7XUyaIGPDAJM0VD5bXDSqIU/HVghk3EKoQFxdBZzTSXXgAXm/Wf5mFhA4nAEEhDkzCXruHfFQ4GJgwcAK2hGFhNj6iX4PUXwDxhb1hhZ9SDT4IZyyTgz2XYPTBGg4GYdpjYRjWFXyoQB32PQDiYQYiGyKmQCcWPwyCYhIiGywGQS4mG5GoQDImG5WoQDYmG5kIQTo2QTxGicHhYxs4iqTIEyIIRCKYiniQdUQ3BP90WEWs+HKy+FaxmHKtGFe1yHOzmFd6tYtbR1e5+Iu++IB/hR4sdwX7IGd1FoxJhEhkFH+62Bd3UC9AsUd6Q24pQypCkS898IpkIF959oz0F43VRnmUVkxF4UtCkIzcyAPemDHFBUt5dGmI5imAx2hcdX+AJRGkVo3z4oTBVSqwVS300kmqMkyZNCjaWCx5Z2lXFUgO9xbKECr6aB5oVhOwhGqKQ0ue52qcUDVdMo1qwg4JgBgvpRO0NZCd8ihiaBAr5Uzlso0FlXnIhTvVZFEYkSp1IGzv2DLlZWzjtDnKZnvNdi/jKIyQ0o8FgUoXgUr/gk8qSRoh8WnYF5PFAnvI0cQL6FWUtqeTdlGRIBSPeZZuMnVq7YYv73aUbWUCRFEUnuJPh5EPTXgCcIMsIdEpDUEA2PSSWcGOylc3KTF7f7cQZ/mGFGmE6wGOCnc7uVNylAFx0QSWrsiW01iP4IB7g7dJUKUAB3APCFBSsGIW5ZB+kFEIxaI7zCeYEEkZ+hKMa6l1GHhmsNkvRtSLtjiMEeia+3iLTVaMWDabvWmb5IiUvDhzxHmcxOhDIYiKqticpfic0Bmd0jmd1Fmd1nmd2Jmd2ikCIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EUS: endoscopic ultrasonography; GIST: gastrointestinal stromal cell tumor.",
"     <br>",
"      * Possible high-risk endoscopic ultrasonography features include irregular border, cystic spaces, ulceration, echogenic foci, and heterogeneity.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Endoscopic ultrasonography surveillance should only be considered after a thorough discussion with the patient regarding the risks and benefits.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 2009; 6:363. Copyright &copy; 2009.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12861=[""].join("\n");
var outline_f12_35_12861=null;
var title_f12_35_12862="Cisplatin plus pemetrexed NSCLC regimen";
var content_f12_35_12862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cisplatin plus pemetrexed for chemotherapy-na&iuml;ve patients with advanced nonsquamous, non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days, for a maximum of six cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pemetrexed",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL normal saline (NS) and administer over 10 minutes. Do not administer with calcium-containing IV fluids such as Lactated Ringer's solution.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 120 minutes, beginning 30 minutes after pemetrexed. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for skin rashes:",
"        </strong>",
"        Premedication with dexamethasone (4 mg orally twice daily for three days starting the day before drug administration) is recommended to reduce cutaneous toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of neutropenic fever approximately 2 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . With pemetrexed, avoid use if creatinine clearance is &lt;45 mL/min. There are recommendations for avoidance of NSAIDs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79 mL/min) because of the potential for decreased clearance of pemetrexed. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", and \"Pemetrexed: Drug information\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vitamin supplementation:",
"        </strong>",
"        Vitamin supplementation with folic acid and intramuscular B12 is recommended prior to administration of pemetrexed and during treatment to reduce both hematologic and nonhematologic side effects",
"        <sup>",
"         [1,2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Electrolytes, renal, and liver function weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Each cycle should not begin until the WBC count is greater than 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000 cells/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . During treatment, if nadir ANC &lt;500/mm",
"        <sup>",
"         3",
"        </sup>",
"        and nadir platelet count &ge;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , reduce dose of both pemetrexed and cisplatin by 25 percent. Regardless of the ANC, reduce dose of both pemetrexed and cisplatin by 25 percent if nadir platelet count &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        without bleeding. If nadir platelet count &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        with bleeding, reduce dose of both pemetrexed and cisplatin by 50 percent",
"        <sup>",
"         [1,2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen only after cumulative doses of cisplatin beyond 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle and cisplatin dose reduced if &lt;60 mL/min. Treatment with pemetrexed should not begin unless creatinine clearance is &ge;45 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis, hepatotoxicity, and other severe non-hematologic toxicity:",
"        </strong>",
"        The dose of pemetrexed should be reduced 50 percent for grade 3 or 4 mucositis. The doses of pemetrexed and cisplatin should be decreased to 75 percent of previous level for any other grade 3 or 4 toxicities or for any diarrhea requiring hospitalization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs; CrCl: creatinine clearance; CBC: complete blood count; WBC: white blood cell; ANC: absolute neutrophil count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Scagliotti GV, et al. J Clin Oncol 2008; 26:3543.",
"      </li>",
"      <li>",
"       Alimta (pemetrexed disodium) injection. US FDA-approved product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 7, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12862=[""].join("\n");
var outline_f12_35_12862=null;
var title_f12_35_12863="Comminuted patella fract";
var content_f12_35_12863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comminuted patellar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEpAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fuZ5ftEv72T75/iPrUfnzf8APWT/AL6NFz/x8y/75/nUdAEnnzf89ZP++jR583/PWT/vo1HRQBJ583/PWT/vo0efN/z1k/76NR0UASefN/z1k/76NHnzf89ZP++jUdFAEnnzf89ZP++jR583/PWT/vo1HRQA/wA+b/nrJ/30aPPl/wCesn/fRqOigCTz5v8AnrJ/30aPPm/56yf99Go6KAJPPm/56yf99Gjz5v8AnrJ/30ajooAk8+b/AJ6yf99Gjz5v+esn/fRqOigCTz5v+esn/fRo8+b/AJ6yf99Go6KAJPPm/wCesn/fRo8+b/nrJ/30ajooAk8+X/nrJ/30aPPm/wCesn/fRqOigCTz5f8AnrJ/30aPPm/56yf99Go6KAJPPm/56yf99Gjz5f8AnrJ/30ajooAk8+X/AJ6yf99Gjz5f+esn/fRqOigCTz5f+esn/fRo8+X/AJ6yf99Go6KAJPPl/wCesn/fRo8+b/nrJ/30ajooAk8+b/nrJ/30aPPm/wCesn/fRqOigCTz5v8AnrJ/30aPPm/56yf99Go6KAJPPm/56yf99Gjz5f8AnrJ/30ajooAk8+b/AJ6yf99Gjz5v+esn/fRqOigCTz5v+esn/fRo8+b/AJ6yf99Go6KAJPPm/wCesn/fRo8+b/nrJ/30ajooAk8+b/nrJ/30aPPm/wCesn/fRqOigCTz5v8AnrJ/30aPPl/56yf99Go6KAJPPl/56yf99Gk8+X/nq/8A30aZSUAP8+X/AJ6v/wB9GpLeaXz4v3j/AHh/EfWoDT7f/j4i/wB4fzoAfc/8fMv++f51HUlz/wAfMv8Avn+dR0AFFFFABRRRQAUUUUAFFFFACUUUUAFFFFABRRRQAUUlFAC0lFFABRRSUALRSUUALRSUUALRSUtABS0lFAC0UlFAC0UUUAFFFFABRRRQACiiloAKKKKACiiigAooooAKKKKAEopaSgApKWigBKfb/wDHxF/vD+dMp9v/AMfEX+8P50APuf8Aj5l/3z/Oo6kuf+PmX/fP86joAKKKKACiiigAooooAKSjtRQAUUUUAFJRRQAUUldt8IfAh+IvjBdCXUBp5aCSfzjD5v3ccbdw9fWgDiaKv67p50rXNR07zPN+yXMlv5m3bv2MVzjtnHSqaxs3QUAMoqwtsx61ItsO9AFOlwavC3Wnrbc/dNAGdg+lLtPpWp9mx/DTha9eBQBk7T6UbT6VsC2+lH2YY7UAY2DSVrm1HoM1E9qPTmgDNoq49rjpULQMKAIaWlKkdRTaAFopKKAHUUlFAC0UUUAFLSUCgBaKKKACiiigAooooAKKKKACg0UGgBKKKKAEp9v/AMfEX+8P50yn2/8Ax8Rf7w/nQA+5/wCPmX/fP86jqS5/4+Zf98/zqOgAooooAKKKKACkoooAKKKSgAoopKACilqWKEt1oAiAJ6V7f+yEhT4wwk97Gf8A9lryGK3CjP6mvaP2Two+MFrtZW/0G4zg5/u0AeY+MbcP408QvjrqVz/6NaqCW49K3PFPlnxdroLqG/tK54zz/rnqmI1UigCoIAB0pwtwe1XVQbcjmkIx2oAqiEdwKd5YHSpsZGBU62U7KGEZwaAKXl+oo8sVoGxdELygqPSljihZQSGOaAM3yznilEZxWt5UUYBC/XNQGUKeBwe9AGeYyBkik8qtASfNjgih0DYO3APcUAZrRZ4I4qJrcZ9K0niwMjkVEV45FAGXLbDniqcltjpW60fHFV5IQc54NAGE8RWmGteWAjtkVTkh9KAKdFSNGQajoAWikpaAFopKWgApaSigBaKKKACiiigAooooAKKKKAEooooASn2//HxF/vD+dMp9v/x8Rf7w/nQA+5/4+Zf98/zqOpLn/j5l/wB8/wA6joAKKKKACkNFFABRRSUAFJS0lABTlUscChELHArRtrb25oAhgtueRzWhFb4xU8UO0CrCqOBQAlqXtp4poGCzRMHRioYAg5HByD9CMGvsL4B+NvDfiyEQnSNK0rxZbRETLb2yReenQyREDO08ZXsfUYJ+S7PT7i4OVQhP7x4FSxLPY3aTWlzLDcRE7JoHKOpIwcMMEcEj8aAPb/j9488PLPd+HfCGl6Sbsuy6hqkdpGSrE/NHG2OX67n7dBzkjwLaO1a9lou5FaWRY4scKOuKtLDaWs3+jxGTH8T+tAGda6ZLIgdv3anoWqz/AGfbouZJfMb0HQVcZZ5+STj0FKLRVVRljzluKAIYbeNFykSKfU80kq5cHecgfStU2P7oSSMEiX0HJqAvFH0jBGO9AGfKhlOd7YHao0txg8bRWqJY541RVCnuQKjlhZX2jpjvQBkbMMRnIqCeL5cba1CAjnd1NMmiDDIxxQBlRwkMMDNTqhIFTOnltwTirdjbmYlgOByfagCk0QjyDyMc1T2joORV+45DPye2KyixRztPFAD3iPVagZOxFWUlBHPBpx2sMjBoAz2j9KryQZ9jWq0IIyv5VA8XqKAMWWHB5HNVJIcdq3pIgeoqlPBtJxzQBjlSOtNq7NF+dVXQg0ANopKKAHUUlLQAZpaSigBaKKKACiiigApDS0GgBKKKKAENPt/+PiL/AHh/OmGn2/8Ax8Rf7w/nQA+5/wCPmX/fP86jqS5/4+Zv98/zqOgApDS0lABRRSUAFFFJQAU5FLtgUgBJwK0bO36UAOtLbpxWlEgUUsMXQKMn2rX07SZblxv+RSfxoAqWNpJdyiOMc9yegro7bT7SwG6UCaQc4q1GbbT0NtYR7pT96Q+tMiiDSATNhjyfegCG+vJJ8RR/Ih5AWqTRgbQwy9XJ2TzGEakD3q5a2DTJnADfzoAoBDKQH4zwBWhDYI2VJwcdT2q6dNSFVdzzgYANV7iRkZlyCoGKAGxRwwNtDFgOCRRJcMoPyDYO+KrRJI7EoSqVK0cmwpk4z6UAIshl3KJCAecVG8TuD8n0+lPFq2CQSG6Cri2jiJFfIYjrQBVhhQAhiVzSTDKrnqDwameNYpARID2JPShmXrxjtQBQlgZvm2kFulRGM5CL19K0jL8nJAGeBUZhRirocZ6mgDPaAs21u3er9rlEKKcc8470sw8ndt2kHgn0qsp2tkE470AM1BUyUVcN14rEuIAG5FbM25t8g+7jjPesmWQtz15oAqeS2flphR15INX0yFOBzSEM/GKAKccpU81MpDe9P8lSdrg+xphhKHINADZEGDVR48ir+D0IqN4x2/KgDImhyCcciqEsfWt2ROvrVGeLGT0oAxZE2mo6vyIAMdqqSJtNAEdLSUUAOopKWgApaSigBaKKKACiikNABSUtFACU+3/4+Iv94fzplPt/+PiL/eH86AH3P/HzL/vn+dR1Jc/8fMv++f51FQAUUUUAFJRRQAlFFTW8e9x6UATWcBYgnvWzDFtxgVHaw7VBxg1tWFsAgllxz90GgCSwttoz3I5reVTFaqYuGbvUOnWvmku2dijLe/tVpX3u3HyKKAGWkagHdjJ7mnvJEGD4DFeCfSopcy58tSABiq5hm2AKPvcHPegCK7lzKVUcHoa09MEgZFcnAGc1jyQOJAo5PfHatm1nECKWwOMY70AXrlz5LA53g8AVSEEjIXlUmoJ7h5JQQcDPetaGVNuN6gAc0AQCKTAUJkHng4q8sEaph2xJ1A9qhS+hMuPl44zUU1xGSGzgBqALKRoWOTjvk0ly6FNqtnjg+tN85dmQwJ9xUSzJKQpXGPyoApsgchcHAPT3poGAwxgg4zWjMIlAwpwecio2iVIAcHJ5yaAM5YsjDEkfSlM2wFduR0FWQQxAFVvszPcdQAeKAK0jDb3560scmBhRn1zUlzGofYvRf1p8UatuIYZxx7UANjiEkMgzgKDgGsN4ir4zkZrdDhIZAMZ6GsiZTvBPAoAaowOaTjd05qVcFPeoyo3HPWgB6qD160xowxyRipkUFRg80Y2j39KAKkkTDkUnlnANXCN8fpiohwAvegCjLHu7c1Vkj65FajAHJxzVeWPII70AYdxCByOtUpY8ituROxHNUJ4tpJoAxXXaabV24jyM1TIwaACikpaAFopKWgAFLSUCgBaQ0tJQAUlLRQAlPt/+PiL/AHh/OmU+3/4+Iv8AeH86AH3P/HzL/vn+dRVJc/8AHzL/AL5/nUdABRRSUAFJS0lACqNxAFbGn2+MEiqVlDvYE10FtFgADtQBYsbcSSgEfKOTWvBEZJBxnt+FR6dDthdgOTxzWnZ7VBYAA0AW1QQw7QcYPJo+UoxYnZ6HvTZCFjDMc5qKFZrmYr0GOpoAdFLsfgfKPXpSHLEnYxxyD2q/DpyxANI6sBztzVpiNyr8qqTgKo6igDCeCVW39N3QjtQqSNJvZcgcV02IWQA7XAPSq1w8cTDEXyDtmgDFe3ckttU5GcUqw7IyXzgitMFZYyMqmelRvbSbezgehoAzBHtkCqMcdcVdtoYpXCyHaBx1qT7KQTlmGBwcd6fFp0zZkIzj1oAmmt12hAyYHr1qmE8tmBfkelWfscjcnHJ555p509wCw4I6g0AQvIpVScnHY0lxP5kOMYI5xTjGxdUKYBwM0SW3OAfzoApQSFhkY+U+lPupw20bdrDuB1pkkTRN8i96cyMylsexyKAEESuNxPI71HLGd4EXHrxVu2tDKq4J9TjtT3RY2IFAGc2Nrqc5A6ms2YZkOSCa2LuIEkg9ayyn7wls9aAIURgeBzTzASCSTnNWUIGAwqbI29OKAM/y2yPTtQysCTnmrbKScjkU0genNAFVSTx3proc5xgipGTDDAp+3cvPWgCoTkjjmmSoeoFWWi65qIg4IoApzIGBIFUJU3Z9q08HPPWqtzHsbI6GgDFnix24rNnTBzW7PHkH0rMuI8ZFAGdRTnGDTaAFpaSigBaKKKACiiigAoopKACn2/8Ax8Rf7w/nTDT7f/j4i/3h/OgB1z/x8S/75/nUdSXP/HxL/vn+dR0AFJQaKAEpyDcwFNqzZx73FAGrp0WACRW5DH8oJqnZQ7QMjjtWmhwvFAGhaRjyFwferccRJBDYXAJqhZszR7Rxz2rWnk2RQpGi8jJY9TQBIQrKEGcd6m2KqrtbBxkA0kQMkZ5VRTzD0IxgD1oAnj3BDwCzDrU0JQKGnGW6AiqcbsGwu4r16VPGHZcMOB0JoAJL1422wqg98VVmuHlb58ZPUgUrL5chIG8980+La+QUwOvFAEaSeVw4+XvmpI5BGSY+jVFOw8xgwyvvViGCKYEqcEe/WgBYZGkJzxWjZSqpVJGwhbr6VB9njSLYceZ2x2qNANuGHGeTQBZmXbPmIhsn1qdx5cn3wSw6DtWWshWbZI2V6CrKoy4O3PHWgDQa2LWvmEqMck+9ZjgHIXt39afJLIV28kDnHQVRkkdJF2HPf6UAOlUtH2yOpNV53JXao49asN5jJy2Q3Yim7MQkM31FABpjGNyB0Ip90mTuVh9KZBtQnGT6n0qeGCW6lARWA/vdqAMqU5PaprjTA1ss8Em7PBUjHNa01hbW3Mx3kdccVFLdKwCHgDkYFAHOFCGwRhh2NS9VxitSSCK5QbyFk7MKgk0+WLLFSyf3hyKAM4ZHA705IgwJOARUrr1xzj0qPGGyTQBFLEA3Tio2HIqdsnk9KhfOD60ARsCODUajnP6VY2kjmm7KAKdwmTnGBVeZN6Ed60JEyuCKqsOTzQBkMvY1n3UXPHSte4TbIffpVSZMg8UAYFzHjkVVrVuI+qms2RdrYoAZS0lLQAtFJS0AFFFFABRRRQAlPt/+PiL/AHh/OmU+3/4+Iv8AeH86AHXP/HzL/vn+dR1Jc/8AHzL/AL5/nUdACUlLSUALWtpUWWBxWUgywrpNMjxECByaANSCPC1a2gDimWyFj7VbjiJc8cCgBdPkWGcbx8p61pX06sVMeNoGBWUY/nI/Wp0jPCjk0AXrIvK/39q9+M1akgvFcjadvZu1T2kKxRBNvzAZ/GrbvJKvJBA4+lAFaKylwvmT7c+gp72AyM3L+nSrOCT8nFSIrNkkDIFAFNtOKY/0nk9yKPsFwCdro/8AumrwCiNieSBmooyQqkHGOeKAKbWN0vLwsT7HNMjAil+feo9Mc1tw3JVuF5xzmpo5I3XMiqxPTIoAymmTfnfuz0OOtMeMyJuD4UHBx1rbl0yyuBnmJiM8dM1nXWiXsalrceZEO6c0AZkjjdleqn8617OZWXGchl4GOlZItXBxIuD3Bq1ECAuTwOKALdyQwxHg7eSaznUF8gE4/SrsZUEtz9fSo/LDHLEDnnFAEAQsvXGKjaIFs9varxhYvtUFicDA5zXSaV4ZWFFu9WzGnVYR1b60AYmj6K11CZpjst15JPVvpU+o3fkAJboBGPujHatbVNVRmaCBERV4RVHSsN45JxuckdjjmgDFu7ppnII5zUGCjYPzDFXJrUl3KrwtQNHgZOeOo64FACNE6oHHTr9Papre6mh5LcEcA09YiV3Z+T36U6RYn2YBjYdxyDQBO1vBexNiMxz/AOz0NZN3p8kO7HzgdwK6GyhlC7oZUkwe/WrUsMssBEiAMT0xjigDh3XbyQR9agdT15rrZdNWeJmELJg4BYYzWbdaQ6A7TyPQ8GgDABIU9aeBlcipLi3kibDpjNRoeMYFACMuV4xVSVMHOOelXh3GajdfWgDLuEDD6VRnAzx0rXmTORjpWdKvUYoAybqI4JFZN0n8QFdBKOOlZNymdwxQBlUU5xhiKbQAtLSUUALRRRQAUUUlABT7f/j4i/3h/OmU+3/4+Iv94fzoAdc/8fEv++f51HUlz/x8y/75/nUVABSUppKAJIBmRa6/To/3SjFcnZjM6j3rttOjyBigDQtY8KKsID09TQF2gD1qeBMjOMCgCu6hTzVnSEEt0pPIHNVblvm+pq/ocRLuVHagDUPzyAKSCT1FPG2Hh2znjpSwIqScAg1DdOTIAM4oAtp5ZXedw9OadEdr/Nk5xg1VjU7QCTgcVYibL7SByMCgCym1VcYGDVVzzhScZq9GEEHTAqr8j7woJ2d6ABSqAM2SwFPhccK2Np5x71G2yRlVsqemMUsYjJOcjFAF+3Z94OQTnFbFq7LKDExHHIB61j6YA7jdwAcgmuqs7WMBipViRwaADzredNt7ax3CdBuGG/MUv/CO6HdDMbXFsSPu53DNWba0hkQsTt7cVdAtoo4zvUseMAdMetAGOvgEzP8A6JeAp3JXp+tOHgGKzTfqF1xn7q9WrROqPAW8ticHkLxWPd63PcAuZAJOwJ6UAbttHYaVCkdnaxxuRnzHOWauf1W/a6llY5yM854rNmu5LiUEykj64xSWO2aVkkb5c80AZs8Ts+6IEA/xHrUtv51vDI20lTjr3rZ8gWzr0kyew4wamurOdriDzI18l+EIPegDDS3SeFWUDn7y96dc6Mott6GTf1bjtXSR2ItrpkVFJkwowMgmrps5HWYAKw5Dqei8UAcFHp/75FVjsk9RxTp9Ont8hkxg8Z5BrqlS12KqZRgN7B+RmmXMYaB5OVuG6J1VhQBzvkw20kbiQb25ZQehqd2nd2nUOR0yDnFQTQlyHt4++PLPJpJJWt4MgtHJ02EevrQBI1zOyCJpWBB+6R1oZhPkEKpH90U5Xa5CsWCyJ0J6GorsvBKTLEVzgjbyDQBWvLKCWN2Ulz0P1rmb2xMZ3R9uoroZZGWRcnbETnBPX1qaSC3u48xna54/GgDiVPzcg07bkHFaOo6c8Rd9pDjquO1ZyAqw96AIXAx71mTgBmrYZQTzWddx4PselAGXKmAcdKy7pSDyK28BhtI5rLvk6+ooAw7lMNmoKvzplaonrQAUUlLQAtFJS0AFIaWkNABT7f8A4+Iv94fzplPt/wDj4i/3h/OgB1z/AMfMv++f51FUtz/x8y/75/nUVABSUUUAXNLXfdoPeu+tIwkY9a4zw1H5uooPTmu4VfbigCwil3wOauL+7iO7tUFt8vpxUz/cY8k0AUJl3OSR9K2NHX9y4A7jNZRGWya6Dw2nmNLFjLY6UASOrRvuGcEYpsiYO4DJ6cVq38H+rRMBhnqOKzEid2YlDkdKAHxRM4JxwOwq1HbhFZmHyhevvU1pDsiRXXLMOCDzVjaDbSRqfmGMcdaAKG1mi+UnkfhVa2BG8tyWbH1xW4lk/kFoznPVe4p8GjPL5aqhXuSecUAZEUbM24qByevStrTtKR4isnHy5JNalvoPlgLEu91BJLdG9qtTafOkQEUON4AbnpigCpZaYvkswOWbouK0Hiit4kjBxJ6A9au2cUVvCygfMcAknkHvTYLQOT5rsCwPHcCgDGUySbiS0eMjg1JAjmRvMfIwGyeprTuhbxoyqp24+/71kzIYJcsx8st3+nFAEdxcxoz+aCEzkCs6ARNKymMt9B2qxqYT7Uu8llcdB2NQw5N0Y1GOODmgBksLib5I9q54J7A1btrKQmaRvkxjbjvmoJ3ZpDu2MR15qX7XPJCoRsqnUZ5NAF2NmtkMMih5NuMVZtZnLsjck4wtRWVtNcoTMhLx/MuDw3tWx4dtllvIncBAOSXGQD6YoAbowjnm2Shhuzgk4xWs9vCIwTuTacEg8t9am1TT4oI5poY96svy4GD9fzplrOkliFEJdwNrCQcHHegDP1Gwt5o1uViMTo2Ny9FB7GqD2yRuqykna2d2M7fcV0FrINRins4kjR1zvjAxkVQgspwk4jX94FKMhXIK/wB4UAc9cS+Xegm3CAdeOvvUOqQWd5G7ldsuBz2rXR13MbiFJMnaCRnms6+iVpSsmU52qBz+YoAw5rJHUrby71UfdHWkYvc26o7FHhACgiteOwhEBkVSsykhSOM1jz3bzzLHcJmZf4uh/GgChewEIj3L/J0yo6GoYxGkDKHHJ61beWeGCR2w8LHlGGelVpoVuUElsqhepx2oAVkEkYSWVWboHz+hrm9X097J+R8jdDWrcuYuyYJ7cGrlokd8rWV6SokB8tj1U0AcdwfaqtyoKA9xxV6/t3s7qSCUYZD3qs7K0ZGB9KAMqQbee9Z94mcse9as44OB3qpKu+M4FAGBMuM1myrhzWzcpz06Vm3Sd8UAVKKKKAFpaSloAKSlpKACn2//AB8Rf7w/nTKfb/8AHxF/vD+dADrn/j4l/wB8/wA6iNS3P/HxL/vn+dRUAJRS0lAHSeC4915K56KldfHksfSua8ER/url/UgV00PGaALUCkK3FSoCeCaiif5W6n2FWLfGR6d80AQSptbGM10PgtC+q7cD7p4rMuIwxBXGPQV03w9t0k1ZgRkhKAH3sciyMXBKrn8KoEONpDDnqa29agIuJMH5SSQvrWdHGvm7XGVPQelAF21tZJQrhc4GAB3rTfSSpXPyu2Bj+6Peo9K3QXCCJcuo5Ye9b8JmvrmOLbn+J2A6getAENhpTSfvETKhgu1f4sd602002jAM2cg/KBwK2rZI4lZkQqQpOScZ4pzRG2dIZl5fBUntnk80AVra2MVsZgrBgMqcZGc4zWY+oYvTEUBIbkgVvavdR2doyR8EttGe/HaubgsrmbDxZJYbiTQBDqDyRFUSPc27d+FPgSV2VzlFUYCt196m+wXc+oqZD+745Xp+Nby6cUvA6oHYA4AGcigDn59OaOM/e81vmCEcVjXUcikCaLO9jkdwa67UrSaczSuGUJhgOn4VhtbmR5WmRiu4846GgDBfasyjy+3UnqanhsC88U8SsWPBIHGKvJpd1IzGGJpFIxgjNdr4C0OTOLi1dA448wYoA8z1vSntJvM2ttYZGBjAzVe0tZI5Mq4HTORXqfjnw04cFCpRG49h1rll8NSzXMEQJxIcgjtigBdIiMCKSdzrgqM/ezXc6Da/aGle1tdylcOp459s1FovhxYLuLdKS6j7xHGO4rvdOgtYiHhK7j8pI70AcHqVpMJWhwVZF6E9c9QKtrpYtpYWi2hVXO1v4geufeurvIT9rkd4A6EDk9M+tQG2S8hlQxKGU/KR/FQB5xPH5WqmSKLrlM9D+NXtOEjXS2a4FyMuhbt7V00bIqxxzW4+XKu/fH1qWGxgsZBc2rLK3mZ+b72PrQBxN3p5iiQwQnYzHcGHQ1zutWJL29zErEHK4x/FXfaraPDaTSS5xO24rj7h/wAKgcxy6W9vIBERFvUDqX//AFUAcFdW3+iWwddgIbbjqGrnLiydg1xAQSvEhPvXoYVLm1dZItrhSGdh0Pr9KydQtSt9JGMGOeFWYDgHigDgruT5hCWUA8buwJ/pUM1pLpke5cFD8zY/hrau9DeSSQoCUQqrbu+elVtSSWLEDqAqDGOu72NAHOSCG7cSeUyN19qiuHeK4WR85/hPtSags8UxfayRE7eOwq7biJ42iLCVSNobuDQBLq1lHr+lfa4Mfb4BtcD+MetcFIrIWUjDA4INdxpLSadeYlyEY7QfWqXinTElZ7y0XDD/AFijp9aAOJkyH9qYVwm6rLqu9gaYygdKAMa9i6kdDWPOnUV0d5H8tYVymGPvQBkOMNim1PcLg1BQAtFJS0ALSUUUAFPt/wDj4i/3h/Oo6kt/+PiL/eH86AHXP/HxL/vH+dRVLc/8fEv++f51FQAlFFFAHaeDBjT5D6tW/FkngVheEB/xK292NdBbjPbAoAsW6fMTnt2q9axbkz09M1VjjIbK9TV2xU7sHtQBMI2VeQBzXbfDPTlaSa9kZhs+RcDqa5Ioc4ORivUfhzAtt4Vur2RT5auzDjqRxigDnfEqJHqUgQMwXv2PrVSwhAVWmAOWweDVn5b68eWUtGzN/F0NbGmxRyCRCmI0GeT1NAFvQrTfqI3BEijTIweuexrq7O2jhaJYYT5mDvA5Ncvocf2iOQvIAxfac9OOmK6e1Z0v7mUSeWYQIxkfeJoAntrUzpdTPE3yjGO49vSmKou7nO1yc8I3GMAVqyJK6FJGCR9yv8R96nhiSW5WSE5Cwkhcc5FAGfLplvdKvmDa0YyFYZ259e9VptOfzEi+07UbGPLTgg9q6q002a5hQhTBu+87c5rdtdOtrXBCbm/vNzjFAHL6d4bukYQyFRbqxJIGCw7Vt2+gQxujPIdy5GF4BrbpCM0AUf7Isv4oQ31OaSHSLCIuVtYiWzuyuavnkEGmjO04A9qAK8VpHEcRwQqg6ELzVVjIbtfORcKeucD61fbeqMzPgY9OlZjRSSXLdGCkEc5yKAJNaFsApuY9ysMc9K5rV7G3W5R7YmLC7gAuQMV1mp2ovYQm7AHNVoLNTDIkm1hjb05oAwtNf/SAwyw6sR2B7V0GnuI5CrKih+V29x71kJbOJCscIgVj2OenFWlgcXOF3crye2e2KANWdgARy8efmOc7ayoWlQ+UkfzBso+cZGfStBlkt7bIKsWHzDHWqVnJJ56TXK7dq7cnqOemKAItR0xxKZN58qQ/NH1ANQx2o+zytEsiBcgquMg9iM10UEjSL86j256j1qrPsaYsj7mU8oeBQBh7GlgEkW+VSP3gkxwazL/T1u4EuYysZAKYHOffj0rtIntc+Qmz58nHrWRf28Vg5kDnyt2x19AeeKAOGOliPUFSaWQRYAcjIGD61ni0cahKUjElswJjJbJUdwDXeahAGs5ik0ckBAK+rLWVcaa66MhjKM8eZF2n5mU85xQBxOtW5CRPbBuF2sAev1965PWIwl4wJzLJ86knOPUV2y+RGWeabBHJ3ep9vauc1/SkE9vLE5cZ4PvQByep27eV5oRmifjjrnFc1abgsqBtjbs7u30r0TWIfPsw8G5JR96P3rgggRwJztfJ4x1oAnnL3KRHzFZk/HNamn3KzwRiWIbkykgz94VzW8wTP8+ARV3SJmmEkSn52GVoAzvFmgPp03nwqXtZOQ3p7GuaJGD616dY3nnxG1uiJFbqr/561x/iDRvs8jy2gLQ5yV7rQBzUvIANYuoJhifet5gSprKvUzn0oAwZ1z2qmRg1pzR4JFUJlwaAIqKKKAFopKKACpLf/j4i/wB4fzqOpLf/AI+Iv94fzoAdc/8AHxL/ALx/nUVS3P8Ax8S/75/nUVACUUUUAdt4Q/5Bb465NdFp7FuMVzng4/8AEvkHo1dLpygzg/w5oA0EX58c1atY2Qkn14pDFiQMcgVoKFIAHQ0ASxqu0vyc8c16ZvGlfDixtom2yXTbzxzzzXB6TY+fcrCuS0jKgHua774hFra7s9Lt0XyrGNUJ7FsUAY9jbvMj7yrOMc+5q7PA1vaIZQA7N8zUzQ5WikT5AxduR6VPeSj+0jHJGWQnG3fzn1xQBU0yYws0W3cHfeWA6eleieE7Xz3/ANN5DDJJ5LHtmuc0nS/MknPk52sM+hGK9I8Oacu1LlUZGGAFb0oArCxleUtHFuQtkKDnIz+ldBbabBBP54GGxyKuQxLEu1RxnNSHoaAGk8+2OtGMlST0rISZ1kcM7KMEs2OntWtHh40PJOAeeKAH4pBnJzS0UAIwDDBGaRRgKDninUUABAIwaha3XBKAK543AcgVNRQBW8pum7JIwWHBNSQRGJdu4sPftS+WM53NUlAEE0TNKrIcdiKVrdednykjtxUw96KAIhHwAOvrjmopIN+8MFbPQkfpVqigCtawtGpDnjOVGentUV1EEIZ8eWP4scrV6muu4YIBB6igDJ1C3MWyZMtIJAyAdjUeqSMyISqK5XDqf4eetaN9K0UY2RhyeAvvUFzaLPEuECzYA+Y9aAMR7ZZ7MmNCoiHIBwDVKO2ltmSe1nYiOPAGeg9K6u3h+zWuNhkJ6qOciqaWckNzPEqLs2kxn0z2NAHn/ivS/tUyX0EO8TRcqRwG9awJLeWfw3PLGj77ZwWHf8K9PvIIbeztFkJG+QruXnafSsjUdAurJ2n08hzKcPAP4vWgDx28uGM8ckYySAZAe/auX1i23zTfMFCkMFI5Ar0HWtPNhrUhlQRwTJux1AOen51ha7prIGuHi+eRNqsOVI7fjQBwssSSW7iRlJz8uKoW8z20waLKqp610Mumbd25cMBjg9PrWK0QiJjbB55z2oA1JR55WbO0sNy471LasLqV1YbZcdexPpUEbB7NShLSRH7o7irdvGWj8+MbH70AcPrlt9l1GZAMDO5R7GsK5HOCK7rxzAZGs7xRlZIwrEeorirpBjI7UAY1zHg5rOnTrW1MuVJrPmjx7igDJIwaSpp02moaAClpKKACpLf/AI+Iv94fzqOpLf8A4+Iv94fzoAdc/wDHxL/vn+dRVLc/8fEv+8f51FQAlFFFAHZeDTi2mH+0K63TF/fY75rj/B/CyD6V3GlR5fdkZFAGsse5CQeV7GpYzkpwRzzU9ugySw7VCCfO4JHzdMUAdz4Btg2uR3DJmO1Uzv8Ah0pviK4a4v5ruRiVkYvg10ng61+weFpLpyRNdttB4+6Otcrr6vdyIA2xM5IUUAP0ed2mUwDLL8+CeD7VctpJmuRMwZtxLZP8J9Kp+H7WVZD5ILAjnjpnivSfCHhGQzRz6g6CLP3O7UAbXhvR5Z9NizviMgDuSMV28MaxRqijgDFKiiNFRFwoGAB2FKx2gnn8KAFFNkJCHb17UvSlIz1oApGJFuF3OCZByv0q7imGMb1YAZHHSn0AFFFFABRRRQAUUUUAFHSiigAooooAKKKKACiiigBGVW6gGm7Rvz3xjpT6KAEAAGAMD2pHXcCOnanUUAULixV7Q2+4bi29CexFVbiKUQRM5Vp0fMpBxx61rnrwOR3NZ9/au0vnRqG3AK6nnIoA4TxZoNs+mSxF1llZTJFIT6seK4Fop/7MubOaNg8ajYSe/pXqWt6azaaYSR5KFijY7egNcXqWniPZdT72RoghjH3hnufyoA81d8XhF6oUAhtg6nFY2qQJJPJLGDjP3sdK6TxNYSbmlVQsinaDnkisplFxZzRu+w4GccAmgDM0qKEyvFLPy6EcDv2rQ0MeWxt5D8r5UBvWshYDESFG1lOfc1p+Y0bRXMP3iByexoAh1izaewmtCmPLJZfrXnE6FWKkYIr1TU43EsF/knzeSD2/CuC8SQCLUZcDAf5higDl51wxHY1QmXBII4PStS5AOPUVUnXcp9aAMa5TIqiRg1rSp14rOnTa1AENFFFABUlv/wAfEX+8P51HUlv/AMfEX+8P50AOuf8Aj5l/3j/Ooqluf+PmU/7Z/nUVACUopKUdaAOr8KNtLfSu/wBMUbc55xXn3hrhhXomlrlV9wM0AdDaITCG7AVBbqZb0Ig+Z2CgVdtm2xgEZFbXw/0tb3xOGkAEMfzsW7UAeiyoY7C0tFGxYIwASODxzWFY6Kl6r3TB1hjY8kdWPp7VtzXBvNfMRD+RF83yegrUktHMTCNzHEeVQe/bFAFfR9JhRHMOdrlQ2PWu90GylhV5LlgQcFFB4FY3h618lwqqfJIDqWHQ966IAWvG/c0rc/SgC1DKXkfpt/h9alP3f8KbEFCDA6e1PoAQZ7jiloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA9Ka4JU46jpTqD2oAyb6AS25iBKvuzjsM9cVl6npizGeJIwJXh2KzjhmHSuhnVEhwz45yCTVSZJCLSTeuU5OTwaAPCvEGmSRvILg7ZmjBODgAiuFvoSpkdN3OG+lfQ3jXQ/t9sk3k75FJ4TnHua8g1bT9moSpO3yn5QAOn1oA5c2wmjW+KhQvyuCf1puDJZSxqMmNt2enFalxa/P5UX+rC4APes3T4WaWWOUkEgrigCRiZLVVJJEaggHvmuV8WxD905ADAcV0zIyXMCjrt2stY/jKA+VGRjAbbxQB59NGS7dqpuuDzzWzPEVOcfWsyZTk47UAUJos5461mXKcH1reKho+RzVC6h4zQBhEYNJU1xGVaoaACpLf/AI+Iv94fzqOpLf8A4+Iv94fzoAdc/wDHxL/vn+dRVLc/8fMv++f51FQAlKOtJSjrQB1Ph0cA16ToQ3RKe1ec+HQML6AV6R4dO6ADBPtigDoziONOn1xXonw+gFtpEt08QCyy9cckDt+leeycAK3YA16loZB0HTYVHJO4nsKALthGTqjTRcee20j0FdbY6cTO5IRlX5eVxmrGjaFHFKJXDAk7ia1ZCUcskYCscZJ5z9KAKMEbvfSqrfL5aqQBwOegNakqmUtHhQF6Z6mqVvcJa3LQyliCDIHHTHpirod3hEhA3Dle2RQBaHQUtRxsTy3VgCB6VJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDJGZGdHwUYcZHQ1FeoqWhx8u0cH0q3Uc6F48LgMDkZ6UAcnqFrcPChXO1mwwz2PeuS8QRW8e9oYULE7WBHP+9XousQXH2fMLFpC3QDt6VyWo6MC8sDZMjoH3YOc96APNNTtzb+UdysTkDP8AKsxbDyr+GSWNf3hDYHau7u9E8pW81fNwmQPTmsmVJna2fy1RkbaQB2oAoXWmQJNdkxAtGdwHoK4HxpHusmIjCLvBFesahayQm5mdifMhBLHHP0rzzxjsk0uAOoBc4z9KAPKLgkEBqzbkmOU7ehFbOp27QyY6g96zbyL7jeooApADbwahnXirPCOB/D3onjVx8hHSgDBvIuCKzCMHFb90nynjkVjXSbXyOhoAgqS3/wCPiL/eH86jqS3/AOPiL/eH86AFuP8Aj4l/3j/OozXST/66X/fb+ZqM/wBKAOepR1rf7UL1FAF7w9wiccmvSvC4zHx61yWh9Er0Lw90WgC87GRW3DOOK9d8F2i3mkRSkkpHEvA9R2rzCX7kn1r2T4ef8idD9TQB0eh6u91I9vt2hMbW749K17wiGFMpu285z0rl/DP/AB+XP0P8666X+P8A3aAMWc7YnjKkGQZVh1Aq9ZeYyGCVw42cMKhk+8n0/rU8P+vH+9QBctkKRgNyRxn1qakH3vwpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBGzg4GTWTdWzGZTKcl12kgdPSteqGp/d/CgDNk02BysBBYlWya53WNJi0+JiIwzMucHsPWu0s/wDj4/7Z/wBawPEnS6/65mgDkPEUqP4Ntrg8yuzQ5x/d6V474zEgS1jb7yKWOPc17TqH/IoaZ/13b+deZeNv+QnN/uj+VAHl97H5gAI4HOTWTfxbIwPQ8V2F13rP1L/UigDipl3KfUVVBKmuoP3vxqrL980Ac7OPyrIu48qw9K7Z+g+lZ83U0AcTT7f/AI+Iv94fzrel/wBYaIf9fF/vr/MUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sunrise view of the knee demonstrates a comminuted fracture of the patella (arrow) with associated soft tissue swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_35_12863=[""].join("\n");
var outline_f12_35_12863=null;
